<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Mass drug administration for malaria - Shah, MP - 2021 | Cochrane Library</title> <meta content="Mass drug administration for malaria - Shah, MP - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008846.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Mass drug administration for malaria - Shah, MP - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008846.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008846.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Mass drug administration for malaria" name="citation_title"/> <meta content="Monica P Shah" name="citation_author"/> <meta content="Centers for Disease Control and Prevention" name="citation_author_institution"/> <meta content="hyy9@cdc.gov" name="citation_author_email"/> <meta content="Jimee Hwang" name="citation_author"/> <meta content="Leslie Choi" name="citation_author"/> <meta content="Liverpool School of Tropical Medicine" name="citation_author_institution"/> <meta content="Kim A Lindblade" name="citation_author"/> <meta content="Centers for Disease Control and Prevention" name="citation_author_institution"/> <meta content="S Patrick Kachur" name="citation_author"/> <meta content="Columbia University Medical Center" name="citation_author_institution"/> <meta content="Meghna Desai" name="citation_author"/> <meta content="Centers for Disease Control and Prevention" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD008846.pub3" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/09/29" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008846.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008846.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008846.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Antimalarials [adverse effects]; *Malaria [drug therapy, epidemiology]; *Malaria, Falciparum; Mass Drug Administration; Parasitemia [drug therapy]" name="citation_keywords"/> <meta content="" name="citation_fulltext_world_readable"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008846.pub3&amp;doi=10.1002/14651858.CD008846.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008846.pub3&amp;doi=10.1002/14651858.CD008846.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008846.pub3&amp;doi=10.1002/14651858.CD008846.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008846.pub3&amp;doi=10.1002/14651858.CD008846.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008846.pub3&amp;doi=10.1002/14651858.CD008846.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008846.pub3&amp;doi=10.1002/14651858.CD008846.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008846.pub3&amp;doi=10.1002/14651858.CD008846.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008846.pub3&amp;doi=10.1002/14651858.CD008846.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008846.pub3&amp;doi=10.1002/14651858.CD008846.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008846.pub3&amp;doi=10.1002/14651858.CD008846.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008846.pub3&amp;doi=10.1002/14651858.CD008846.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008846.pub3&amp;doi=10.1002/14651858.CD008846.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008846.pub3&amp;doi=10.1002/14651858.CD008846.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008846.pub3&amp;doi=10.1002/14651858.CD008846.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008846.pub3&amp;doi=10.1002/14651858.CD008846.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008846.pub3&amp;doi=10.1002/14651858.CD008846.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008846.pub3&amp;doi=10.1002/14651858.CD008846.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008846.pub3&amp;doi=10.1002/14651858.CD008846.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008846.pub3&amp;doi=10.1002/14651858.CD008846.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008846.pub3&amp;doi=10.1002/14651858.CD008846.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008846.pub3&amp;doi=10.1002/14651858.CD008846.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008846.pub3&amp;doi=10.1002/14651858.CD008846.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008846.pub3&amp;doi=10.1002/14651858.CD008846.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="Xx9QLps0";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008846\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008846\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008846\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008846\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","pt","ms","hr","fa","fr"],languageCode:"en",accessStatus:"open-access",doi:"10.1002/14651858.CD008846.pub3",title:"Mass drug administration for malaria",firstPublishedDate:"Sep 29, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Infectious Diseases Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xx9QLps0&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008846.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008846.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008846.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008846.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008846.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008846.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008846.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008846.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008846.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008846.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5029 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008846.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008846.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008846.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008846.pub3/full#CD008846-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008846.pub3/full#CD008846-sec-0108"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008846.pub3/full#CD008846-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008846.pub3/full#CD008846-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008846.pub3/full#CD008846-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008846.pub3/full#CD008846-sec-0017"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008846.pub3/full#CD008846-sec-0048"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008846.pub3/full#CD008846-sec-0100"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008846.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008846.pub3/appendices#CD008846-sec-0113"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008846.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008846.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/supinfo/CD008846StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/supinfo/CD008846StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008846.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008846.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008846.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008846.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008846.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008846.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Authors. Cochrane Database of Systematic Reviews published by John Wiley &amp; Sons, Ltd. on behalf of The Cochrane Collaboration." data-creative-commons="true" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Mass drug administration for malaria</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008846.pub3/information#CD008846-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Monica P Shah</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008846.pub3/information#CD008846-cr-0005">Jimee Hwang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008846.pub3/information#CD008846-cr-0006">Leslie Choi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008846.pub3/information#CD008846-cr-0007">Kim A Lindblade</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008846.pub3/information#CD008846-cr-0008">S Patrick Kachur</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008846.pub3/information#CD008846-cr-0009">Meghna Desai</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/information/en#CD008846-sec-0119">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 29 September 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008846.pub3">https://doi.org/10.1002/14651858.CD008846.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008846-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008846-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008846-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008846-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008846-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD008846-abs-0006">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008846-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008846-abs-0001" lang="en"> <section id="CD008846-sec-0001"> <h3 class="title" id="CD008846-sec-0001">Background</h3> <p>Studies evaluating mass drug administration (MDA) in malarious areas have shown reductions in malaria immediately following the intervention. However, these effects vary by endemicity and are not sustained. Since the 2013 version of this Cochrane Review on this topic, additional studies have been published. </p> </section> <section id="CD008846-sec-0002"> <h3 class="title" id="CD008846-sec-0002">Objectives</h3> <p><b>Primary objectives</b> </p> <p>To assess the sustained effect of MDA with antimalarial drugs on:</p> <p>‐ the reduction in malaria transmission in moderate‐ to high‐transmission settings;</p> <p>‐ the interruption of transmission in very low‐ to low‐transmission settings.</p> <p><b>Secondary objective</b> </p> <p>To summarize the risk of drug‐associated adverse effects following MDA.</p> </section> <section id="CD008846-sec-0003"> <h3 class="title" id="CD008846-sec-0003">Search methods</h3> <p>We searched several trial registries, citation databases, conference proceedings, and reference lists for relevant articles up to 11 February 2021. We also communicated with researchers to identify additional published and unpublished studies. </p> </section> <section id="CD008846-sec-0004"> <h3 class="title" id="CD008846-sec-0004">Selection criteria</h3> <p>Randomized controlled trials (RCTs) and non‐randomized studies comparing MDA to no MDA with balanced co‐interventions across study arms and at least two geographically distinct sites per study arm. </p> </section> <section id="CD008846-sec-0005"> <h3 class="title" id="CD008846-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed trials for eligibility and extracted data. We calculated relative risk (RR) and rate ratios with corresponding 95% confidence intervals (CIs) to compare prevalence and incidence, respectively, in MDA compared to no‐MDA groups. We stratified analyses by malaria transmission and by malaria species. For cluster‐randomized controlled trials (cRCTs), we adjusted standard errors using the intracluster correlation coefficient. We assessed the certainty of the evidence using the GRADE approach. For non‐randomized controlled before‐and‐after (CBA) studies, we summarized the data using difference‐in‐differences (DiD) analyses. </p> </section> <section id="CD008846-sec-0006"> <h3 class="title" id="CD008846-sec-0006">Main results</h3> <p>Thirteen studies met our criteria for inclusion. Ten were cRCTs and three were CBAs.</p> <p><b>Cluster‐randomized controlled trials</b> </p> <p><i>Moderate‐ to high‐endemicity areas (prevalence ≥ 10%)</i> </p> <p>We included data from two studies conducted in The Gambia and Zambia. </p> <p>At one to three months after MDA, the <i>Plasmodium falciparum</i> (hereafter, <i>P falciparum</i>) parasitaemia prevalence estimates may be higher compared to control but the CIs included no effect (RR 1.76, 95% CI 0.58 to 5.36; Zambia study; low‐certainty evidence); parasitaemia incidence was probably lower (RR 0.61, 95% CI 0.40 to 0.92; The Gambia study; moderate‐certainty evidence); and confirmed malaria illness incidence may be substantially lower,  but the CIs included no effect (rate ratio 0.41, 95% CI 0.04 to 4.42; Zambia study; low‐certainty evidence).  </p> <p>At four to six months after MDA, MDA showed little or no effect on <i>P falciparum</i> parasitaemia prevalence (RR 1.18, 95% CI 0.89 to 1.56; The Gambia study; moderate‐certainty evidence) and, no persisting effect was demonstrated with parasitaemia incidence (rate ratio 0.91, 95% CI 0.55 to 1.50; The Gambia study). </p> <p><i>Very low‐ to low‐endemicity</i> <i>areas (prevalence &lt; 10%)</i> </p> <p>Seven studies from Cambodia, Laos, Myanmar (two studies), Vietnam, Zambia, and Zanzibar evaluated the effects of multiple rounds of MDA on <i>P falciparum</i>. Immediately following MDA (less than one month after MDA), parasitaemia prevalence was reduced (RR 0.12, 95% CI 0.03 to 0.52; one study; low‐certainty evidence). At one to three months after MDA, there was a reduction in both parasitaemia incidence (rate ratio 0.37, 95% CI 0.21 to 0.55; 1 study; moderate‐certainty evidence) and prevalence (RR 0.25, 95% CI 0.15 to 0.41; 7 studies; low‐certainty evidence). For confirmed malaria incidence, absolute rates were low, and it is uncertain whether MDA had an effect on this outcome (rate ratio 0.58, 95% CI 0.12 to 2.73; 2 studies; very low‐certainty evidence).  </p> <p>For <i>P falciparum</i> prevalence, the relative differences declined over time, from RR 0.63 (95% CI 0.36 to 1.12; 4 studies) at four to six months after MDA, to RR 0.86 (95% CI 0.55 to 1.36; 5 studies) at 7 to 12 months after MDA. Longer‐term prevalence estimates showed overall low absolute risks, and relative effect estimates of the effect of MDA on prevalence varied from RR 0.82 (95% CI 0.20 to 3.34) at 13 to 18 months after MDA, to RR 1.25 (95% CI 0.25 to 6.31) at 31 to 36 months after MDA in one study. </p> <p>Five studies from Cambodia, Laos, Myanmar (2 studies), and Vietnam evaluated the effect of MDA on <i>Plasmodium vivax</i> (hereafter, <i>P vivax</i> ). One month following MDA, <i>P vivax</i>  prevalence was lower (RR 0.18, 95% CI 0.08 to 0.40; 1 study; low‐certainty evidence). At one to three months after MDA, there was a reduction in <i>P vivax</i>  prevalence (RR 0.15, 95% CI 0.10 to 0.24; 5 studies; low‐certainty evidence). The immediate reduction on <i>P vivax</i> prevalence was not sustained over time, from RR 0.78 (95% CI 0.63 to 0.95; 4 studies) at four to six months after MDA, to RR 1.12 (95% CI 0.94 to 1.32; 5 studies) at 7 to 12 months after MDA. One of the studies in Myanmar provided estimates of longer‐term effects, where overall absolute risks were low, ranging from RR 0.81 (95% CI 0.44 to 1.48) at 13 to 18 months after MDA, to RR 1.20 (95% CI 0.44 to 3.29) at 31 to 36 months after MDA. </p> <p><b>Non‐randomized studies</b> </p> <p>Three CBA studies were conducted in moderate‐ to high‐transmission areas in Burkina Faso, Kenya, and Nigeria. There was a reduction in <i>P falciparum</i> parasitaemia prevalence in MDA groups compared to control groups during MDA (DiD range: ‐15.8 to ‐61.4 percentage points), but the effect varied at one to three months after MDA (DiD range: 14.9 to ‐41.1 percentage points).  </p> </section> <section id="CD008846-sec-0007"> <h3 class="title" id="CD008846-sec-0007">Authors' conclusions</h3> <p>In moderate‐ to high‐transmission settings, no studies reported important effects on <i>P falciparum</i> parasitaemia prevalence within six months after MDA. In very low‐ to low‐transmission settings, parasitaemia prevalence and incidence were reduced initially for up to three months for both <i>P falciparum</i> and <i>P vivax</i>; longer‐term data did not demonstrate an effect after four months, but absolute risks in both intervention and control groups were low. No studies provided evidence of interruption of malaria transmission.  </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008846-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008846-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008846-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008846-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD008846-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD008846-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD008846-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD008846-abs-0007">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008846-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD008846-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008846-abs-0002" lang="en"> <h3>Administration of antimalarial drugs to whole populations for reducing malaria</h3> <p><b>What is mass drug administration (MDA) for malaria?</b> </p> <p>MDA for malaria consists of giving a full treatment course of antimalarial medicine (even to persons with no symptoms of malaria and regardless of whether malaria is present) to every member of a defined population or every person living in a defined geographical area (except to those for whom the medicine could be harmful) at approximately the same time and often at repeated intervals. </p> <p><b>How can MDA reduce malaria transmission in a population?</b> </p> <p>The life cycle of the malaria parasite consists of human liver, human blood, and mosquito stages. Malaria infection begins with the bite of an <i>Anopheles</i> species mosquito carrying the malaria parasite. During the bite, the infective mosquito injects the malaria parasite into the human host. After initially replicating in the liver, the parasites are released into the bloodstream. During the blood stage, parasites multiply in red blood cells, sometimes causing fever and other symptoms characteristic of malaria. Some of these parasites become a form which is infectious to mosquitoes. When the infected person is bitten again, the mosquito ingests blood containing the parasites, which then restarts the transmission cycle. </p> <p>MDA with antimalarial drugs temporarily prevents new and clears existing malaria infections in the population. Depending on the characteristics of the antimalarial drug used, MDA targets parasites at different stages, which can lead to reduced disease burden and transmission in the population. Whether MDA can successfully reduce or interrupt malaria transmission may depend on how much malaria there is in the area; the use of other tools to control malaria, including preventing mosquito bites; the proportion of the population who receive at least one round of MDA; population movement; and when MDA rounds occur in relation to the peak malaria transmission season. </p> <p><b>What was the aim of the review?</b> </p> <p>To guide policy‐making and future research for malaria control and elimination, the aim of this review was to update the evidence evaluating the effect of MDA compared to no MDA on malaria outcomes in moderate‐ to high‐transmission settings and very low‐ to low‐transmission settings. Our search of relevant published and unpublished literature identified 13 studies that met our inclusion criteria. </p> <p><b>What are the main findings of the review?</b> </p> <p>Malaria burden was compared in people receiving MDA and those who did not receive MDA, at different time points. The findings differed by malaria transmission setting. In areas with malaria prevalence of 10% or higher (moderate‐ to high‐transmission areas), based on one trial, MDA did not reduce malaria in the population (low‐certainty evidence). In areas with malaria prevalence under 10% (very low‐ to low‐endemicity areas), evidence from seven trials indicates that MDA reduced malaria in the population immediately after MDA has stopped (low‐certainty evidence), but we are uncertain if the decline continues long‐term because the number of malaria cases in both intervention and control groups were low (very low‐certainty evidence). </p> <p>In all settings of malaria transmission, the type of antimalarial drug used for MDA, co‐interventions such as mosquito control, coverage of MDA, and risk of re‐introduction may have an impact on the effect of MDA compared to no MDA. However, we were unable to explore these factors due to the limited number of studies. </p> <p><b>How up to date is the review?</b> </p> <p>We included studies available up to 11 February 2021.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008846-sec-0108" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008846-sec-0108"></div> <h3 class="title" id="CD008846-sec-0109">Implications for practice</h3> <section id="CD008846-sec-0109"> <p>In moderate‐ to high‐transmission settings, only two studies contributed data to assess the effect of MDA on outcomes. Based on results from a single trial, MDA probably reduces parasitaemia incidence, but does not reduce parasitaemia prevalence at one to three months after MDA. However, it is worth noting that there was a large overall reduction in parasitaemia prevalence in both the intervention and control arms from baseline to post‐MDA. The second trial showed no effect of a single round of MDA at four to six months after MDA. Given the absence of data in moderate‐ to high‐transmission settings at time points after six months, we were unable to determine the longer‐term effects of MDA on malaria transmission. </p> <p>In very low‐ to low‐transmission settings, MDA probably reduces <i>P falciparum</i> parasitaemia incidence at under one month, and <i>P falciparum</i> and <i>P vivax</i> prevalence at one to three months after MDA. The short‐ and long‐term effects of MDA on <i>P falciparum</i> and <i>P vivax</i> parasitaemia prevalence at time periods after four months is uncertain due to very low‐certainty evidence, but the immediate large reduction in parasitaemia prevalence is not sustained over time. Based on data provided in studies conducted in very low‐ to low‐transmission settings, we did not find evidence in any study of interruption of transmission as measured by a reduction to zero indigenous cases following MDA. </p> <p>Other variables, such as type of antimalarial drug, MDA coverage, number of rounds, and co‐interventions, may affect the impact of MDA on malaria outcomes and should be considered when conducting MDA. Additionally, the degree of population mobility and potential for importation of parasites also plays an important role in the effect of MDA. These considerations should be weighed carefully in recommendations surrounding MDA. </p> <p>Our findings in very low‐ to low‐transmission settings support the existing WHO Malaria Policy Advisory Committee's (MPAC) 2015 recommendations on the use of MDA in areas approaching elimination with high coverage of vector control and surveillance, good access to treatment, and limited risk of re‐introduction of infection (<a href="./references#CD008846-bbs2-0055" title="World Health Organization. The role of mass drug administration, mass screening and treatment, and focal screening and treatment for malaria; WHO; November 2015. Available at www.who.int/malaria/publications/atoz/role-of-mda-for-malaria.pdf?ua=1.">WHO 2015a</a>). These recommendations are currently being updated through a revised guideline development process at WHO (<a href="./references#CD008846-bbs2-0060" title="World Health Organization. Improving WHO's malaria policy-making and dissemination processes; WHO; July 2020. Available at www.who.int/malaria/policy/overview/en/.">WHO 2020b</a>). </p> </section> <h3 class="title" id="CD008846-sec-0110">Implications for research</h3> <section id="CD008846-sec-0110"> <p>Given the addition of several cRCTs since the publication of the previous review on this topic (<a href="./references#CD008846-bbs2-0062" title="PoirotE , SkarbinskiJ , SinclairD , KachurSP , SlutskerL , HwangJ . Mass drug administration for malaria. Cochrane Database of Systematic Reviews2013, Issue 12 10.1002/14651858.CD008846.pub2 10.1002/14651858.CD008846.pub2. Art. No: CD008846. [DOI: 10.1002/14651858.CD008846.pub2]">Poirot 2013</a>), this updated review provides additional information about MDA in the context of a renewed interest in MDA as a strategy to accelerate progress towards malaria elimination. Although several studies, conducted more recently in very low‐ to low‐endemicity settings, attempted to collect data on outcomes at longer time points following MDA, the certainty of the evidence on the sustained effect of MDA was very low due to high risk of bias and large imprecision. Although of higher certainty evidence compared to trials conducted in very low‐ to low‐endemicity settings, none of the included studies in moderate‐ to high‐endemicity settings measured the effect of MDA after four to six months. Future studies should measure the longer‐term effect of MDA and ensure that outcomes from a sufficient number and representative sample of participants are collected to obtain more precise estimates of effect. In relation to study design, cRCTs should be designed with a sufficient number of clusters to help to ensure that measured and unmeasured confounders are balanced across randomized arms, studies designed for interrupted time series analysis should include sufficient pre‐ and post‐intervention data to adequately capture seasonal malaria trends, and co‐interventions should be balanced across study arms. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008846-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008846-sec-0008"></div> <div class="table" id="CD008846-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">MDA compared to no MDA for Plasmodium falciparum malaria (moderate to high endemicity, short‐term follow‐up)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> People of all ages living in an area with moderate to high endemicity of <i>P falciparum</i> malaria (≥ 10% prevalence)<br/><b>Setting:</b> Moderate to high endemicity defined as ≥10% prevalence of <i>P falciparum</i><br/><b>Intervention:</b> MDA<br/><b>Comparison:</b> Control (no MDA or placebo) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no MDA</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with MDA</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Follow‐up: 1 to 3 months</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parasitaemia prevalence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 100<br/>(3 to 27) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.76<br/>(0.58 to 5.36) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>786<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b,c</sup> </p> <p>Due to imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 1‐3 months post‐MDA, parasite prevalence may increase in MDA compared no MDA. However, the effects vary and it is possible that MDA makes little or no difference on parasitaemia prevalence. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parasitaemia incidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>68 events per 100 person‐years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>42 events per 100 person‐years<br/>(27 to 63) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio 0.61<br/>(0.40 to 0.92) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>739<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a,b,d</sup> </p> <p>Due to imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 1‐3 months post‐MDA, there is probably a reduction in parasitaemia incidence in MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confirmed malaria illness incidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000 population</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000 population<br/>(1 to 122) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio 0.41<br/>(0.04 to 4.42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>144,422<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b,c</sup> </p> <p>Due to imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 1‐3 months post‐MDA, there may be a reduction in confirmed malaria illness incidence in MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Follow‐up: 4 to 6 months</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parasitaemia prevalence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>55 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>65 per 100<br/>(49 to 86) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.18<br/>(0.89 to 1.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1414<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a,b,d</sup> </p> <p>Due to imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 4‐6 months post‐MDA, there is probably little or no effect on parasitaemia prevalence in MDA compared to no MDA </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parasitaemia incidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>129 events per 100 person‐years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>118 events per 100 person‐years<br/>(71 to 194) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio 0.91<br/>(0.55 to 1.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1376<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a,b,d,e</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if MDA has an effect on parasitaemia incidence at 4‐6 months post‐MDA</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>cRCT:</b> cluster‐randomized controlled trial; <b>MDA:</b> mass drug administration; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Not downgraded for inconsistency; the comparison presented is reported from a single study.<br/><sup>b</sup>Not downgraded for indirectness; outcome was evaluated in all ages or assessed in children (considered the most appropriate population to measure malaria transmission in moderate‐ to high‐endemicity areas).<br/><sup>c</sup>Downgraded 2 levels for imprecision due to very wide CIs.<br/><sup>d</sup>Downgraded 1 level for imprecision due to wide CIs.<br/><sup>e</sup>Downgraded 2 levels for risk of bias since malaria cases in outcome were defined as fever plus parasitaemia &gt; 5000, which excludes all afebrile and low density infections and results in an underestimate of the outcome. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008846-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">MDA compared to no MDA for Plasmodium falciparum malaria (very low to low endemicity, short‐term follow‐up)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> People of all ages living in an area with very low to low endemicity of <i>P falciparum</i> malaria (&lt; 10% prevalence)<br/><b>Setting:</b> Very low to low endemicity defined as &lt; 10% prevalence of <i>P falciparum</i><br/><b>Intervention:</b> MDA<br/><b>Comparison:</b> Control (no MDA or placebo) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with MDA</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Follow‐up: &lt; 1 month</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parasitaemia prevalence<br/>follow up: range &lt; 1 month </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 100<br/>(0 to 6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.12<br/>(0.03 to 0.52) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1232<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a‐d</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At &lt; 1 month post‐MDA, there may a reduction in parasitaemia prevalence in MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Follow‐up: 1 to 3 months</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parasitaemia prevalence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 100</p> <p>(0 to 1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR: 0.25</p> <p>(0.15 to 0.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17,454<br/>(7 RCTs)<sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>e‐i</sup> </p> <p>Due to risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 1‐3 months post‐MDA, there may a reduction in parasitaemia prevalence in MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parasitaemia incidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 events per 100 person‐years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 events per 100 person‐years<br/>(3 to 10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio 0.37<br/>(0.21 to 0.66) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>736<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>b,d,,j</sup> </p> <p>Due to imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 1‐3 months post‐MDA, there is probably a reduction in parasitaemia incidence in MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confirmed malaria illness incidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000 population</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000 population<br/>(1 to 17) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio: 0.58</p> <p>(0.12 to 2.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130,651<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a,j‐l</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if MDA has an effect on confirmed malaria illness incidence at 1‐3 months post‐MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Follow‐up: 4 to 6 months</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parasitaemia prevalence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 100</p> <p>(2 to 6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR: 0.63</p> <p>(0.36 to 1.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5670</p> <p>(4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>c,d,f,l</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if MDA has an effect on parasitaemia prevalence at 4‐6 months post‐MDA compared to no MDA. </p> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confirmed malaria illness incidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000 population</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000 population<br/>(0 to 53) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio 0.93<br/>(0.07 to 12.43) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23,251<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a,b,k,l</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if MDA has an effect on confirmed malaria illness incidence at 4‐6 months post‐MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Follow‐up: 7 to 12 months</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parasitaemia prevalence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 100</p> <p>(3 to 6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR: 0.86</p> <p>(0.55 to 1.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7760</p> <p>(5 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>c,d,l,m</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if MDA has an effect on parasitaemia prevalence at 7‐12 months post‐MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confirmed malaria illness incidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000 population</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000 population (2 to 12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio 0.47</p> <p>(0.21 to 1.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26,576<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>d,f,j,l</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if MDA has an effect on confirmed malaria illness incidence at 7‐12 months post‐MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>cRCT:</b> cluster‐randomized controlled trial; <b>MDA:</b> mass drug administration; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded 1 level for risk of bias due to several criteria scored as high or unclear risk of bias.<br/><sup>b</sup>Not downgraded for inconsistency; the comparison presented is reported from a single study.<br/><sup>c</sup>Not downgraded for indirectness; all ages are at similar risk of malaria transmission, given the local epidemiology of malaria in this study setting and the outcomes were assessed by a highly sensitive diagnostic method (ultrasensitive PCR).<br/><sup>d</sup>Downgraded 1 level for imprecision due to wide CIs.<br/><sup>e</sup>Eight included studies reported parasitaemia prevalence during the 1‐3 month post‐MDA follow‐up period; however, one study did not contribute data in the meta‐analysis due to no events at baseline before MDA or at any follow‐up time points.<br/><sup>f</sup>Downgraded 2 levels for risk of bias due to several criteria scored as high or unclear risk of bias, including baseline imbalance and high risk of contamination in several studies.<br/><sup>g</sup>Not downgraded for inconsistency based on I<sup>2</sup> statistic; however, reasons for heterogeneity explored in post‐hoc sub‐group analysis by continent (sub‐Saharan Africa and Southeast Asia; <a href="./references#CD008846-fig-0014" title="">Analysis 4.1</a>).<br/><sup>h</sup>Not downgraded for indirectness; all ages are at similar risk of malaria transmission, given the local epidemiology of malaria in this study setting so there is no concern with assessing this outcome in different age groups across studies.<br/><sup>i</sup>Not downgraded for imprecision due to appreciable benefit of pooled effect as reported by seven studies.<br/><sup>j</sup>Not downgraded for indirectness since outcome was assessed in all ages and by routine detection methods.<br/><sup>k</sup>Downgraded 2 levels for imprecision due to very wide CIs.<br/><sup>l</sup>Not downgraded for inconsistency based on I<sup>2</sup> statistic.<br/><sup>m</sup>Downgraded 2 levels for risk of bias due to several criteria scored as high or unclear risk of bias, including baseline imbalance, high risk of contamination, and a large unexplained increase in sampled population in the MDA group at this time point.<br/>  </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008846-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">MDA compared to no MDA for Plasmodium falciparum malaria (very low to low endemicity, long‐term follow‐up)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> People of all ages living in an area with very low to low endemicity of <i>P falciparum</i> malaria ( &lt; 10% prevalence)<br/><b>Setting:</b> Very low to low endemicity defined as &lt; 10% prevalence of <i>P falciparum</i><br/><b>Intervention:</b> MDA<br/><b>Comparison:</b> Control (no MDA or placebo) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with MDA</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Follow‐up: 13 to 18 months</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parasitaemia prevalence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 100<br/>(1 to 14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.82<br/>(0.20 to 3.34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1537<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a‐d</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if MDA has an effect on parasitaemia prevalence at 13‐18 months post‐MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confirmed malaria illness incidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000 population</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000 population<br/>(3 to 51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio 0.77<br/>(0.20 to 3.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23,251<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>b,d‐f</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if MDA has an effect on confirmed malaria illness incidence at 13‐18 months post‐MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Follow‐up: 19 to 24 months</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parasitaemia prevalence<br/>follow‐up: range 19 to 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 100<br/>(0 to 6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.34<br/>(0.06 to 1.97) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1393<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a‐d</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if MDA has an effect on parasitaemia prevalence at 19‐24 months post‐MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Follow‐up: 25 months and above</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parasitaemia prevalence<br/>follow‐up: range 25 to 30 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 100<br/>(1 to 12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.89<br/>(0.22 to 3.62) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1521<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a‐d</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if MDA has an effect on parasitaemia prevalence at 25‐30 months post‐MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parasitaemia prevalence<br/>follow‐up: range 31 to 36 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 100<br/>(1 to 19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.25<br/>(0.25 to 6.31) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1679<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a‐d</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if MDA has an effect on parasitaemia prevalence at 31‐36 months post‐MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>cRCT:</b> cluster‐randomized controlled trial; <b>MDA:</b> mass drug administration; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded 2 levels for risk of bias due to several criteria scored as high or unclear risk of bias, including baseline imbalance, high risk of contamination, and a large unexplained increase in sampled population in the MDA group at this time point.<br/><sup>b</sup>Not downgraded for inconsistency; the comparison presented is reported from a single study.<br/><sup>c</sup>Not downgraded for indirectness; all ages are at similar risk of malaria transmission, given the local epidemiology of malaria in this study setting and the outcomes were assessed by a highly sensitive diagnostic method (ultrasensitive PCR).<br/><sup>d</sup>Downgraded 2 levels for imprecision due to very wide CIs.<br/><sup>e</sup>Downgraded 1 level for risk of bias due to several criteria scored as high or unclear risk of bias.<br/><sup>f</sup>Not downgraded for indirectness since outcome was assessed in all ages and by routine detection methods. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008846-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">MDA compared to no MDA for P vivax malaria (very low to low endemicity, short‐term follow‐up)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> People of all ages living in an area with very low to low endemicity of <i>P vivax</i> malaria (&lt; 10% prevalence)<br/><b>Setting:</b> Very low to low endemicity defined as &lt; 10% prevalence of <i>P vivax</i><br/><b>Intervention:</b> MDA<br/><b>Comparison:</b> Control (no MDA or placebo) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with MDA</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Follow‐up: &lt; 1 month</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parasitaemia prevalence<br/>follow up: range &lt; 1 month </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 100<br/>(2 to 11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.18<br/>(0.08 to 0.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1232<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a‐d</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At &lt; 1 month post‐MDA, there may a reduction in parasitaemia prevalence in MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Follow‐up: 1 to 3 months</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parasitaemia prevalence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 100</p> <p>(1 to 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR: 0.15</p> <p>(0.10 to 0.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6896</p> <p>(5 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>c,e‐g</sup> </p> <p>Due to risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 1‐3 months post‐MDA, there may a reduction in parasitaemia prevalence in MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Follow‐up: 4 to 6 months</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parasitaemia prevalence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 100</p> <p>(7 to 10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR: 0.78</p> <p>(0.63 to 0.95)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5670</p> <p>(4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>c,d,f,h</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if MDA reduces parasitaemia prevalence at 4‐6 months post‐MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Follow‐up: 7 to 12 months</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parasitaemia prevalence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 100</p> <p>(9 to 13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR: 1.12</p> <p>(0.94 to 1.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7760</p> <p>(5 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>c,d,h,i</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if MDA has an effect on parasitaemia prevalence at 7‐12 months post‐MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confirmed malaria illness incidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41 per 1000 population</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>57 per 1000 population (40 to 80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio: 1.38</p> <p>(0.97 to 1.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3325</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>d,f,h,j</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if MDA has an effect on confirmed malaria illness incidence at 7‐12 months post‐MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>cRCT:</b> cluster‐randomized controlled trial; <b>MDA:</b> mass drug administration; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded 1 level for risk of bias due to several criteria scored as high or unclear risk of bias.<br/><sup>b</sup>Not downgraded for inconsistency; the comparison presented is reported from a single study.<br/><sup>c</sup>Not downgraded for indirectness; all ages are at similar risk of malaria transmission, given the local epidemiology of malaria in this study setting and the outcomes were assessed by a highly sensitive diagnostic method (ultrasensitive PCR).<br/><sup>d</sup>Downgraded 1 level for imprecision due to wide CIs.<br/><sup>e</sup>Not downgraded for imprecision due to appreciable benefit of pooled effect as reported by five studies.<br/><sup>f</sup>Downgraded 2 levels for risk of bias due to several criteria scored as high or unclear risk of bias, including baseline imbalance and high risk of contamination.<br/><sup>g</sup>Not downgraded for inconsistency despite the large value of the I<sup>2</sup> statistic since the direction of effect was consistent with large imprecision.<br/><sup>h</sup>Not downgraded for inconsistency based on I<sup>2</sup> statistic.<br/><sup>i</sup>Downgraded 2 levels for risk of bias due to several criteria scored as high or unclear risk of bias, including a large unexplained increase in sampled population in the MDA group at this time point.<br/><sup>j</sup>Not downgraded for indirectness since outcome was assessed in all ages and by routine detection methods. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD008846-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">MDA compared to no MDA for P vivax malaria (very low to low endemicity, long‐term follow‐up)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> People of all ages living in an area with very low to low endemicity of <i>P vivax</i> malaria (&lt; 10% prevalence)<br/><b>Setting:</b> Very low to low endemicity &lt; 10% prevalence of <i>P vivax</i><br/><b>Intervention:</b> MDA<br/><b>Comparison:</b> Control (no MDA or placebo) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with MDA</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Follow‐up: 13 to 18 months</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parasitaemia prevalence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 100<br/>(8 to 25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.81<br/>(0.44 to 1.48) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1537<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a‐d</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if MDA reduces parasitaemia prevalence at 13‐18 months post‐MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Follow‐up: 19 to 24 months</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parasitaemia prevalence<br/>follow‐up: range 19 to 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 100<br/>(4 to 20) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.84<br/>(0.38 to 1.83) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1393<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a‐d</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if MDA reduces parasitaemia prevalence at 19‐24 months post‐MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Follow‐up: 25 months and above</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parasitaemia prevalence<br/>follow‐up: range 25 to 30 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 100<br/>(4 to 21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.89<br/>(0.41 to 1.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1521<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a‐d</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if MDA reduces parasitaemia prevalence at 25‐30 months post‐MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parasitaemia prevalence<br/>follow‐up: range 31 to 36 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 100<br/>(3 to 20) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.20<br/>(0.44 to 3.29) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1679<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a‐c,e</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if MDA reduces parasitaemia prevalence at 31‐36 months post‐MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>cRCT:</b> cluster‐randomized controlled trial; <b>MDA:</b> mass drug administration; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded 2 levels for risk of bias due to several criteria scored as high or unclear risk of bias, including a large unexplained increase in sampled population in the MDA group at this time point.<br/><sup>b</sup>Not downgraded for inconsistency; the comparison presented is reported from a single study.<br/><sup>c</sup>Not downgraded for indirectness; all ages are at similar risk of malaria transmission, given the local epidemiology of malaria in this study setting and the outcomes were assessed by a highly sensitive diagnostic method (ultrasensitive PCR).<br/><sup>d</sup>Downgraded 1 level for imprecision due to wide CIs.<br/><sup>e</sup>Downgraded 2 levels for imprecision due to very wide CIs. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008846-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008846-sec-0009"></div> <section id="CD008846-sec-0010"> <h3 class="title" id="CD008846-sec-0010">Description of the condition</h3> <p>Malaria remains a leading cause of morbidity and mortality, and was responsible for an estimated 229 million clinical cases and 409,000 deaths in 2019, mostly in children under five years of age living in sub‐Saharan Africa. Malaria is a parasitic disease that is transmitted to humans by the bite of a female <i>Anopheles</i> species mosquito. Among the four <i>Plasmodium</i> species of human malaria (<i>P falciparum</i> , <i>P vivax</i> , <i>P ovale</i> , and <i>P malariae</i> ), <i>P falciparum</i> and <i>P vivax</i> cause the largest number of malaria cases, while <i>P falciparum </i>is responsible for a majority of severe and fatal infections. Without effective treatment, malaria may manifest with severe complications and lead to death (<a href="./references#CD008846-bbs2-0059" title="World Health Organization. World malaria report 2020: 20 years of global progress and challenges; WHO; 2020. Available at www.who.int/publications/i/item/9789240015791.">WHO 2020a</a>). </p> <p>Since 2000, the global burden of malaria has been reduced considerably due to the expansion of effective malaria control strategies such as vector control and case management (<a href="./references#CD008846-bbs2-0031" title="BhattS , WeissDJ , CameronE , BisanzioD , MappinB , DalrympleU , et al. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature2015;526:207-11.">Bhatt 2015</a>; <a href="./references#CD008846-bbs2-0059" title="World Health Organization. World malaria report 2020: 20 years of global progress and challenges; WHO; 2020. Available at www.who.int/publications/i/item/9789240015791.">WHO 2020a</a>). Currently recommended vector control tools include the use of insecticide‐treated bed nets (ITNs), indoor residual spraying (IRS) with insecticides, and larval source management. Case management of malaria, which relies on the prompt diagnosis (parasitological confirmation) and administration of effective antimalarial treatment, has been enhanced by the use of rapid diagnostic tests (RDTs) and artemisinin‐based combination therapy (ACTs). Intermittent preventive treatment (IPT) with antimalarial drugs in certain high risk populations, such as pregnant women, children, and infants, is another key malaria control strategy. However, challenges in achieving and maintaining high levels of coverage with these proven interventions, as well as the emergence of insecticide resistance in mosquitos and antimalarial drug resistance in parasites, threaten the success of these interventions. Therefore, additional strategies must be considered to complement existing tools to accelerate progress towards malaria elimination. Recent World Malaria Reports from the World Health Organization (WHO) have noted a stagnation in reductions of malaria cases (<a href="./references#CD008846-bbs2-0059" title="World Health Organization. World malaria report 2020: 20 years of global progress and challenges; WHO; 2020. Available at www.who.int/publications/i/item/9789240015791.">WHO 2020a</a>). This finding underscores the need for continued evaluation and improved targeting of malaria control and elimination strategies to identify those activities that will have a positive impact on malaria transmission. </p> <p>In the past decade, there has been renewed interest in mass drug administration (MDA), which was a component of many malaria elimination programmes during the eradication era in the mid‐twentieth century. MDA has been used widely for controlling and eliminating the five most highly prevalent neglected tropical diseases (lymphatic filariasis, onchocerciasis, schistosomiasis, soil‐transmitted helminths, and trachoma) (<a href="./references#CD008846-bbs2-0043" title="HotezPJ . Mass drug administration and integrated control for the world's high-prevalence neglected tropical diseases. Clinical Pharmacology &amp; Therapeutics2009;85(6):659-64.">Hotez 2009</a>). However, the role of MDA for malaria has been less clear due to the fear of rapid emergence of antimalarial drug resistance and the varying success of the intervention in sustaining reductions in malaria burden and interrupting malaria transmission. A Cochrane Review found MDA to be effective in reducing malaria parasitaemia prevalence within one month following the intervention (<a href="./references#CD008846-bbs2-0062" title="PoirotE , SkarbinskiJ , SinclairD , KachurSP , SlutskerL , HwangJ . Mass drug administration for malaria. Cochrane Database of Systematic Reviews2013, Issue 12 10.1002/14651858.CD008846.pub2 10.1002/14651858.CD008846.pub2. Art. No: CD008846. [DOI: 10.1002/14651858.CD008846.pub2]">Poirot 2013</a>), but results on sustaining the impact four to six months after the intervention were mixed or the evidence was of low quality. Since the publication of the previous review, additional studies have been conducted to assess both the immediate‐ and longer‐term effects of MDA in low‐transmission and moderate‐ to high‐transmission settings. The additional evidence provides the opportunity to address gaps in knowledge surrounding MDA as a strategy to accelerate progress towards malaria elimination across transmission settings. </p> </section> <section id="CD008846-sec-0011"> <h3 class="title" id="CD008846-sec-0011">Description of the intervention</h3> <p>MDA for malaria consists of administering a full therapeutic course of antimalarial medicine (irrespective of the presence of symptoms or infection) to every member of a defined population or every person living in a defined geographical area (except to those for whom the medicine is contraindicated) at approximately the same time and often at repeated intervals. MDA for malaria is intended to reduce or interrupt transmission, curtail morbidity and mortality, or prevent reoccurrence and resulting malaria transmission (<a href="./references#CD008846-bbs2-0055" title="World Health Organization. The role of mass drug administration, mass screening and treatment, and focal screening and treatment for malaria; WHO; November 2015. Available at www.who.int/malaria/publications/atoz/role-of-mda-for-malaria.pdf?ua=1.">WHO 2015a</a>). </p> <p>Many early studies of MDA for malaria (dating back to the 1930s) observed a marked decrease in parasite prevalence following MDA, but often MDA did not result in interruption of transmission. Subsequent studies that evaluated MDA in conjunction with other malaria control tools, including the Garki Project conducted in 1969 in Northern Nigeria (<a href="./references#CD008846-bbs2-0047" title="MolineauxL , GramicciaG . The Garki Project: research on the epidemiology and control of malaria in the Sudan Savanna of West Africa; World Health Organization (WHO) 1980. Available at apps.who.int/iris/bitstream/handle/10665/40316/9241560614.pdf?sequence=1&amp;isAllowed=y.">Molineaux 1980</a>), often demonstrated substantial decreases in, but not interruption of, malaria transmission (<a href="./references#CD008846-bbs2-0039" title="GreenwoodB . The use of anti-malarial drugs to prevent malaria in the population of malaria-endemic areas. American Journal of Tropical Medicine and Hygiene2004;70(1):1-7.">Greenwood 2004</a>; <a href="./references#CD008846-bbs2-0054" title="vonSeidleinL , GreenwoodBM . Mass administration of antimalaria drugs. Trends in Parasitology2003;19(10):452-60.">von Seidlein 2003</a>). In Nicaragua, MDA was administered to approximately 8 million people in 1981 and resulted in marked immediate decline in malaria incidence, but rates eventually reverted back to those observed prior to MDA (<a href="./references#CD008846-bbs2-0037" title="GarfieldRM , VermundSH . Changes in malaria incidence after mass drug administration in Nicaragua. Lancet1983;2(8348):500-3.">Garfield 1983</a>). Notably, MDA in conjunction with ITNs on Aneityum Island, Vanuatu in 1991 was an exception, and interruption of transmission was achieved following eight rounds of MDA with chloroquine, sulfadoxine‐pyrimethamine, and primaquine (<a href="./references#CD008846-bbs2-0022" title="KanekoA , ChanC , IsozumiR , KalkoaM , ChavesLF , WatanabeN , et al. Sustainable malaria elimination on Aneityum Island, Vanuatu, 1991-2014. American Journal of Tropical Medicine and Hygiene2014;91(5 Supplement 1):197. KanekoA , ChanC , TaleoG , WatanabeN , KalkoaM , IamarS , et al. Community-directed malaria freedom on Aneityum Island, Vanuatu, 1991-2014. Malaria Journal2014;13(Supplement 1):P50. KanekoA , TaleoG , KalkoaM , YamarS , KobayakawaT , BjorkmanA . Malaria eradication on islands. Lancet2000;356(9241):1560-4. ">Kaneko 2000 VUT</a>). On another island setting (Anjouan Island, Comoros), two rounds of MDA, with artemisinin‐piperaquine or artemisinin‐piperaquine with single low dose primaquine, were associated with a rapid 99% decrease in malaria cases (from 7362 before to 47 cases after MDA rounds) (<a href="./references#CD008846-bbs2-0016" title="DengC , HuangB , WangQ , WuW , ZhengS , ZhangH , et al. Large-scale artemisinin–piperaquine mass drug administration with or without primaquine dramatically reduces malaria in a highly endemic region of Africa. Clinical Infectious Diseases2018;67(11):1670-6. ">Deng 2018 COM</a>). More recently, the role of MDA to curb malaria morbidity and mortality in complex emergency settings was highlighted during the Ebola outbreak in West Africa (<a href="./references#CD008846-bbs2-0015" title="AregawiM , SmithSJ , Sillah-KanuM , SeppehJ , KamaraAR , WilliamsRO , et al. Impact of the mass drug administration for malaria in response to the Ebola outbreak in Sierra Leone. Malaria Journal2016;15:480. ">Aregawi 2016 SLE</a>; <a href="./references#CD008846-bbs2-0044" title="KuehneA , TiffanyE , LasryE , JanssensM , BesseC , OkontoC , et al. Impact and lessons learned from mass drug administrations of malaria chemoprevention during the Ebola outbreak in Monrovia, Liberia, 2014. PLoS One2016;11(8):e0161311. [DOI: 10.1371/journal.pone.0161311]">Kuehne 2016</a>). </p> </section> <section id="CD008846-sec-0012"> <h3 class="title" id="CD008846-sec-0012">How the intervention might work</h3> <p>MDA targets the human parasite reservoir through the administration of a curative antimalarial dose to the entire population, irrespective of symptoms or parasitaemia. MDA provides a prophylactic effect, whereby new infections are temporarily prevented, and a treatment effect, in which parasitaemia is cleared. Unlike case management, in which symptomatic cases are treated, MDA also targets asymptomatic malaria infections, that are believed to  contribute to ongoing malaria transmission (<a href="./references#CD008846-bbs2-0045" title="LindbladeKA , SteinhardtL , SamuelsA , KachurSP , SlutskerL . The silent threat: asymptomatic parasitemia and malaria transmission. Expert Review of Anti-infective Therapy2013;11(6):623-639.">Lindblade 2013</a>). Theoretically, in combination with high levels of vector control, clearing the human parasite reservoir could lead to an interruption of transmission in areas of low endemicity or a temporary decline in malaria burden in higher transmission settings. However, MDA effectiveness may be limited by factors such as antimalarial properties and operational considerations including population coverage, risk of re‐introduction, and timing. </p> <p>The <i>Plasmodium</i> parasite life cycle includes stages in humans (liver and blood) and mosquitoes. In particular, parasitic infections during the exo‐erythrocytic and erythrocytic cycles in humans have important implications for clinical illness, diagnosis, treatment, and prevention. Once <i>Plasmodium</i> sporozoites are injected by mosquitoes in a human host, parasites invade and multiply in liver cells, leading to hepatocytic rupture and the release of parasites into the blood stream. <i>P vivax</i> and <i>P ovale</i> can persist in a dormant liver stage as hypnozoites, leading to relapsing erythrocytic stage infections months or years after initial infection. During the blood stage, asexual reproduction of merozoites in red blood cells results in a cycle of parasite maturation and erythrocytic destruction, triggering clinical symptoms such as fever, headache, and chills. Some parasites undergo sexual differentiation (gametocytes) in humans, which subsequently leads to malaria transmission once the gametocytes are ingested during a mosquito blood meal. </p> <p>The life cycle of the <i>Plasmodium</i> parasite offers numerous vulnerable stages that could be exploited in a MDA strategy to reduce disease burden and transmission. Most antimalarial drugs are effective schizonticides against asexual blood stage parasites and can eliminate blood stream infections and prevent illness, and may reduce the overall density of asexual parasites, leading to a decline in gametocyte density. Artemisinins and 8‐aminoquinolines (e.g. primaquine and tafenoquine) have gametocytocidal properties and act directly on circulating gametocytes. Primaquine has long been the only available drug with unique activity against mature gametocytes of <i>P falciparum</i> and the hypnozoite stage of <i>P vivax</i> and <i>P ovale</i> species, reducing the possibility of transmission and relapse (<a href="./references#CD008846-bbs2-0056" title="World Health Organization. Policy brief on single-dose primaquine as a gametocytocide in Plasmodium falciparum malaria; WHO; January 2015. Available at www.who.int/malaria/publications/atoz/who_htm_gmp_2015.1.pdf.">WHO 2015b</a>). Tafenoquine, another 8‐aminoquinoline, recently received regulatory approval for the radical cure of <i>P vivax</i> infections in persons older than 16 years (<a href="./references#CD008846-bbs2-0038" title="GlaxoSmithKline (GSK). Product label for Krintafel; patient information approved by the US Food and Drug Administration; July 2018. Available at www.accessdata.fda.gov/drugsatfda_docs/label/2018/210795s000lbl.pdf.">GlaxoSmithKline 2018</a>). The addition of ivermectin, or other endectocides, could potentially reduce malaria transmission by shortening the lifespan of mosquitos, thus preventing parasite development in the mosquito. Although ivermectin is not an antimalarial drug, it is often used to control other parasitic infections in malaria‐endemic settings and the effect of MDA with ivermectin on malaria transmission has been summarized in a separate Cochrane Review (<a href="./references#CD008846-bbs2-0033" title="ChaccourC , LinesJ , WhittyCJ . Effect of ivermectin on Anopheles gambiae mosquitoes fed on humans: the potential of oral insecticides in malaria control. Journal of Infectious Diseases2010;202(1):113-6.">Chaccour 2010</a>; <a href="https://archie.cochrane.org/sections/documents/view?version=z1804041254118737456603428211825&amp;format=REVMAN_GRAPHS#REF-Tesh-1990" target="_blank">Tesh 1990</a>; <a href="./references#CD008846-bbs2-0034" title="de Souza DK, Thomas R, Bradley J, Leyrat C, Boakye DA, Okebe J. Ivermectin treatment in humans for reducing malaria transmission. Cochrane Database of Systematic Reviews2021, Issue 6. Art. No: CD013117. [DOI: 10.1002/14651858.CD013117.pub2]">de Souza 2021</a>). </p> <p>Operationally, high levels of MDA coverage may not be achieved since a proportion of the population may be excluded from MDA due to contraindications to antimalarials or health conditions, absence during treatment rounds, or refusal. Although conducting multiple rounds of MDA can improve intervention coverage, the same people are often repeatedly excluded from MDA rounds, which reduces the effective coverage, or the proportion of the population receiving at least one round of MDA. High rates of population movement or migration also pose a challenge by increasing the risk of re‐introduction. Additionally, mathematical modelling has provided insights into the optimal timing in which rounds should take place in relation to the malaria transmission season. Implementation of MDA prior to the rainy season has been shown to have the greatest effect, due to widespread parasite clearance just prior to the high transmission season (<a href="./references#CD008846-bbs2-0032" title="BradyOJ , SlaterHC , Pemberton-RossP , WengerE , MaudeRJ , GhaniAC , et al. Role of mass drug administration in elimination of Plasmodium falciparum malaria: a consensus modelling study. Lancet Global Health2017;5(7):e680-7.">Brady 2017</a>; <a href="./references#CD008846-bbs2-0049" title="OkellLC , GriffinJT , KleinschmidtI , HollingsworthTD , ChurcherTS , WhiteMJ , et al. The potential contribution of mass treatment to the control of Plasmodium falciparum malaria. PLoS ONE2011;6(5):1-11.">Okell 2011</a>). </p> </section> <section id="CD008846-sec-0013"> <h3 class="title" id="CD008846-sec-0013">Why it is important to do this review</h3> <p>Despite unprecedented success in malaria control, progress has stalled in recent years (<a href="./references#CD008846-bbs2-0029" title="AlonsoP , EngelsD , ReederJ . Renewed push to strengthen vector control globally. Lancet2017;389(10086):2270-1.">Alonso 2017</a>). In addition to increased financial and political commitment, technical and operational strategies are needed to accelerate progress towards malaria elimination. Given the variable success of MDA, more recent studies have been conducted with consideration of transmission setting, seasonality of malaria, duration of intervention, MDA coverage, antimalarials with longer prophylactic action, and measurement of longer‐term effects. Recent mathematical models have suggested that malaria reduction following MDA is more likely to be sustained in lower transmission settings compared to higher, in conjunction with vector control interventions, and when the intervention is continued over two years compared to one (<a href="./references#CD008846-bbs2-0032" title="BradyOJ , SlaterHC , Pemberton-RossP , WengerE , MaudeRJ , GhaniAC , et al. Role of mass drug administration in elimination of Plasmodium falciparum malaria: a consensus modelling study. Lancet Global Health2017;5(7):e680-7.">Brady 2017</a>; <a href="./references#CD008846-bbs2-0049" title="OkellLC , GriffinJT , KleinschmidtI , HollingsworthTD , ChurcherTS , WhiteMJ , et al. The potential contribution of mass treatment to the control of Plasmodium falciparum malaria. PLoS ONE2011;6(5):1-11.">Okell 2011</a>). Additionally, there has been recent debate within the malaria community on the role of MDA in malaria elimination (<a href="./references#CD008846-bbs2-0036" title="Eisele, TP. Mass drug administration can be a valuable addition to the malaria elimination toolbox. Malaria Journal2019;18:281.">Eisele 2019</a>; <a href="./references#CD008846-bbs2-0046" title="MendisK . Mass drug administration should be implemented as a tool to accelerate elimination: against. Malaria Journal2019;18:279.">Mendis 2019</a>). </p> <p>Currently, the WHO recommends the use of MDA for <i>P falciparum</i> in areas approaching elimination, for the elimination of <i>P falciparum</i> in areas of multidrug resistance in the Greater Mekong subregion, epidemics, and complex emergency settings (<a href="./references#CD008846-bbs2-0055" title="World Health Organization. The role of mass drug administration, mass screening and treatment, and focal screening and treatment for malaria; WHO; November 2015. Available at www.who.int/malaria/publications/atoz/role-of-mda-for-malaria.pdf?ua=1.">WHO 2015a</a>). At the time the recommendations were released (2015), insufficient evidence was available to provide guidance on the use of MDA for <i>P vivax</i> , or for the use of MDA for <i>P falciparum</i> in areas of moderate to high transmission. However, use of MDA could be considered in areas approaching interruption of transmission of <i>P falciparum</i> with good coverage of vector control, implementation of surveillance, access to treatment, and minimal risk of re‐introduction of infection. Since the publication of the previous Cochrane Review (<a href="./references#CD008846-bbs2-0062" title="PoirotE , SkarbinskiJ , SinclairD , KachurSP , SlutskerL , HwangJ . Mass drug administration for malaria. Cochrane Database of Systematic Reviews2013, Issue 12 10.1002/14651858.CD008846.pub2 10.1002/14651858.CD008846.pub2. Art. No: CD008846. [DOI: 10.1002/14651858.CD008846.pub2]">Poirot 2013</a>), and the release of the WHO guidelines, additional studies have been conducted in both very low‐ to low‐transmission settings and moderate‐ to high‐transmission settings, including both <i>P falciparum</i> and <i>P vivax</i>. Due to renewed interest in MDA as a strategy to accelerate progress towards malaria elimination, an update to the previous review to address whether MDA provides sustained impact in very low‐ to low‐transmission settings and moderate‐ to high‐transmission settings will provide evidence to evaluate the appropriateness of existing recommendations, guide future policies, highlight current knowledge gaps, and direct future research. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008846-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008846-sec-0014"></div> <section id="CD008846-sec-0015"> <h3 class="title" id="CD008846-sec-0015">Primary objectives</h3> <p>To assess the sustained effect of mass drug administration (MDA) with antimalarial drugs on: </p> <p> <ul id="CD008846-list-0001"> <li> <p>the reduction in malaria transmission in moderate‐ to high‐transmission settings;</p> </li> <li> <p>the interruption of transmission in very low‐ to low‐transmission settings.</p> </li> </ul> </p> </section> <section id="CD008846-sec-0016"> <h3 class="title" id="CD008846-sec-0016">Secondary objective</h3> <p>To summarize the risk of drug‐associated adverse effects following MDA.</p> </section> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008846-sec-0017" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008846-sec-0017"></div> <section id="CD008846-sec-0018"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008846-sec-0019"> <h4 class="title">Types of studies</h4> <p>We considered the following study designs.</p> <p> <ul id="CD008846-list-0002"> <li> <p>Randomized controlled trials (RCTs) with: (a) the unit of randomization being a cluster, and (b) at least two clusters per arm. </p> </li> <li> <p>Randomized cross‐over trials with: (a) the unit of randomization being a cluster, (b) at least two clusters per arm, and (c) a suitable washout period during which the intervention is no longer applied. </p> </li> <li> <p>Quasi‐experimental designs, including stepped wedge where sites are randomly allocated.</p> </li> <li> <p>Non‐randomized controlled before‐and‐after studies (CBAs) with: (a) a contemporaneous control group, and (b) at least two sites per arm. </p> </li> <li> <p>Interrupted time series (ITS) studies with: (a) a clearly defined point in time when the intervention occurred, and (b) at least three data points collected over one year both before and after MDA. </p> </li> </ul> </p> <p>We excluded studies if we observed any of the following.</p> <p> <ul id="CD008846-list-0003"> <li> <p>The follow‐up periods for the intervention and control periods were not identical.</p> </li> <li> <p>The intervention was applied at the individual level.</p> </li> <li> <p>There was no control arm for RCTs or CBAs, or insufficient pre‐ or post‐intervention data points for ITS. </p> </li> </ul> </p> </section> <section id="CD008846-sec-0020"> <h4 class="title">Types of participants</h4> <p>Children and adults living in areas of any malaria endemicities were included and analysed by transmission setting according to the objectives. Due to the nature of the intervention, we included only studies that were carried out on entire populations at the same time. We excluded studies in which chemoprevention was delivered in the form of individually‐timed, intermittent, preventive treatment in sub‐populations (i.e. pregnant women, children or infants) or seasonal malaria chemoprevention. We did not exclude studies in special groups (i.e. refugees and soldiers), but none of these met eligibility criteria. </p> </section> <section id="CD008846-sec-0021"> <h4 class="title">Types of interventions</h4> <section id="CD008846-sec-0022"> <h5 class="title">Intervention</h5> <p>For the purpose of this review, we defined MDA as the direct administration of a full therapeutic course of antimalarial medicine (irrespective of the presence of symptoms or infection) to every member of a defined population or every person living in a defined geographical area (except for those for whom the medicine was contraindicated) at approximately the same time and often at repeated intervals. We included only studies that provided doses of antimalarials intended for curative purposes. </p> </section> <section id="CD008846-sec-0023"> <h5 class="title">Control</h5> <p>We included studies in which all other malaria and non‐malaria co‐interventions were balanced in all arms. These included the use of ITNs, IRS, source reduction activities, environmental management, mass drug campaigns for other neglected tropical diseases, and mass nutritional supplementation activities such as vitamin A distribution. </p> </section> </section> <section id="CD008846-sec-0024"> <h4 class="title">Types of outcome measures</h4> <p>Studies must have reported at least one primary outcome for inclusion.</p> <section id="CD008846-sec-0025"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD008846-list-0004"> <li> <p>Parasitaemia prevalence, as measured by microscopy, malaria RDT, or molecular method, such as polymerase chain reaction (PCR). </p> </li> <li> <p>Parasitaemia incidence (e.g. incidence of infection through active surveillance as measured in a cohort). </p> </li> <li> <p>Confirmed malaria illness incidence, defined as febrile illness with diagnostically confirmed parasitaemia (<a href="./references#CD008846-bbs2-0057" title='World Health Organization. Annex 1. Defining the term "malaria case"; WHO Malaria Policy Advisory Committee Meeting; August 2015. Available at www.who.int/malaria/mpac/mpac-sept2015-terminology-annex1.pdf?ua=1.'>WHO 2015c</a>) (e.g. incidence of confirmed clinical infection as measured in passive or routine surveillance data collected at health facilities). </p> </li> </ul> </p> </section> <section id="CD008846-sec-0026"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD008846-list-0005"> <li> <p>All‐cause and malaria‐specific mortality.</p> </li> <li> <p>Gametocytaemia prevalence, as measured by microscopy or molecular method.</p> </li> <li> <p>Known adverse effects related to MDA drugs using WHO definitions (<a href="./references#CD008846-bbs2-0035" title="EdwardsIR , AronsonJK . Adverse drug reactions: definitions, diagnosis, and management. Lancet2000;356(9237):1255-9.">Edwards 2000</a>). </p> </li> </ul> </p> </section> </section> </section> <section id="CD008846-sec-0027"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD008846-sec-0028"> <h4 class="title">Electronic searches</h4> <section id="CD008846-sec-0029"> <h5 class="title">Search strategy for identification of studies</h5> <p>We attempted to identify all relevant studies regardless of language or publication status (published, unpublished, in press, ongoing). </p> </section> <section id="CD008846-sec-0030"> <h5 class="title">Databases</h5> <p>We searched the following databases on 11 February 2021, using the search terms and strategy described in <a href="./appendices#CD008846-sec-0114">Appendix 1</a>. </p> <p> <ul id="CD008846-list-0006"> <li> <p>Cochrane Infectious Diseases Group Specialized Register (searched 11 February 2021).</p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL), published in the Cochrane Library (Issue 2 of 12, February 2021). </p> </li> <li> <p>MEDLINE (PubMed; 1966 to 11 February 2021).</p> </li> <li> <p>Embase (Ovid; 1947 to 11 February 2021).</p> </li> <li> <p>LILACS (Latin American and Caribbean Health Science Information database, BIREME; 1982 to 11 February 2021). </p> </li> </ul> </p> <p>We also searched the WHO International Clinical Trials Registry Platform (ICTRP; <a href="http://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp/en/</a>) and ClinicalTrials.gov (<a href="https://clinicaltrials.gov/ct2/home" target="_blank">clinicaltrials.gov/ct2/home</a>) for trials in progress, using 'malaria' and 'mass drug administration' as search terms. </p> </section> </section> <section id="CD008846-sec-0031"> <h4 class="title">Searching other resources</h4> <section id="CD008846-sec-0032"> <h5 class="title">Reference lists </h5> <p>We checked the reference lists of all studies and articles identified by the above methods and of previously published reviews, as well as references listed in review articles (<a href="./references#CD008846-bbs2-0039" title="GreenwoodB . The use of anti-malarial drugs to prevent malaria in the population of malaria-endemic areas. American Journal of Tropical Medicine and Hygiene2004;70(1):1-7.">Greenwood 2004</a>; <a href="./references#CD008846-bbs2-0048" title="NewbyG , HwangJ , KoitaK , ChenI , GreenwoodB , vonSeidleinL , et al. Review of mass drug administration for malaria and its operational challenges. American Journal of Tropical Medicine and Hygiene2015;93(1):125-134.">Newby 2015</a>; <a href="./references#CD008846-bbs2-0062" title="PoirotE , SkarbinskiJ , SinclairD , KachurSP , SlutskerL , HwangJ . Mass drug administration for malaria. Cochrane Database of Systematic Reviews2013, Issue 12 10.1002/14651858.CD008846.pub2 10.1002/14651858.CD008846.pub2. Art. No: CD008846. [DOI: 10.1002/14651858.CD008846.pub2]">Poirot 2013</a>; <a href="./references#CD008846-bbs2-0053" title="ShanksGD . Control and elimination of Plasmodium vivax. Advances in Parasitology2012;80:301-41.">Shanks 2012</a>; <a href="./references#CD008846-bbs2-0054" title="vonSeidleinL , GreenwoodBM . Mass administration of antimalaria drugs. Trends in Parasitology2003;19(10):452-60.">von Seidlein 2003</a>). </p> </section> <section id="CD008846-sec-0033"> <h5 class="title">Conference proceedings</h5> <p>We searched the following recent proceedings for relevant abstracts.</p> <p> <ul id="CD008846-list-0007"> <li> <p>Sixth Multilateral Initiative on Malaria Pan‐African Malaria Conference (Durban, South Africa; October 2013). </p> </li> <li> <p>American Society of Tropical Medicine and Hygiene (ASTMH) 62nd Annual Meeting (Washington, DC, USA; November 2013). </p> </li> <li> <p>ASTMH 63rd Annual Meeting (New Orleans, LA, USA; November 2014).</p> </li> <li> <p>ASTMH 64th Annual Meeting (Philadelphia, PA, USA; October 2015).</p> </li> <li> <p>ASTMH 65th Annual Meeting (Atlanta, GA, USA; November 2016).</p> </li> <li> <p>ASTMH 66th Annual Meeting (Baltimore, MD, USA; November 2017).</p> </li> <li> <p>ASTMH 67th Annual Meeting (New Orleans, Louisiana, USA; October 2018).</p> </li> </ul> </p> </section> <section id="CD008846-sec-0034"> <h5 class="title">Researchers and organizations</h5> <p>In addition to the electronic searches described above, we reached out to the Malaria Elimination Initiative and other relevant groups to identify both published and unpublished studies that might be available from other sources. We also contacted the Malaria Eradication Research Agenda Consortium and the Bill and Melinda Gates Foundation. </p> </section> </section> </section> <section id="CD008846-sec-0035"> <h3 class="title" id="CD008846-sec-0035">Data collection and analysis</h3> <section id="CD008846-sec-0036"> <h4 class="title">Selection of studies</h4> <p>Two review authors (MPS and MD) independently assessed the titles and abstracts of trials identified by the literature searches. We obtained the full‐text versions of any potentially relevant articles identified by at least one of the review authors. The same two review authors assessed the full‐text articles of potentially relevant studies for inclusion, using an eligibility form based on predetermined inclusion criteria. We resolved any disagreements by discussion and consensus, with arbitration by a third review author (KAL) when necessary. We ensured that multiple publications of the same trial were included only once. We listed studies excluded after full‐text assessment, together with their reasons for exclusion, in the <a href="./references#CD008846-sec-0127" title="">Characteristics of excluded studies</a> table. We illustrated the study selection process using a Preferred Reporting Items of Systematic reviews and Meta‐Analyses (PRISMA) diagram. </p> </section> <section id="CD008846-sec-0037"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (MPS and MD) independently extracted information from the trials using pre‐piloted electronic data extraction forms. In case of differences in extracted data, the two review authors discussed these differences to reach consensus. If unresolved, further discussion involved a third review author (KAL). In case of missing data, we contacted the original study author(s) for clarification. </p> <p>We extracted the following data.</p> <p> <ul id="CD008846-list-0008"> <li> <p>Trial design: type of trial; method of participant selection; adjustment for clustering (for cRCTs); sample size; method of blinding of participants and personnel. </p> </li> <li> <p>Participants: trial settings (country, transmission season, endemicity, antimalarial drug resistance context, parasite and vector species of interest) and population characteristics; recruitment rates; withdrawal and loss to follow‐up. </p> </li> <li> <p>Intervention: MDA regimen, coverage, and timing (number of rounds/campaigns, years of implementation, and timing relative to transmission season). </p> </li> <li> <p>Outcomes: definition of outcome; diagnostic or surveillance method; number of events; number of participants or person time; time point at which outcome was assessed in relation to MDA; statistical power; unit of analysis; incomplete outcomes or missing data. </p> </li> </ul> </p> <p>For dichotomous data (parasitaemia prevalence and gametocytaemia prevalence), we extracted the number of participants experiencing each outcome and the number of participants in each treatment group. For count data (parasitaemia incidence, confirmed malaria illness incidence, and mortality), we extracted the number of events in the treatment and control groups, and the total person time at risk in each group or the rate ratio, and a measure of variance (for example, standard error). We did not extract any continuous data. </p> <p>For cRCTs, we recorded the number of clusters randomized, number of clusters analysed, and the intracluster correlation coefficient (ICC) value. </p> <p>For non‐randomized studies, there were no studies that reported adjusted measures of intervention effects, so we were unable to obtain an effect estimate that controlled for confounding. </p> <p>We included pre‐intervention data up to one year prior to the intervention. We included all post‐MDA data, and outcomes were reported according to designated time points of: less than 1 month, 1 to 3 months, 4 to 6 months, 7 to 12 months, 13 to 18 months, 19 to 24 months, 25 to 30 months, and 31 to 36 months after MDA. For studies with multiple rounds of MDA, we defined 'during MDA' as the intervention time period ‐ i.e. the time between the start of the first round and end of the last round of MDA ‐ and the 'post‐MDA' follow‐up period as the time following the last round of MDA. </p> </section> <section id="CD008846-sec-0038"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (MPS and MD) independently assessed the risk of bias for each included cluster‐RCT using the Cochrane risk of bias tool and the five additional criteria listed in Section 16.3.2 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> that relate specifically to cluster‐RCTs (<a href="./references#CD008846-bbs2-0041" title="HigginsJP , DeeksJJ , AltmanDG , on behalf of the Cochrane Statistical Methods Group. Chapter 16: Special topics in statistics. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011a</a>; <a href="./references#CD008846-bbs2-0042" title="HigginsJP , AltmanDG , GøtzschePC , JüniP , MoherD , OxmanAD , et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ2011;343:d5928.">Higgins 2011b</a>). We assessed non‐randomized controlled studies for risk of bias using the Cochrane Effective Practice and Organisation of Care (EPOC) risk of bias tool. We resolved any discrepancies through discussion or by consulting a third review author (KAL). We classified judgements of risk of bias as either at low, high, or unclear risk of bias, and we used summary graphs (risk of bias summary and risk of bias graph) to display results. </p> </section> <section id="CD008846-sec-0039"> <h4 class="title">Measures of treatment effect</h4> <p>We compared intervention and control groups by calculating risk ratios (RR) or rate ratios for incidence data. We presented all results with their corresponding 95% confidence intervals (CIs). At all time periods, a RR less than 1.0 indicates that parasitaemia prevalence was lower in the MDA compared to control arm, while a RR greater than 1.0 indicates that parasitaemia prevalence was higher in the MDA compared to control arm. Similarly, a rate ratio less than 1.0 can be interpreted as a lower rate of malaria infection (incidence) in the MDA compared to control arm, and a rate ratio greater than 1.0 reflects a higher malaria incidence measured in the MDA compared to control arm. </p> <p>For non‐randomized studies, since adjusted effect measures were not provided, we did not present a measure of treatment effect. Instead, we described the effect of MDA compared to no MDA using a difference‐in‐differences (DiD) analysis in which we calculated the difference in dichotomous outcomes between pre‐ and during‐MDA time periods, and pre‐ and post‐MDA time periods within intervention and control arms and then took the difference of those values between intervention and control groups. </p> </section> <section id="CD008846-sec-0040"> <h4 class="title">Unit of analysis issues</h4> <p>Since a variety of analytical methods were used to adjust for clustering in cRCTs, we extracted raw data and estimated effective sample sizes adjusted for clustering using either: (1) the study‐provided ICC (as indicated in the <a href="./references#CD008846-sec-0126" title="">Characteristics of included studies</a> tables), or, (2) for studies that did not report an ICC, an estimated ICC calculated as the average of other study‐provided ICCs in the same malaria transmission setting (0.02766 for areas of very low to low transmission, and 0.1225 for areas of moderate to high transmission). We only presented results from cRCTs that were adjusted for clustering. No cRCTs included multiple intervention arms so adjustment for multiple comparison in meta‐analysis was not required (<a href="./references#CD008846-bbs2-0052" title="RichardsonM , GarnerP , DoneganS . Cluster randomised trials in Cochrane Reviews: evaluation of methodological and reporting practice. PLoS One2016;11(3):e0151818. [DOI: 10.1371/journal.pone.0151818]">Richardson 2016</a>). </p> </section> <section id="CD008846-sec-0041"> <h4 class="title">Dealing with missing data</h4> <p>We attempted to contact study investigators to obtain missing data. We applied no imputation measures for working with missing data. </p> </section> <section id="CD008846-sec-0042"> <h4 class="title">Assessment of heterogeneity</h4> <p>We inspected forest plots for overlapping CIs and assessed statistical heterogeneity in each meta‐analysis using the I² statistic and Chi² test. We regarded heterogeneity as moderate if the I² statistic values were between 30% and 60%; substantial if they were between 50% and 90%; and considerable if they were between 75% and 100%. We regarded a Chi² test statistic with a P value of less than or equal to 0.10 as indicative of statistically significant heterogeneity. We explored clinical and methodological heterogeneity through consideration of the trial populations, methods, and interventions, and by visualization of trial results. </p> <p>If there was considerable heterogeneity (i.e. an I² statistic value of 75% to 100%) and inconsistency in the direction of the effect, then we did not perform a meta‐analysis. </p> </section> <section id="CD008846-sec-0043"> <h4 class="title">Assessment of reporting biases</h4> <p>Since there were fewer than 10 trials included in each meta‐analysis, we did not investigate reporting biases (such as publication bias) using funnel plots. </p> </section> <section id="CD008846-sec-0044"> <h4 class="title">Data synthesis</h4> <p>We analysed data using Review Manager 5 (RevMan 5) (<a href="./references#CD008846-bbs2-0051" title="Review Manager 5 (RevMan 5). Version 5.4.1. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 5</a>). We used a fixed‐effect meta‐analysis to combine data if heterogeneity was absent. We pooled estimates where considerable heterogeneity was present if the direction of effect was consistent. </p> <p>Malaria endemicity was classified as very low to low (prevalence of <i>P falciparum</i> or <i>P vivax</i> &lt; 10%), or moderate to high (≥ 10%) (<a href="./references#CD008846-bbs2-0058" title="World Health Organization. A framework for malaria elimination; WHO; March 2017. Available at apps.who.int/iris/bitstream/handle/10665/254761/9789241511988-eng.pdf?sequence=1.">WHO 2017</a>). Study‐specific endemicity was defined by baseline malaria prevalence by microscopy or RDT or annual parasite incidence in the control group, and preferentially using data from (1) children, or (2) all ages. If only molecular data were available, we used a tool developed by <a href="./references#CD008846-bbs2-0050" title="OkellLC , BousemaT , GriffinJT , OuédraogoAL , GhaniAC , DrakeleyCJ . Factors determining the occurrence of submicroscopic malaria infections and their relevance for control. Nature Communications2012;3:1237.">Okell 2012</a> to estimate microscopy prevalence from PCR data in the control group at baseline. </p> <p>For the main objective in moderate‐ to high‐transmission settings, we defined a reduction in malaria transmission as a 50% reduction in median malaria parasite prevalence or incidence, or both, at 12 months post‐intervention. For the main objective in very low‐ to low‐transmission settings, we considered interruption of transmission as a reduction in number of indigenous malaria infections to zero at six months post‐intervention. To evaluate both objectives, we stratified analyses by study design (i.e. cRCTs and non‐randomized controlled studies) and post‐intervention time periods (i.e. less than 1 month after MDA, 1 to 3 months, 4 to 6 months, 7 to 12 months, 13 to 18 months, 19 to 24 months, 25 to 30 months, and 31 to 36 months after MDA). For studies with data from multiple time points within the same post‐intervention time period (<a href="./references#CD008846-bbs2-0004" title="LandierJ , KajeechiwaL , ThwinMM , ParkerDM , ChaumeauV , WiladphaingernJ , et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar. Wellcome Open Research2017;2:81. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Landier 2017 MMRa</a>; <a href="./references#CD008846-bbs2-0008" title="PongvongsaT , PhommasoneK , AdhikariB , HenriquesG , ChotivanichK , HanboonkunupakarnB , et al. The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin-piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos. Malaria Journal2018;17(1):405. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Pongvongsa 2018 LAO</a>; <a href="./references#CD008846-bbs2-0011" title="TripuraR , PetoTJ , CheaN , ChanD , MukakaM , SirithiranontP , et al. A controlled trial of mass drug administration to interrupt transmission of multidrug-resistant falciparum malaria in Cambodian villages. Clinical Infectious Diseases2018;67(6):817-26. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Tripura 2018 KHM</a>; <a href="./references#CD008846-bbs2-0013" title="vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">von Seidlein 2019 VNM</a>), we used the latest time point for analysis for that category. We did not stratify studies by number of MDA rounds due to few studies after previous stratification. We only conducted a meta‐analysis if we identified a sufficient number of studies (&gt; 1) with both an outcome indicator estimate and a measure of precision. </p> </section> <section id="CD008846-sec-0045"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We stratified outcomes by malaria transmission setting (very low‐ to low‐transmission and moderate‐ to high‐transmission settings) and <i>Plasmodium</i> species (<i>P falciparum</i> or <i>P vivax</i> ). Given the few number of studies after stratification, we did not carry out subgroup analyses to explore causes of heterogeneity. However, for a single outcome where studies conducted in sub‐Saharan Africa and Southeast Asia were combined (<i>P falciparum</i> prevalence at one to three months after MDA in very low‐ to low‐endemicity settings), we carried out a supplementary post‐hoc subgroup analysis by continent (Africa and Asia), to consider whether the geographical differences in malaria epidemiology may explain heterogeneity in effect of MDA. </p> </section> <section id="CD008846-sec-0046"> <h4 class="title">Sensitivity analysis</h4> <p>Due to an insufficient number of studies, we did not perform sensitivity analyses on the primary outcomes to assess the effect of excluding trials at high risk of bias (for baseline imbalance and incomplete outcome data) on the overall results. We did not undertake sensitivity analyses to investigate the impact of varying the ICC value on meta‐analysis results since the ICC values were obtained directly from studies or applied from comparable studies. </p> </section> <section id="CD008846-sec-0047"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We assessed the certainty of evidence using the GRADE approach (<a href="./references#CD008846-bbs2-0040" title="GuyattGH , OxmanAD , SchunemannHJ , TugwellP , KnottnerusA . GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. Journal of Clinical Epidemiology2011;64(4):380-2.">Guyatt 2011</a>). We rated each important outcome as described by <a href="./references#CD008846-bbs2-0030" title="BalshemH , HelfandM , SchünemannHJ , OxmanAD , KunzR , BrozekJ , et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology2011;54(4):401-6.">Balshem 2011</a>. </p> <p> <ul id="CD008846-list-0009"> <li> <p>High: we are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p>Moderate: we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect. </p> </li> <li> <p>Low: our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p>Very low: we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> <p>RCTs started as high quality evidence but could be downgraded if there were valid reasons within the following five categories: risk of bias, imprecision, inconsistency, indirectness, and publication bias. We summarized our findings in a summary of findings table. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008846-sec-0048" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008846-sec-0048"></div> <section id="CD008846-sec-0049"> <h3 class="title">Description of studies</h3> <p>Detailed descriptions of included studies, excluded studies, studies awaiting classification, and ongoing studies are provided in the <a href="./references#CD008846-sec-0126" title="">Characteristics of included studies</a>, <a href="./references#CD008846-sec-0127" title="">Characteristics of excluded studies</a>, <a href="./references#CD008846-sec-0128" title="">Characteristics of studies awaiting classification</a>, and Characteristics of ongoing studies tables, respectively. </p> <section id="CD008846-sec-0050"> <h4 class="title">Results of the search</h4> <p>The last published version of this review included 32 studies: two cRCTs, eight non‐randomized trials, and 22 uncontrolled before‐and‐after studies (<a href="./references#CD008846-bbs2-0062" title="PoirotE , SkarbinskiJ , SinclairD , KachurSP , SlutskerL , HwangJ . Mass drug administration for malaria. Cochrane Database of Systematic Reviews2013, Issue 12 10.1002/14651858.CD008846.pub2 10.1002/14651858.CD008846.pub2. Art. No: CD008846. [DOI: 10.1002/14651858.CD008846.pub2]">Poirot 2013</a>). </p> <p>Following the revised inclusion criteria, which restricted the review to more rigorous study designs with a control group and balanced co‐interventions across study arms (described in detail in <a href="#CD008846-sec-0123">Differences between protocol and review</a>), the updated literature search (to 11 February 2021) identified 462 records. After de‐duplication and removal of studies excluded by the previous review's literature search in 2012, we screened 251 titles. Of those, we assessed 39 full‐text articles for study eligibility (<a href="#CD008846-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD008846-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD008846-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_n/nCD008846-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD008846-sec-0051"> <h4 class="title">Included studies</h4> <p>A total of 13 studies met the criteria for inclusion, comprising five studies included in the previous review (<a href="./references#CD008846-bbs2-0003" title="EscudieA , HamonJ , SchneiderJ . Results of mass antimalarial chemoprophylaxis with a combination of 4-aminoquinoline and 8-aminoquinoline under rural African conditions in the region of Bobo-Dioulasso (Upper Volta) 1960. Comparative study in a zone treated with DDT and outside this zone. Medecine Tropicale1962;22(2):268-305. SchneiderJ , EscudieA , HamonJ . Eradication of malaria and chemotherapy. Results obtained with the association amino-4 quinoline + amino-8 quinoline in the pilot area of Bobo-Dioulasso (Haute- Volta) [Eradication du paludismeet chimiotherapie resultats d’un essai de l’association:amino–4 quinoleine/amino–8 quinoleine dans la zonepilote de Bobo–Dioulasso (Haute Volta)]. Bulletin de la Societe de Pathologie Exotique1961;54(5):1012-25. ">Escudie 1962 BFA</a>; <a href="./references#CD008846-bbs2-0006" title="BroggerRC , MathewsHM , StoreyJ , AshkarTS , BroggerS , MolineauxL . Changing patterns in the humoral immune response to malaria before, during and after the application of control measures: a longitudinal study in the West African savanna. Bulletin of the World Health Organization1978;56(4):579-600. MolineauxL , BroggerRC , MathewsHM , StoreyJ , AshkarTS . Longitudinal serological study of malaria in infants in the West African savanna. Comparisons in infants exposed to, or protected from, transmission from birth. Bulletin of the World Health Organisation1978;56(4):573-8. MolineauxL , GramicciaG . The Garki Project. Research on the epidemiology and control of malaria in the Sudan Savanna of West Africa. 1980. https://apps.who.int/iris/handle/10665/40316 (accessed prior to 8 July 2021). MolineauxL , StoreyJ , CohenJE , ThomasA . A longitudinal study of human malaria in the West African savanna in the absence of control measures: relationships between different Plasmodium species, in particular P. falciparum and P. malariae. American Journal of Tropical Medicine and Hygiene1980;29(5):725-37. ">Molineaux 1980 NGA</a>; <a href="./references#CD008846-bbs2-0009" title="RobertsJM . Pyrimethamine (Daraprim) in the control of epidemic malaria. American Journal of Tropical Medicine and Hygiene1956;59(9):201-8. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part I. Before the campaign. American Journal of Tropical Medicine and Hygiene1964;67(7):161-8. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part II. The campaign. American Journal of Tropical Medicine and Hygiene1964;67(8):191-9. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part III. After the campaign. American Journal of Tropical Medicine and Hygiene1964;67(9):230-7. ">Roberts 1964 KEN</a>; <a href="./references#CD008846-bbs2-0010" title="ShekalagheSA , DrakeleyC , vanden BoschS , ter BraakR , vanden BikilaardtW , MwanzivaC , et al. A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania. Malaria Journal2011;10:247. ShekalagheSA , ter BraakR , DaouM , KavisheR , vanden BijilaardtW , vanden BoschS , et al. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A) individuals. Antimicrobial Agents and Chemotherapy2010;54(5):1762-8. ">Shekalaghe 2011 TZA</a>; <a href="./references#CD008846-bbs2-0012" title="De MartinS , vonSeidleinL , DeenJL , PinderM , WalravenG , GreenwoodB . Community perceptions of a mass administration of an antimalarial drug combination in The Gambia. Tropical Medicine &amp; International Health2001;6(6):442-8. vonSeidleinL , WalravenG , MilliganPJ , AlexanderN , MannehF , DeenJL , et al. The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia. Transactions of the Royal Society of Tropical Medicine &amp; Hygiene2003;97(2):217-25. ">von Seidlein 2003 GMB</a>), and eight new studies (<a href="./references#CD008846-bbs2-0001" title="BennettA , PorterTR ,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C, et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in Southern Province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in Southern Province, Zambia: An evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. [DOI: 10.1186/s13063-015-0862-3]MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBa</a>; <a href="./references#CD008846-bbs2-0002" title="BennettA , Porter TR,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C,   et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in southern province, Zambia: an evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence  in southern province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of Plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBb</a>; <a href="./references#CD008846-bbs2-0004" title="LandierJ , KajeechiwaL , ThwinMM , ParkerDM , ChaumeauV , WiladphaingernJ , et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar. Wellcome Open Research2017;2:81. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Landier 2017 MMRa</a>; <a href="./references#CD008846-bbs2-0005" title="HeatonJ , McCleanA , SweMM , SoeK , IndrasutaC , KhantZS , et al. Speeding up malaria elimination; a cluster randomized controlled trial of mass drug administration in Southeast Myanmar, an area with artemisinin resistance. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):411. McLeanAR , IndrasutaC , KhantZS , PhyoAK , MaungSM , HeatonJ , et al. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infectious Diseases 2021 June 17 [Epub ahead of print]. [DOI: 10.1016/S1473-3099(20)30997-X]">McLean 2021 MMR</a>; <a href="./references#CD008846-bbs2-0007" title="MorrisU , MsellemM , MkaliH , IslamA , Aydin-SchmidtB , JovelI , et al. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission. BMC Medicine2018;16:215. [DOI: 10.1186/s12916-018-1202-8]">Morris 2018 TZA</a>; <a href="./references#CD008846-bbs2-0008" title="PongvongsaT , PhommasoneK , AdhikariB , HenriquesG , ChotivanichK , HanboonkunupakarnB , et al. The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin-piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos. Malaria Journal2018;17(1):405. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Pongvongsa 2018 LAO</a>; <a href="./references#CD008846-bbs2-0011" title="TripuraR , PetoTJ , CheaN , ChanD , MukakaM , SirithiranontP , et al. A controlled trial of mass drug administration to interrupt transmission of multidrug-resistant falciparum malaria in Cambodian villages. Clinical Infectious Diseases2018;67(6):817-26. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Tripura 2018 KHM</a>; <a href="./references#CD008846-bbs2-0013" title="vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">von Seidlein 2019 VNM</a>). Since clusters in the Eisele trial were randomized by areas of low and high malaria transmission and the outcomes were stratified by endemicity (specified a priori by design), we considered this trial as two studies (<a href="./references#CD008846-bbs2-0001" title="BennettA , PorterTR ,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C, et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in Southern Province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in Southern Province, Zambia: An evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. [DOI: 10.1186/s13063-015-0862-3]MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBa</a>; <a href="./references#CD008846-bbs2-0002" title="BennettA , Porter TR,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C,   et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in southern province, Zambia: an evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence  in southern province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of Plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBb</a>). Four studies were part of a multi‐county trial conducted in Southeast Asia (<a href="./references#CD008846-bbs2-0004" title="LandierJ , KajeechiwaL , ThwinMM , ParkerDM , ChaumeauV , WiladphaingernJ , et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar. Wellcome Open Research2017;2:81. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Landier 2017 MMRa</a>; <a href="./references#CD008846-bbs2-0008" title="PongvongsaT , PhommasoneK , AdhikariB , HenriquesG , ChotivanichK , HanboonkunupakarnB , et al. The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin-piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos. Malaria Journal2018;17(1):405. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Pongvongsa 2018 LAO</a>; <a href="./references#CD008846-bbs2-0011" title="TripuraR , PetoTJ , CheaN , ChanD , MukakaM , SirithiranontP , et al. A controlled trial of mass drug administration to interrupt transmission of multidrug-resistant falciparum malaria in Cambodian villages. Clinical Infectious Diseases2018;67(6):817-26. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Tripura 2018 KHM</a>; <a href="./references#CD008846-bbs2-0013" title="vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">von Seidlein 2019 VNM</a>). We analysed these as separate studies due to differences in study design (differences in antimalarial drug used for MDA, timing of MDA in relation to the transmission season, and follow‐up time periods) and heterogeneity of effects. </p> <section id="CD008846-sec-0052"> <h5 class="title">Cluster‐randomized trials</h5> <p>Ten cRCTs were included in the qualitative syntheses: two from moderate‐ to high‐endemicity areas (high: <a href="./references#CD008846-bbs2-0002" title="BennettA , Porter TR,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C,   et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in southern province, Zambia: an evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence  in southern province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of Plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBb</a>; <a href="./references#CD008846-bbs2-0012" title="De MartinS , vonSeidleinL , DeenJL , PinderM , WalravenG , GreenwoodB . Community perceptions of a mass administration of an antimalarial drug combination in The Gambia. Tropical Medicine &amp; International Health2001;6(6):442-8. vonSeidleinL , WalravenG , MilliganPJ , AlexanderN , MannehF , DeenJL , et al. The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia. Transactions of the Royal Society of Tropical Medicine &amp; Hygiene2003;97(2):217-25. ">von Seidlein 2003 GMB</a>), and eight from very low‐ to low‐endemicity areas (very low: <a href="./references#CD008846-bbs2-0007" title="MorrisU , MsellemM , MkaliH , IslamA , Aydin-SchmidtB , JovelI , et al. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission. BMC Medicine2018;16:215. [DOI: 10.1186/s12916-018-1202-8]">Morris 2018 TZA</a>; <a href="./references#CD008846-bbs2-0010" title="ShekalagheSA , DrakeleyC , vanden BoschS , ter BraakR , vanden BikilaardtW , MwanzivaC , et al. A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania. Malaria Journal2011;10:247. ShekalagheSA , ter BraakR , DaouM , KavisheR , vanden BijilaardtW , vanden BoschS , et al. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A) individuals. Antimicrobial Agents and Chemotherapy2010;54(5):1762-8. ">Shekalaghe 2011 TZA</a>; <a href="./references#CD008846-bbs2-0011" title="TripuraR , PetoTJ , CheaN , ChanD , MukakaM , SirithiranontP , et al. A controlled trial of mass drug administration to interrupt transmission of multidrug-resistant falciparum malaria in Cambodian villages. Clinical Infectious Diseases2018;67(6):817-26. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Tripura 2018 KHM</a>; <a href="./references#CD008846-bbs2-0013" title="vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">von Seidlein 2019 VNM</a>; low: <a href="./references#CD008846-bbs2-0001" title="BennettA , PorterTR ,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C, et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in Southern Province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in Southern Province, Zambia: An evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. [DOI: 10.1186/s13063-015-0862-3]MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBa</a>; <a href="./references#CD008846-bbs2-0004" title="LandierJ , KajeechiwaL , ThwinMM , ParkerDM , ChaumeauV , WiladphaingernJ , et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar. Wellcome Open Research2017;2:81. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Landier 2017 MMRa</a>; <a href="./references#CD008846-bbs2-0005" title="HeatonJ , McCleanA , SweMM , SoeK , IndrasutaC , KhantZS , et al. Speeding up malaria elimination; a cluster randomized controlled trial of mass drug administration in Southeast Myanmar, an area with artemisinin resistance. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):411. McLeanAR , IndrasutaC , KhantZS , PhyoAK , MaungSM , HeatonJ , et al. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infectious Diseases 2021 June 17 [Epub ahead of print]. [DOI: 10.1016/S1473-3099(20)30997-X]">McLean 2021 MMR</a>; <a href="./references#CD008846-bbs2-0008" title="PongvongsaT , PhommasoneK , AdhikariB , HenriquesG , ChotivanichK , HanboonkunupakarnB , et al. The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin-piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos. Malaria Journal2018;17(1):405. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Pongvongsa 2018 LAO</a>). </p> <p>Five studies were conducted in sub‐Saharan Africa and five studies were conducted in Southeast Asia. Trial locations in sub‐Saharan Africa were Southern Province, Zambia (<a href="./references#CD008846-bbs2-0001" title="BennettA , PorterTR ,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C, et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in Southern Province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in Southern Province, Zambia: An evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. [DOI: 10.1186/s13063-015-0862-3]MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBa</a>; <a href="./references#CD008846-bbs2-0002" title="BennettA , Porter TR,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C,   et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in southern province, Zambia: an evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence  in southern province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of Plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBb</a>), Unguja Island, Tanzania (<a href="./references#CD008846-bbs2-0007" title="MorrisU , MsellemM , MkaliH , IslamA , Aydin-SchmidtB , JovelI , et al. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission. BMC Medicine2018;16:215. [DOI: 10.1186/s12916-018-1202-8]">Morris 2018 TZA</a>), Lower Moshi, Tanzania (<a href="./references#CD008846-bbs2-0010" title="ShekalagheSA , DrakeleyC , vanden BoschS , ter BraakR , vanden BikilaardtW , MwanzivaC , et al. A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania. Malaria Journal2011;10:247. ShekalagheSA , ter BraakR , DaouM , KavisheR , vanden BijilaardtW , vanden BoschS , et al. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A) individuals. Antimicrobial Agents and Chemotherapy2010;54(5):1762-8. ">Shekalaghe 2011 TZA</a>), and Farafenni, The Gambia (<a href="./references#CD008846-bbs2-0012" title="De MartinS , vonSeidleinL , DeenJL , PinderM , WalravenG , GreenwoodB . Community perceptions of a mass administration of an antimalarial drug combination in The Gambia. Tropical Medicine &amp; International Health2001;6(6):442-8. vonSeidleinL , WalravenG , MilliganPJ , AlexanderN , MannehF , DeenJL , et al. The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia. Transactions of the Royal Society of Tropical Medicine &amp; Hygiene2003;97(2):217-25. ">von Seidlein 2003 GMB</a>). Study locations in Southeast Asia included Kayin (Karen) state, Myanmar (<a href="./references#CD008846-bbs2-0004" title="LandierJ , KajeechiwaL , ThwinMM , ParkerDM , ChaumeauV , WiladphaingernJ , et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar. Wellcome Open Research2017;2:81. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Landier 2017 MMRa</a>), Southeast Myanmar (<a href="./references#CD008846-bbs2-0005" title="HeatonJ , McCleanA , SweMM , SoeK , IndrasutaC , KhantZS , et al. Speeding up malaria elimination; a cluster randomized controlled trial of mass drug administration in Southeast Myanmar, an area with artemisinin resistance. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):411. McLeanAR , IndrasutaC , KhantZS , PhyoAK , MaungSM , HeatonJ , et al. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infectious Diseases 2021 June 17 [Epub ahead of print]. [DOI: 10.1016/S1473-3099(20)30997-X]">McLean 2021 MMR</a>), Savannakhet province, Laos (<a href="./references#CD008846-bbs2-0008" title="PongvongsaT , PhommasoneK , AdhikariB , HenriquesG , ChotivanichK , HanboonkunupakarnB , et al. The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin-piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos. Malaria Journal2018;17(1):405. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Pongvongsa 2018 LAO</a>), Battambang province, Cambodia (<a href="./references#CD008846-bbs2-0011" title="TripuraR , PetoTJ , CheaN , ChanD , MukakaM , SirithiranontP , et al. A controlled trial of mass drug administration to interrupt transmission of multidrug-resistant falciparum malaria in Cambodian villages. Clinical Infectious Diseases2018;67(6):817-26. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Tripura 2018 KHM</a>), and Binh Phuoc and Ninh Thuan provinces, Vietnam (<a href="./references#CD008846-bbs2-0013" title="vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">von Seidlein 2019 VNM</a>). </p> <p>One cRCT conducted in an area of very low malaria transmission of Tanzania reported zero events at both baseline and follow‐up time points for several outcomes and was excluded from quantitative syntheses (<a href="./references#CD008846-bbs2-0010" title="ShekalagheSA , DrakeleyC , vanden BoschS , ter BraakR , vanden BikilaardtW , MwanzivaC , et al. A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania. Malaria Journal2011;10:247. ShekalagheSA , ter BraakR , DaouM , KavisheR , vanden BijilaardtW , vanden BoschS , et al. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A) individuals. Antimicrobial Agents and Chemotherapy2010;54(5):1762-8. ">Shekalaghe 2011 TZA</a>). The nine remaining cRCTs provided data for comparison of MDA versus no MDA in this review: three studies compared MDA to placebo or no MDA (<a href="./references#CD008846-bbs2-0005" title="HeatonJ , McCleanA , SweMM , SoeK , IndrasutaC , KhantZS , et al. Speeding up malaria elimination; a cluster randomized controlled trial of mass drug administration in Southeast Myanmar, an area with artemisinin resistance. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):411. McLeanAR , IndrasutaC , KhantZS , PhyoAK , MaungSM , HeatonJ , et al. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infectious Diseases 2021 June 17 [Epub ahead of print]. [DOI: 10.1016/S1473-3099(20)30997-X]">McLean 2021 MMR</a>; <a href="./references#CD008846-bbs2-0007" title="MorrisU , MsellemM , MkaliH , IslamA , Aydin-SchmidtB , JovelI , et al. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission. BMC Medicine2018;16:215. [DOI: 10.1186/s12916-018-1202-8]">Morris 2018 TZA</a>; <a href="./references#CD008846-bbs2-0012" title="De MartinS , vonSeidleinL , DeenJL , PinderM , WalravenG , GreenwoodB . Community perceptions of a mass administration of an antimalarial drug combination in The Gambia. Tropical Medicine &amp; International Health2001;6(6):442-8. vonSeidleinL , WalravenG , MilliganPJ , AlexanderN , MannehF , DeenJL , et al. The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia. Transactions of the Royal Society of Tropical Medicine &amp; Hygiene2003;97(2):217-25. ">von Seidlein 2003 GMB</a>), four studies compared MDA to delayed MDA (<a href="./references#CD008846-bbs2-0004" title="LandierJ , KajeechiwaL , ThwinMM , ParkerDM , ChaumeauV , WiladphaingernJ , et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar. Wellcome Open Research2017;2:81. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Landier 2017 MMRa</a>; <a href="./references#CD008846-bbs2-0008" title="PongvongsaT , PhommasoneK , AdhikariB , HenriquesG , ChotivanichK , HanboonkunupakarnB , et al. The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin-piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos. Malaria Journal2018;17(1):405. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Pongvongsa 2018 LAO</a>; <a href="./references#CD008846-bbs2-0011" title="TripuraR , PetoTJ , CheaN , ChanD , MukakaM , SirithiranontP , et al. A controlled trial of mass drug administration to interrupt transmission of multidrug-resistant falciparum malaria in Cambodian villages. Clinical Infectious Diseases2018;67(6):817-26. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Tripura 2018 KHM</a>; <a href="./references#CD008846-bbs2-0013" title="vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">von Seidlein 2019 VNM</a>), while two studies (<a href="./references#CD008846-bbs2-0001" title="BennettA , PorterTR ,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C, et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in Southern Province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in Southern Province, Zambia: An evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. [DOI: 10.1186/s13063-015-0862-3]MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBa</a>; <a href="./references#CD008846-bbs2-0002" title="BennettA , Porter TR,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C,   et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in southern province, Zambia: an evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence  in southern province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of Plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBb</a>) compared MDA and focal MDA (household‐level MDA where a member tested positive by RDT) separately to no MDA and we included only the MDA arm for comparison. </p> <section id="CD008846-sec-0053"> <h6 class="title">Interventions</h6> <p>Characteristics of the intervention have been summarized in <a href="#CD008846-tbl-0006">Table 1</a>. </p> <div class="table" id="CD008846-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Description of studies</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study ID (Design)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Year(s) of study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Malaria endemicity<sup>a</sup> </b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b><i>Plasmodium</i> species</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Antimalarial drug resistance</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>MDA group</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Control group</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Co‐intervention(s)</b><sup>b</sup> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes reported (months of follow‐up post‐MDA<sup>c</sup>)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Drug</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Rounds, interval, and duration implemented</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population targeted (coverage)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008846-bbs2-0001" title="BennettA , PorterTR ,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C, et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in Southern Province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in Southern Province, Zambia: An evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. [DOI: 10.1186/s13063-015-0862-3]MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBa</a> (cRCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2014‐2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>P falciparum</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Widespread resistance to CQ and SP, but no evidence of resistance to artemisinin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DHAp</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 rounds administered at start of rainy season, during rainy season, during dry season, and at start of rainy season over 15 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37,694</p> <p>(79% in round 1; 63% in round 2; 76% in round 3; 66% in round 4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No drug and no placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IRS, ITNs, and enhanced standard of care</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD008846-list-0010"> <li> <p>Parasitaemia prevalence (2)</p> </li> <li> <p>Parasitaemia incidence (2)</p> </li> <li> <p>Confirmed malaria case incidence (2)</p> </li> <li> <p>Adverse effects</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008846-bbs2-0002" title="BennettA , Porter TR,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C,   et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in southern province, Zambia: an evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence  in southern province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of Plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBb</a> (cRCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2014‐2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>P falciparum</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Widespread resistance to CQ and SP, but no evidence of resistance to artemisinin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DHAp</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 rounds administered at start of rainy season, during rainy season, during dry season, and at start of rainy season over 15 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45,442</p> <p>(79% in round 1; 63% in round 2; 76% in round 3; 66% in round 4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No drug and no placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IRS, ITNs, and enhanced standard of care</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD008846-list-0011"> <li> <p>Parasitaemia prevalence (2)</p> </li> <li> <p>Parasitaemia incidence (2)</p> </li> <li> <p>Confirmed malaria case incidence (2)</p> </li> <li> <p>Adverse effects</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD008846-bbs2-0003" title="EscudieA , HamonJ , SchneiderJ . Results of mass antimalarial chemoprophylaxis with a combination of 4-aminoquinoline and 8-aminoquinoline under rural African conditions in the region of Bobo-Dioulasso (Upper Volta) 1960. Comparative study in a zone treated with DDT and outside this zone. Medecine Tropicale1962;22(2):268-305. SchneiderJ , EscudieA , HamonJ . Eradication of malaria and chemotherapy. Results obtained with the association amino-4 quinoline + amino-8 quinoline in the pilot area of Bobo-Dioulasso (Haute- Volta) [Eradication du paludismeet chimiotherapie resultats d’un essai de l’association:amino–4 quinoleine/amino–8 quinoleine dans la zonepilote de Bobo–Dioulasso (Haute Volta)]. Bulletin de la Societe de Pathologie Exotique1961;54(5):1012-25. ">Escudie 1962 BFA</a> (CBA) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1960‐1961</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><i>P falciparum,</i> </p> <p><i>P ovale,</i> </p> <p><i>P malariae</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>ND</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>AQ‐PQ or CQ‐PQ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(Low frequency MDA)</p> <p>7 rounds administered 28 days apart over 7 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1890</p> <p>(75% to 91% per round)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No drug and no placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>None (IRS arms excluded)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD008846-list-0012"> <li> <p>Parasitaemia prevalence (3)</p> </li> <li> <p>Gametocytaemia prevalence (3)</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(High frequency MDA)</p> <p>15 rounds administered 14 days apart over 7 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2560</p> <p>(84% to 97% per round)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD008846-list-0013"> <li> <p>Parasitaemia prevalence (3)</p> </li> <li> <p>Gametocytaemia prevalence (3)</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008846-bbs2-0004" title="LandierJ , KajeechiwaL , ThwinMM , ParkerDM , ChaumeauV , WiladphaingernJ , et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar. Wellcome Open Research2017;2:81. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Landier 2017 MMRa</a> (cRCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2013‐2015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>P falciparum,</i> </p> <p><i>P vivax</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Artemisinin resistance firmly established</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DHAp with PQ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 rounds administered 1 month apart over 3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1434 (66% in round 1, 56% in round 2, and 65% in round 3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Delayed MDA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITNs, uninterrupted access to case management</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD008846-list-0014"> <li> <p>Parasitaemia prevalence (7)</p> </li> <li> <p>Confirmed malaria illness incidence (7)</p> </li> <li> <p>Adverse effects</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008846-bbs2-0005" title="HeatonJ , McCleanA , SweMM , SoeK , IndrasutaC , KhantZS , et al. Speeding up malaria elimination; a cluster randomized controlled trial of mass drug administration in Southeast Myanmar, an area with artemisinin resistance. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):411. McLeanAR , IndrasutaC , KhantZS , PhyoAK , MaungSM , HeatonJ , et al. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infectious Diseases 2021 June 17 [Epub ahead of print]. [DOI: 10.1016/S1473-3099(20)30997-X]">McLean 2021 MMR</a> (cRCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2014‐2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>P falciparum,</i> </p> <p><i>P vivax</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Artemisinin resistance: Kelch 13 mutation in 57% of samples at baseline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DHAp with PQ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 rounds administered 1 month apart over 3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4622</p> <p>(86% in round 1, 86% in round 2, 88% in round 3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No drug and no placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITNs, routine malaria control by village health workers</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD008846-list-0015"> <li> <p>Parasitaemia prevalence (31)</p> </li> <li> <p>Adverse effects</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD008846-bbs2-0006" title="BroggerRC , MathewsHM , StoreyJ , AshkarTS , BroggerS , MolineauxL . Changing patterns in the humoral immune response to malaria before, during and after the application of control measures: a longitudinal study in the West African savanna. Bulletin of the World Health Organization1978;56(4):579-600. MolineauxL , BroggerRC , MathewsHM , StoreyJ , AshkarTS . Longitudinal serological study of malaria in infants in the West African savanna. Comparisons in infants exposed to, or protected from, transmission from birth. Bulletin of the World Health Organisation1978;56(4):573-8. MolineauxL , GramicciaG . The Garki Project. Research on the epidemiology and control of malaria in the Sudan Savanna of West Africa. 1980. https://apps.who.int/iris/handle/10665/40316 (accessed prior to 8 July 2021). MolineauxL , StoreyJ , CohenJE , ThomasA . A longitudinal study of human malaria in the West African savanna in the absence of control measures: relationships between different Plasmodium species, in particular P. falciparum and P. malariae. American Journal of Tropical Medicine and Hygiene1980;29(5):725-37. ">Molineaux 1980 NGA</a> (CBA) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1970‐1975</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><i>P falciparum,</i> </p> <p><i>P malariae,</i> </p> <p><i>P ovale</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>ND</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>SP</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(Low frequency MDA)</p> <p>9 rounds administered 10 weeks apart over 18 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14,129</p> <p>(73% to 92% per round)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No drug and no placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>IRS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD008846-list-0016"> <li> <p>Parasitaemia prevalence (0)</p> </li> <li> <p>Gametocytaemia prevalence (0)</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(High frequency MDA)</p> <p>23 rounds administered 2 weeks apart during the wet seasons and 10 weeks apart during the dry seasons over 18 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1810</p> <p>(72% to 91% per round)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008846-bbs2-0007" title="MorrisU , MsellemM , MkaliH , IslamA , Aydin-SchmidtB , JovelI , et al. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission. BMC Medicine2018;16:215. [DOI: 10.1186/s12916-018-1202-8]">Morris 2018 TZA</a> (cRCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2016‐2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>P falciparum,</i> </p> <p><i>P malariae,</i> </p> <p><i>P ovale,</i> and </p> <p><i>P vivax</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No evidence of resistance to first line treatment AS‐AQ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DHAp with PQ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 rounds administered 4 weeks apart over 6 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10,944</p> <p>(91% in round 1, 88% in round 2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No drug and no placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IRS and ITNs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD008846-list-0017"> <li> <p>Parasitaemia prevalence (0)</p> </li> <li> <p>Confirmed malaria illness incidence (14)</p> </li> <li> <p>Adverse effects</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008846-bbs2-0008" title="PongvongsaT , PhommasoneK , AdhikariB , HenriquesG , ChotivanichK , HanboonkunupakarnB , et al. The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin-piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos. Malaria Journal2018;17(1):405. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Pongvongsa 2018 LAO</a> (cRCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2016‐2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>P falciparum,</i> </p> <p><i>P vivax</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DHAp with PQ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 rounds administered 1 month apart over 3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1006 (81% in round 1, 80% in round 2, and 82% in round 3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Delayed MDA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITNs, uninterrupted access to case management</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD008846-list-0018"> <li> <p>Parasitaemia prevalence (10)</p> </li> <li> <p>Adverse effects</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008846-bbs2-0009" title="RobertsJM . Pyrimethamine (Daraprim) in the control of epidemic malaria. American Journal of Tropical Medicine and Hygiene1956;59(9):201-8. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part I. Before the campaign. American Journal of Tropical Medicine and Hygiene1964;67(7):161-8. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part II. The campaign. American Journal of Tropical Medicine and Hygiene1964;67(8):191-9. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part III. After the campaign. American Journal of Tropical Medicine and Hygiene1964;67(9):230-7. ">Roberts 1964 KEN</a> (CBA) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1953‐1954</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>P falciparum</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pyrimethamine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 rounds administered 1 year apart over 13 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101,000</p> <p>(95% in round 1, 93% in round 2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No drug and no placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD008846-list-0019"> <li> <p>Parasitaemia prevalence (7)</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008846-bbs2-0010" title="ShekalagheSA , DrakeleyC , vanden BoschS , ter BraakR , vanden BikilaardtW , MwanzivaC , et al. A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania. Malaria Journal2011;10:247. ShekalagheSA , ter BraakR , DaouM , KavisheR , vanden BijilaardtW , vanden BoschS , et al. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A) individuals. Antimicrobial Agents and Chemotherapy2010;54(5):1762-8. ">Shekalaghe 2011 TZA</a> (cRCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>P falciparum</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SP+AS with PQ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 round over 16 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1110</p> <p>(95%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITNs, single treatment campaign for trachoma with azithromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD008846-list-0020"> <li> <p>Parasitaemia prevalence (4)</p> </li> <li> <p>Confirmed malaria illness incidence (4)</p> </li> <li> <p>Gametocytaemia prevalence (4)</p> </li> <li> <p>Adverse effects</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008846-bbs2-0011" title="TripuraR , PetoTJ , CheaN , ChanD , MukakaM , SirithiranontP , et al. A controlled trial of mass drug administration to interrupt transmission of multidrug-resistant falciparum malaria in Cambodian villages. Clinical Infectious Diseases2018;67(6):817-26. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Tripura 2018 KHM</a> (cRCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2014‐2016</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>P falciparum,</i> </p> <p><i>P vivax</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reduced susceptibility to artemisinins and ACT partner drug resistance</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DHAp</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 rounds administered 1 month apart over 3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>858 (74% in round 1, 60% in round 2, and 71% in round 3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Delayed MDA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITNs, uninterrupted access to case management</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD008846-list-0021"> <li> <p>Parasitaemia prevalence (10)</p> </li> <li> <p>Confirmed malaria case incidence (9)</p> </li> <li> <p>Adverse effects</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008846-bbs2-0012" title="De MartinS , vonSeidleinL , DeenJL , PinderM , WalravenG , GreenwoodB . Community perceptions of a mass administration of an antimalarial drug combination in The Gambia. Tropical Medicine &amp; International Health2001;6(6):442-8. vonSeidleinL , WalravenG , MilliganPJ , AlexanderN , MannehF , DeenJL , et al. The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia. Transactions of the Royal Society of Tropical Medicine &amp; Hygiene2003;97(2):217-25. ">von Seidlein 2003 GMB</a> (cRCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1999</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>P falciparum</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SP+AS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 round over 1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12,331</p> <p>(89%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD008846-list-0022"> <li> <p>Parasitaemia prevalence (5)</p> </li> <li> <p>Parasitaemia incidence (5)</p> </li> <li> <p>Gametocytaemia prevalence (5)</p> </li> <li> <p>Malaria‐specific mortality</p> </li> <li> <p>Adverse effects</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008846-bbs2-0013" title="vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">von Seidlein 2019 VNM</a> (cRCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2013‐2015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>P falciparum,</i> </p> <p><i>P vivax</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No evidence of resistance to DHAp at the start of study, but treatment failure to DHAp has increased following study </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DHAp with PQ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 rounds administered 1 month apart over 3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1439 (83% in round 1, 98% in round 2, and 99% in round 3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Delayed MDA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITNs, uninterrupted access to case management</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD008846-list-0023"> <li> <p>Parasitaemia prevalence (10)</p> </li> <li> <p>Adverse effects</p> </li> </ul> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ACT = artemisinin‐based combination therapy, AQ = amodiaquine, AS = artesunate, CBA = controlled before‐and‐after study, CQ = chloroquine, cRCT = cluster‐randomized controlled trial, DHAp = dihydroartemisinin piperaquine, ITNs = insecticide‐treated bed nets, IRS = indoor residual spraying, MDA = mass drug administration, PQ = primaquine, SP = sulfadoxine‐ (or sulfalene‐) pyrimethamine, NA = not applicable, ND = not described. </p> <p><sup>a</sup>Malaria endemicity classified as very low (&gt; 0% to &lt; 1%), low (1% to &lt; 10%), moderate (10% to &lt; 35%) or high (≥ 35%) (<a href="./references#CD008846-bbs2-0058" title="World Health Organization. A framework for malaria elimination; WHO; March 2017. Available at apps.who.int/iris/bitstream/handle/10665/254761/9789241511988-eng.pdf?sequence=1.">WHO 2017</a>).<br/><sup>b</sup>Co‐interventions were balanced across intervention and control groups, as per inclusion criteria.<br/><sup>c</sup>Post‐MDA refers to the length of time, in months, after the last round of MDA that the outcome was evaluated. </p> </div> </div> <section id="CD008846-sec-0054"> <p><b>Moderate‐ to high‐transmission areas</b></p> <p>One study administered four rounds of MDA with dihydroartemisinin piperaquine (DHAp) to all persons older than three months, except for pregnant women in the first trimester (<a href="./references#CD008846-bbs2-0002" title="BennettA , Porter TR,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C,   et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in southern province, Zambia: an evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence  in southern province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of Plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBb</a>). The four MDA rounds occurred at the start of the rainy season, during the rainy season, during the dry season, and again at the start of the rainy season. MDA coverage was 88.1% in round one and 72.0% in round two. Both study arms received LLINs and IRS with Actellic (an insecticide) at baseline before MDA. The second trial administered a single round of MDA with sulfadoxine‐pyrimethamine plus artesunate at the start of the rainy season to all persons six months of age or older, except for pregnant women (<a href="./references#CD008846-bbs2-0012" title="De MartinS , vonSeidleinL , DeenJL , PinderM , WalravenG , GreenwoodB . Community perceptions of a mass administration of an antimalarial drug combination in The Gambia. Tropical Medicine &amp; International Health2001;6(6):442-8. vonSeidleinL , WalravenG , MilliganPJ , AlexanderN , MannehF , DeenJL , et al. The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia. Transactions of the Royal Society of Tropical Medicine &amp; Hygiene2003;97(2):217-25. ">von Seidlein 2003 GMB</a>). MDA coverage among the target population was 89% and no co‐interventions were provided. </p> </section> <section id="CD008846-sec-0055"> <p><b>Very low‐ to low‐transmission areas</b></p> <p>Seven studies administered multiple rounds of MDA with dihydroartemisinin piperaquine (<a href="./references#CD008846-bbs2-0001" title="BennettA , PorterTR ,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C, et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in Southern Province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in Southern Province, Zambia: An evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. [DOI: 10.1186/s13063-015-0862-3]MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBa</a>; <a href="./references#CD008846-bbs2-0004" title="LandierJ , KajeechiwaL , ThwinMM , ParkerDM , ChaumeauV , WiladphaingernJ , et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar. Wellcome Open Research2017;2:81. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Landier 2017 MMRa</a>; <a href="./references#CD008846-bbs2-0005" title="HeatonJ , McCleanA , SweMM , SoeK , IndrasutaC , KhantZS , et al. Speeding up malaria elimination; a cluster randomized controlled trial of mass drug administration in Southeast Myanmar, an area with artemisinin resistance. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):411. McLeanAR , IndrasutaC , KhantZS , PhyoAK , MaungSM , HeatonJ , et al. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infectious Diseases 2021 June 17 [Epub ahead of print]. [DOI: 10.1016/S1473-3099(20)30997-X]">McLean 2021 MMR</a>; <a href="./references#CD008846-bbs2-0007" title="MorrisU , MsellemM , MkaliH , IslamA , Aydin-SchmidtB , JovelI , et al. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission. BMC Medicine2018;16:215. [DOI: 10.1186/s12916-018-1202-8]">Morris 2018 TZA</a>; <a href="./references#CD008846-bbs2-0008" title="PongvongsaT , PhommasoneK , AdhikariB , HenriquesG , ChotivanichK , HanboonkunupakarnB , et al. The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin-piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos. Malaria Journal2018;17(1):405. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Pongvongsa 2018 LAO</a>; <a href="./references#CD008846-bbs2-0011" title="TripuraR , PetoTJ , CheaN , ChanD , MukakaM , SirithiranontP , et al. A controlled trial of mass drug administration to interrupt transmission of multidrug-resistant falciparum malaria in Cambodian villages. Clinical Infectious Diseases2018;67(6):817-26. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Tripura 2018 KHM</a>; <a href="./references#CD008846-bbs2-0013" title="vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">von Seidlein 2019 VNM</a>). Five of these studies also added a single dose of primaquine at each round (<a href="./references#CD008846-bbs2-0004" title="LandierJ , KajeechiwaL , ThwinMM , ParkerDM , ChaumeauV , WiladphaingernJ , et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar. Wellcome Open Research2017;2:81. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Landier 2017 MMRa</a>; <a href="./references#CD008846-bbs2-0005" title="HeatonJ , McCleanA , SweMM , SoeK , IndrasutaC , KhantZS , et al. Speeding up malaria elimination; a cluster randomized controlled trial of mass drug administration in Southeast Myanmar, an area with artemisinin resistance. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):411. McLeanAR , IndrasutaC , KhantZS , PhyoAK , MaungSM , HeatonJ , et al. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infectious Diseases 2021 June 17 [Epub ahead of print]. [DOI: 10.1016/S1473-3099(20)30997-X]">McLean 2021 MMR</a>; <a href="./references#CD008846-bbs2-0007" title="MorrisU , MsellemM , MkaliH , IslamA , Aydin-SchmidtB , JovelI , et al. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission. BMC Medicine2018;16:215. [DOI: 10.1186/s12916-018-1202-8]">Morris 2018 TZA</a>; <a href="./references#CD008846-bbs2-0008" title="PongvongsaT , PhommasoneK , AdhikariB , HenriquesG , ChotivanichK , HanboonkunupakarnB , et al. The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin-piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos. Malaria Journal2018;17(1):405. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Pongvongsa 2018 LAO</a>; <a href="./references#CD008846-bbs2-0013" title="vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">von Seidlein 2019 VNM</a>). The interval between rounds varied across studies. In <a href="./references#CD008846-bbs2-0001" title="BennettA , PorterTR ,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C, et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in Southern Province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in Southern Province, Zambia: An evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. [DOI: 10.1186/s13063-015-0862-3]MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBa</a>, MDA was administered at the start of the rainy season, during the rainy season, during the dry season, and at the start of the rainy season. In <a href="./references#CD008846-bbs2-0005" title="HeatonJ , McCleanA , SweMM , SoeK , IndrasutaC , KhantZS , et al. Speeding up malaria elimination; a cluster randomized controlled trial of mass drug administration in Southeast Myanmar, an area with artemisinin resistance. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):411. McLeanAR , IndrasutaC , KhantZS , PhyoAK , MaungSM , HeatonJ , et al. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infectious Diseases 2021 June 17 [Epub ahead of print]. [DOI: 10.1016/S1473-3099(20)30997-X]">McLean 2021 MMR</a>, three rounds of MDA were administered one month apart during the dry season. The two rounds of MDA in <a href="./references#CD008846-bbs2-0007" title="MorrisU , MsellemM , MkaliH , IslamA , Aydin-SchmidtB , JovelI , et al. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission. BMC Medicine2018;16:215. [DOI: 10.1186/s12916-018-1202-8]">Morris 2018 TZA</a> were administered two months apart. The three rounds of MDA in <a href="./references#CD008846-bbs2-0004" title="LandierJ , KajeechiwaL , ThwinMM , ParkerDM , ChaumeauV , WiladphaingernJ , et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar. Wellcome Open Research2017;2:81. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Landier 2017 MMRa</a> and <a href="./references#CD008846-bbs2-0008" title="PongvongsaT , PhommasoneK , AdhikariB , HenriquesG , ChotivanichK , HanboonkunupakarnB , et al. The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin-piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos. Malaria Journal2018;17(1):405. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Pongvongsa 2018 LAO</a>, conducted one month apart, were administered at the start and during rainy season. Three rounds of MDA in <a href="./references#CD008846-bbs2-0011" title="TripuraR , PetoTJ , CheaN , ChanD , MukakaM , SirithiranontP , et al. A controlled trial of mass drug administration to interrupt transmission of multidrug-resistant falciparum malaria in Cambodian villages. Clinical Infectious Diseases2018;67(6):817-26. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Tripura 2018 KHM</a> were administered during rainy season, while three rounds of MDA took place at the end of the transmission season in <a href="./references#CD008846-bbs2-0013" title="vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">von Seidlein 2019 VNM</a>. </p> <p>Most studies administering MDA with dihydroartemisinin piperaquine excluded pregnant women in their first trimester, with the exception of <a href="./references#CD008846-bbs2-0011" title="TripuraR , PetoTJ , CheaN , ChanD , MukakaM , SirithiranontP , et al. A controlled trial of mass drug administration to interrupt transmission of multidrug-resistant falciparum malaria in Cambodian villages. Clinical Infectious Diseases2018;67(6):817-26. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Tripura 2018 KHM</a>, which excluded all pregnant women from MDA. Studies administering a single dose of primaquine excluded all pregnant women from primaquine. After these exclusions, MDA was administered to all persons three months of age and older (<a href="./references#CD008846-bbs2-0001" title="BennettA , PorterTR ,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C, et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in Southern Province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in Southern Province, Zambia: An evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. [DOI: 10.1186/s13063-015-0862-3]MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBa</a>), six months of age and older (<a href="./references#CD008846-bbs2-0004" title="LandierJ , KajeechiwaL , ThwinMM , ParkerDM , ChaumeauV , WiladphaingernJ , et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar. Wellcome Open Research2017;2:81. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Landier 2017 MMRa</a>; <a href="./references#CD008846-bbs2-0007" title="MorrisU , MsellemM , MkaliH , IslamA , Aydin-SchmidtB , JovelI , et al. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission. BMC Medicine2018;16:215. [DOI: 10.1186/s12916-018-1202-8]">Morris 2018 TZA</a>; <a href="./references#CD008846-bbs2-0008" title="PongvongsaT , PhommasoneK , AdhikariB , HenriquesG , ChotivanichK , HanboonkunupakarnB , et al. The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin-piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos. Malaria Journal2018;17(1):405. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Pongvongsa 2018 LAO</a>; <a href="./references#CD008846-bbs2-0011" title="TripuraR , PetoTJ , CheaN , ChanD , MukakaM , SirithiranontP , et al. A controlled trial of mass drug administration to interrupt transmission of multidrug-resistant falciparum malaria in Cambodian villages. Clinical Infectious Diseases2018;67(6):817-26. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Tripura 2018 KHM</a>; <a href="./references#CD008846-bbs2-0013" title="vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">von Seidlein 2019 VNM</a>), or 12 months of age and older (<a href="./references#CD008846-bbs2-0005" title="HeatonJ , McCleanA , SweMM , SoeK , IndrasutaC , KhantZS , et al. Speeding up malaria elimination; a cluster randomized controlled trial of mass drug administration in Southeast Myanmar, an area with artemisinin resistance. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):411. McLeanAR , IndrasutaC , KhantZS , PhyoAK , MaungSM , HeatonJ , et al. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infectious Diseases 2021 June 17 [Epub ahead of print]. [DOI: 10.1016/S1473-3099(20)30997-X]">McLean 2021 MMR</a>). MDA coverage ranged from 66% to 95% in the first round and was generally lower (56% to 99%) in subsequent rounds for all studies except <a href="./references#CD008846-bbs2-0013" title="vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">von Seidlein 2019 VNM</a>, in which coverage increased in subsequent rounds. All studies provided ITNs to all study arms. In addition, <a href="./references#CD008846-bbs2-0001" title="BennettA , PorterTR ,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C, et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in Southern Province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in Southern Province, Zambia: An evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. [DOI: 10.1186/s13063-015-0862-3]MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBa</a> and <a href="./references#CD008846-bbs2-0007" title="MorrisU , MsellemM , MkaliH , IslamA , Aydin-SchmidtB , JovelI , et al. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission. BMC Medicine2018;16:215. [DOI: 10.1186/s12916-018-1202-8]">Morris 2018 TZA</a> included a single round of IRS at baseline; <a href="./references#CD008846-bbs2-0004" title="LandierJ , KajeechiwaL , ThwinMM , ParkerDM , ChaumeauV , WiladphaingernJ , et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar. Wellcome Open Research2017;2:81. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Landier 2017 MMRa</a>, <a href="./references#CD008846-bbs2-0008" title="PongvongsaT , PhommasoneK , AdhikariB , HenriquesG , ChotivanichK , HanboonkunupakarnB , et al. The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin-piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos. Malaria Journal2018;17(1):405. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Pongvongsa 2018 LAO</a>, <a href="./references#CD008846-bbs2-0011" title="TripuraR , PetoTJ , CheaN , ChanD , MukakaM , SirithiranontP , et al. A controlled trial of mass drug administration to interrupt transmission of multidrug-resistant falciparum malaria in Cambodian villages. Clinical Infectious Diseases2018;67(6):817-26. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Tripura 2018 KHM</a>, and <a href="./references#CD008846-bbs2-0013" title="vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">von Seidlein 2019 VNM</a> provided uninterrupted access to case management in study villages; and <a href="./references#CD008846-bbs2-0010" title="ShekalagheSA , DrakeleyC , vanden BoschS , ter BraakR , vanden BikilaardtW , MwanzivaC , et al. A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania. Malaria Journal2011;10:247. ShekalagheSA , ter BraakR , DaouM , KavisheR , vanden BijilaardtW , vanden BoschS , et al. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A) individuals. Antimicrobial Agents and Chemotherapy2010;54(5):1762-8. ">Shekalaghe 2011 TZA</a> included a single treatment campaign for trachoma with azithromycin. </p> <p>One study administered a single round of sulfadoxine‐pyrimethamine plus artesunate with a single dose of primaquine three to five weeks prior to the start of the rainy season (<a href="./references#CD008846-bbs2-0010" title="ShekalagheSA , DrakeleyC , vanden BoschS , ter BraakR , vanden BikilaardtW , MwanzivaC , et al. A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania. Malaria Journal2011;10:247. ShekalagheSA , ter BraakR , DaouM , KavisheR , vanden BijilaardtW , vanden BoschS , et al. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A) individuals. Antimicrobial Agents and Chemotherapy2010;54(5):1762-8. ">Shekalaghe 2011 TZA</a>). All persons older than 12 months received MDA. However, pregnant women or individuals who were anaemic did not receive primaquine. </p> </section> </section> <section id="CD008846-sec-0056"> <h6 class="title">Outcomes</h6> <p>Outcome data are summarized in <a href="#CD008846-tbl-0007">Table 2</a>. </p> <div class="table" id="CD008846-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Description of outcomes</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID (design)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Parasitaemia prevalence</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Parasitaemia incidence</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Confirmed malaria illness incidence</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>All‐cause or malaria‐specific mortality</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Gametocytaemia prevalence</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Adverse effects</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008846-bbs2-0001" title="BennettA , PorterTR ,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C, et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in Southern Province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in Southern Province, Zambia: An evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. [DOI: 10.1186/s13063-015-0862-3]MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBa</a> (cRCT) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008846-bbs2-0002" title="BennettA , Porter TR,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C,   et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in southern province, Zambia: an evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence  in southern province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of Plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBb</a> (cRCT) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008846-bbs2-0003" title="EscudieA , HamonJ , SchneiderJ . Results of mass antimalarial chemoprophylaxis with a combination of 4-aminoquinoline and 8-aminoquinoline under rural African conditions in the region of Bobo-Dioulasso (Upper Volta) 1960. Comparative study in a zone treated with DDT and outside this zone. Medecine Tropicale1962;22(2):268-305. SchneiderJ , EscudieA , HamonJ . Eradication of malaria and chemotherapy. Results obtained with the association amino-4 quinoline + amino-8 quinoline in the pilot area of Bobo-Dioulasso (Haute- Volta) [Eradication du paludismeet chimiotherapie resultats d’un essai de l’association:amino–4 quinoleine/amino–8 quinoleine dans la zonepilote de Bobo–Dioulasso (Haute Volta)]. Bulletin de la Societe de Pathologie Exotique1961;54(5):1012-25. ">Escudie 1962 BFA</a> (CBA) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008846-bbs2-0004" title="LandierJ , KajeechiwaL , ThwinMM , ParkerDM , ChaumeauV , WiladphaingernJ , et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar. Wellcome Open Research2017;2:81. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Landier 2017 MMRa</a> (cRCT) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008846-bbs2-0005" title="HeatonJ , McCleanA , SweMM , SoeK , IndrasutaC , KhantZS , et al. Speeding up malaria elimination; a cluster randomized controlled trial of mass drug administration in Southeast Myanmar, an area with artemisinin resistance. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):411. McLeanAR , IndrasutaC , KhantZS , PhyoAK , MaungSM , HeatonJ , et al. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infectious Diseases 2021 June 17 [Epub ahead of print]. [DOI: 10.1016/S1473-3099(20)30997-X]">McLean 2021 MMR</a> (cRCT) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008846-bbs2-0006" title="BroggerRC , MathewsHM , StoreyJ , AshkarTS , BroggerS , MolineauxL . Changing patterns in the humoral immune response to malaria before, during and after the application of control measures: a longitudinal study in the West African savanna. Bulletin of the World Health Organization1978;56(4):579-600. MolineauxL , BroggerRC , MathewsHM , StoreyJ , AshkarTS . Longitudinal serological study of malaria in infants in the West African savanna. Comparisons in infants exposed to, or protected from, transmission from birth. Bulletin of the World Health Organisation1978;56(4):573-8. MolineauxL , GramicciaG . The Garki Project. Research on the epidemiology and control of malaria in the Sudan Savanna of West Africa. 1980. https://apps.who.int/iris/handle/10665/40316 (accessed prior to 8 July 2021). MolineauxL , StoreyJ , CohenJE , ThomasA . A longitudinal study of human malaria in the West African savanna in the absence of control measures: relationships between different Plasmodium species, in particular P. falciparum and P. malariae. American Journal of Tropical Medicine and Hygiene1980;29(5):725-37. ">Molineaux 1980 NGA</a> (CBA) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008846-bbs2-0007" title="MorrisU , MsellemM , MkaliH , IslamA , Aydin-SchmidtB , JovelI , et al. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission. BMC Medicine2018;16:215. [DOI: 10.1186/s12916-018-1202-8]">Morris 2018 TZA</a> (cRCT) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008846-bbs2-0008" title="PongvongsaT , PhommasoneK , AdhikariB , HenriquesG , ChotivanichK , HanboonkunupakarnB , et al. The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin-piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos. Malaria Journal2018;17(1):405. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Pongvongsa 2018 LAO</a> (cRCT) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008846-bbs2-0009" title="RobertsJM . Pyrimethamine (Daraprim) in the control of epidemic malaria. American Journal of Tropical Medicine and Hygiene1956;59(9):201-8. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part I. Before the campaign. American Journal of Tropical Medicine and Hygiene1964;67(7):161-8. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part II. The campaign. American Journal of Tropical Medicine and Hygiene1964;67(8):191-9. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part III. After the campaign. American Journal of Tropical Medicine and Hygiene1964;67(9):230-7. ">Roberts 1964 KEN</a> (CBA) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008846-bbs2-0010" title="ShekalagheSA , DrakeleyC , vanden BoschS , ter BraakR , vanden BikilaardtW , MwanzivaC , et al. A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania. Malaria Journal2011;10:247. ShekalagheSA , ter BraakR , DaouM , KavisheR , vanden BijilaardtW , vanden BoschS , et al. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A) individuals. Antimicrobial Agents and Chemotherapy2010;54(5):1762-8. ">Shekalaghe 2011 TZA</a> (cRCT) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008846-bbs2-0011" title="TripuraR , PetoTJ , CheaN , ChanD , MukakaM , SirithiranontP , et al. A controlled trial of mass drug administration to interrupt transmission of multidrug-resistant falciparum malaria in Cambodian villages. Clinical Infectious Diseases2018;67(6):817-26. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Tripura 2018 KHM</a> (cRCT) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008846-bbs2-0012" title="De MartinS , vonSeidleinL , DeenJL , PinderM , WalravenG , GreenwoodB . Community perceptions of a mass administration of an antimalarial drug combination in The Gambia. Tropical Medicine &amp; International Health2001;6(6):442-8. vonSeidleinL , WalravenG , MilliganPJ , AlexanderN , MannehF , DeenJL , et al. The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia. Transactions of the Royal Society of Tropical Medicine &amp; Hygiene2003;97(2):217-25. ">von Seidlein 2003 GMB</a> (cRCT) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008846-bbs2-0013" title="vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">von Seidlein 2019 VNM</a> (cRCT) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CBA = controlled before‐and‐after study, cRCT = cluster‐randomized controlled trial</p> </div> </div> <section id="CD008846-sec-0057"> <p><b>Moderate‐ to high‐transmission areas</b></p> <p>All outcomes reported were for <i>P falciparum.</i> In <a href="./references#CD008846-bbs2-0002" title="BennettA , Porter TR,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C,   et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in southern province, Zambia: an evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence  in southern province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of Plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBb</a>, parasitaemia prevalence was measured by RDT prior to MDA, during MDA (following the first two rounds), and one to three months after MDA. In <a href="./references#CD008846-bbs2-0012" title="De MartinS , vonSeidleinL , DeenJL , PinderM , WalravenG , GreenwoodB . Community perceptions of a mass administration of an antimalarial drug combination in The Gambia. Tropical Medicine &amp; International Health2001;6(6):442-8. vonSeidleinL , WalravenG , MilliganPJ , AlexanderN , MannehF , DeenJL , et al. The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia. Transactions of the Royal Society of Tropical Medicine &amp; Hygiene2003;97(2):217-25. ">von Seidlein 2003 GMB</a>, parasitaemia prevalence was measured by microscopy prior to MDA and four to six months after MDA. Both studies also reported parasitaemia incidence, but measured the outcome differently. <a href="./references#CD008846-bbs2-0002" title="BennettA , Porter TR,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C,   et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in southern province, Zambia: an evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence  in southern province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of Plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBb</a> measured parasitaemia incidence by RDT through active surveillance in a cohort of persons three months of age and older, for two months following the fourth round of MDA. In <a href="./references#CD008846-bbs2-0012" title="De MartinS , vonSeidleinL , DeenJL , PinderM , WalravenG , GreenwoodB . Community perceptions of a mass administration of an antimalarial drug combination in The Gambia. Tropical Medicine &amp; International Health2001;6(6):442-8. vonSeidleinL , WalravenG , MilliganPJ , AlexanderN , MannehF , DeenJL , et al. The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia. Transactions of the Royal Society of Tropical Medicine &amp; Hygiene2003;97(2):217-25. ">von Seidlein 2003 GMB</a>, parasitaemia incidence was captured through weekly surveillance in children under 11 years for cases with temperatures of 37.5 °C and higher, and <i>P falciparum</i> parasitaemia above 5000 parasites per µL by microscopy for five months following MDA. <a href="./references#CD008846-bbs2-0002" title="BennettA , Porter TR,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C,   et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in southern province, Zambia: an evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence  in southern province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of Plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBb</a> reported confirmed malaria illness incidence prior to MDA and one to three months after MDA. Only <a href="./references#CD008846-bbs2-0012" title="De MartinS , vonSeidleinL , DeenJL , PinderM , WalravenG , GreenwoodB . Community perceptions of a mass administration of an antimalarial drug combination in The Gambia. Tropical Medicine &amp; International Health2001;6(6):442-8. vonSeidleinL , WalravenG , MilliganPJ , AlexanderN , MannehF , DeenJL , et al. The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia. Transactions of the Royal Society of Tropical Medicine &amp; Hygiene2003;97(2):217-25. ">von Seidlein 2003 GMB</a> reported the secondary outcomes of gametocytaemia prevalence (pre‐MDA and four to six months after MDA) and malaria‐specific mortality. Both studies monitored adverse effects in the MDA study arm. </p> </section> <section id="CD008846-sec-0058"> <p><b>Very low‐ to low‐transmission areas</b></p> <p>All studies reported <i>P falciparum</i> parasitaemia prevalence, but the measurement of outcomes differed across studies with respect to follow‐up time points, population sampled, and detection method. <a href="./references#CD008846-bbs2-0001" title="BennettA , PorterTR ,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C, et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in Southern Province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in Southern Province, Zambia: An evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. [DOI: 10.1186/s13063-015-0862-3]MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBa</a>, <a href="./references#CD008846-bbs2-0004" title="LandierJ , KajeechiwaL , ThwinMM , ParkerDM , ChaumeauV , WiladphaingernJ , et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar. Wellcome Open Research2017;2:81. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Landier 2017 MMRa</a>, <a href="./references#CD008846-bbs2-0005" title="HeatonJ , McCleanA , SweMM , SoeK , IndrasutaC , KhantZS , et al. Speeding up malaria elimination; a cluster randomized controlled trial of mass drug administration in Southeast Myanmar, an area with artemisinin resistance. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):411. McLeanAR , IndrasutaC , KhantZS , PhyoAK , MaungSM , HeatonJ , et al. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infectious Diseases 2021 June 17 [Epub ahead of print]. [DOI: 10.1016/S1473-3099(20)30997-X]">McLean 2021 MMR</a>, <a href="./references#CD008846-bbs2-0008" title="PongvongsaT , PhommasoneK , AdhikariB , HenriquesG , ChotivanichK , HanboonkunupakarnB , et al. The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin-piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos. Malaria Journal2018;17(1):405. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Pongvongsa 2018 LAO</a>, <a href="./references#CD008846-bbs2-0011" title="TripuraR , PetoTJ , CheaN , ChanD , MukakaM , SirithiranontP , et al. A controlled trial of mass drug administration to interrupt transmission of multidrug-resistant falciparum malaria in Cambodian villages. Clinical Infectious Diseases2018;67(6):817-26. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Tripura 2018 KHM</a>, and <a href="./references#CD008846-bbs2-0013" title="vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">von Seidlein 2019 VNM</a> reported prevalence at baseline before MDA. The timing of the first prevalence measure reported by <a href="./references#CD008846-bbs2-0007" title="MorrisU , MsellemM , MkaliH , IslamA , Aydin-SchmidtB , JovelI , et al. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission. BMC Medicine2018;16:215. [DOI: 10.1186/s12916-018-1202-8]">Morris 2018 TZA</a> started and extended past the first round of MDA and, therefore, was classified as during MDA. <a href="./references#CD008846-bbs2-0001" title="BennettA , PorterTR ,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C, et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in Southern Province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in Southern Province, Zambia: An evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. [DOI: 10.1186/s13063-015-0862-3]MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBa</a> also reported parasitaemia prevalence during MDA following the first two MDA rounds. All studies reported the outcome at one to three months after MDA. Four studies reported prevalence at four to six months after MDA (<a href="./references#CD008846-bbs2-0004" title="LandierJ , KajeechiwaL , ThwinMM , ParkerDM , ChaumeauV , WiladphaingernJ , et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar. Wellcome Open Research2017;2:81. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Landier 2017 MMRa</a>; <a href="./references#CD008846-bbs2-0008" title="PongvongsaT , PhommasoneK , AdhikariB , HenriquesG , ChotivanichK , HanboonkunupakarnB , et al. The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin-piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos. Malaria Journal2018;17(1):405. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Pongvongsa 2018 LAO</a>; <a href="./references#CD008846-bbs2-0011" title="TripuraR , PetoTJ , CheaN , ChanD , MukakaM , SirithiranontP , et al. A controlled trial of mass drug administration to interrupt transmission of multidrug-resistant falciparum malaria in Cambodian villages. Clinical Infectious Diseases2018;67(6):817-26. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Tripura 2018 KHM</a>; <a href="./references#CD008846-bbs2-0013" title="vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">von Seidlein 2019 VNM</a>). Five studies provided prevalence at 7 to 12 months after MDA (<a href="./references#CD008846-bbs2-0004" title="LandierJ , KajeechiwaL , ThwinMM , ParkerDM , ChaumeauV , WiladphaingernJ , et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar. Wellcome Open Research2017;2:81. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Landier 2017 MMRa</a>; <a href="./references#CD008846-bbs2-0005" title="HeatonJ , McCleanA , SweMM , SoeK , IndrasutaC , KhantZS , et al. Speeding up malaria elimination; a cluster randomized controlled trial of mass drug administration in Southeast Myanmar, an area with artemisinin resistance. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):411. McLeanAR , IndrasutaC , KhantZS , PhyoAK , MaungSM , HeatonJ , et al. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infectious Diseases 2021 June 17 [Epub ahead of print]. [DOI: 10.1016/S1473-3099(20)30997-X]">McLean 2021 MMR</a>; <a href="./references#CD008846-bbs2-0008" title="PongvongsaT , PhommasoneK , AdhikariB , HenriquesG , ChotivanichK , HanboonkunupakarnB , et al. The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin-piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos. Malaria Journal2018;17(1):405. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Pongvongsa 2018 LAO</a>; <a href="./references#CD008846-bbs2-0011" title="TripuraR , PetoTJ , CheaN , ChanD , MukakaM , SirithiranontP , et al. A controlled trial of mass drug administration to interrupt transmission of multidrug-resistant falciparum malaria in Cambodian villages. Clinical Infectious Diseases2018;67(6):817-26. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Tripura 2018 KHM</a>; <a href="./references#CD008846-bbs2-0013" title="vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">von Seidlein 2019 VNM</a>). Additionally, <a href="./references#CD008846-bbs2-0005" title="HeatonJ , McCleanA , SweMM , SoeK , IndrasutaC , KhantZS , et al. Speeding up malaria elimination; a cluster randomized controlled trial of mass drug administration in Southeast Myanmar, an area with artemisinin resistance. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):411. McLeanAR , IndrasutaC , KhantZS , PhyoAK , MaungSM , HeatonJ , et al. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infectious Diseases 2021 June 17 [Epub ahead of print]. [DOI: 10.1016/S1473-3099(20)30997-X]">McLean 2021 MMR</a> reported outcomes at 13 to 18 months after MDA and at all additional follow‐up intervals through to 31 to 36 months after MDA. </p> <p><a href="./references#CD008846-bbs2-0001" title="BennettA , PorterTR ,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C, et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in Southern Province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in Southern Province, Zambia: An evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. [DOI: 10.1186/s13063-015-0862-3]MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBa</a> measured parasitaemia prevalence by RDT in children aged 5 years and older. Five studies evaluated the outcome by ultrasensitive PCR (uPCR) in either adults aged 18 to 55 years (<a href="./references#CD008846-bbs2-0005" title="HeatonJ , McCleanA , SweMM , SoeK , IndrasutaC , KhantZS , et al. Speeding up malaria elimination; a cluster randomized controlled trial of mass drug administration in Southeast Myanmar, an area with artemisinin resistance. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):411. McLeanAR , IndrasutaC , KhantZS , PhyoAK , MaungSM , HeatonJ , et al. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infectious Diseases 2021 June 17 [Epub ahead of print]. [DOI: 10.1016/S1473-3099(20)30997-X]">McLean 2021 MMR</a>), or persons six months of age and older (<a href="./references#CD008846-bbs2-0004" title="LandierJ , KajeechiwaL , ThwinMM , ParkerDM , ChaumeauV , WiladphaingernJ , et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar. Wellcome Open Research2017;2:81. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Landier 2017 MMRa</a>; <a href="./references#CD008846-bbs2-0008" title="PongvongsaT , PhommasoneK , AdhikariB , HenriquesG , ChotivanichK , HanboonkunupakarnB , et al. The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin-piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos. Malaria Journal2018;17(1):405. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Pongvongsa 2018 LAO</a>; <a href="./references#CD008846-bbs2-0011" title="TripuraR , PetoTJ , CheaN , ChanD , MukakaM , SirithiranontP , et al. A controlled trial of mass drug administration to interrupt transmission of multidrug-resistant falciparum malaria in Cambodian villages. Clinical Infectious Diseases2018;67(6):817-26. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Tripura 2018 KHM</a>; <a href="./references#CD008846-bbs2-0013" title="vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">von Seidlein 2019 VNM</a>). <a href="./references#CD008846-bbs2-0007" title="MorrisU , MsellemM , MkaliH , IslamA , Aydin-SchmidtB , JovelI , et al. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission. BMC Medicine2018;16:215. [DOI: 10.1186/s12916-018-1202-8]">Morris 2018 TZA</a> measured prevalence by 18s‐quantitative PCR (qPCR) in persons of all ages. <i>P falciparum</i> parasitaemia incidence was only reported in <a href="./references#CD008846-bbs2-0001" title="BennettA , PorterTR ,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C, et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in Southern Province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in Southern Province, Zambia: An evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. [DOI: 10.1186/s13063-015-0862-3]MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBa</a> and measured by RDT through active surveillance in a cohort of persons three months of age and older, for two months following MDA. Confirmed malaria illness incidence was reported prior to MDA and at: one to three months after MDA in <a href="./references#CD008846-bbs2-0001" title="BennettA , PorterTR ,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C, et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in Southern Province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in Southern Province, Zambia: An evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. [DOI: 10.1186/s13063-015-0862-3]MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBa</a>, <a href="./references#CD008846-bbs2-0007" title="MorrisU , MsellemM , MkaliH , IslamA , Aydin-SchmidtB , JovelI , et al. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission. BMC Medicine2018;16:215. [DOI: 10.1186/s12916-018-1202-8]">Morris 2018 TZA</a>, and <a href="./references#CD008846-bbs2-0011" title="TripuraR , PetoTJ , CheaN , ChanD , MukakaM , SirithiranontP , et al. A controlled trial of mass drug administration to interrupt transmission of multidrug-resistant falciparum malaria in Cambodian villages. Clinical Infectious Diseases2018;67(6):817-26. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Tripura 2018 KHM</a>; four to six months after MDA in <a href="./references#CD008846-bbs2-0007" title="MorrisU , MsellemM , MkaliH , IslamA , Aydin-SchmidtB , JovelI , et al. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission. BMC Medicine2018;16:215. [DOI: 10.1186/s12916-018-1202-8]">Morris 2018 TZA</a>; 7 to 12 months after MDA in <a href="./references#CD008846-bbs2-0004" title="LandierJ , KajeechiwaL , ThwinMM , ParkerDM , ChaumeauV , WiladphaingernJ , et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar. Wellcome Open Research2017;2:81. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Landier 2017 MMRa</a>, <a href="./references#CD008846-bbs2-0007" title="MorrisU , MsellemM , MkaliH , IslamA , Aydin-SchmidtB , JovelI , et al. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission. BMC Medicine2018;16:215. [DOI: 10.1186/s12916-018-1202-8]">Morris 2018 TZA</a>, and <a href="./references#CD008846-bbs2-0011" title="TripuraR , PetoTJ , CheaN , ChanD , MukakaM , SirithiranontP , et al. A controlled trial of mass drug administration to interrupt transmission of multidrug-resistant falciparum malaria in Cambodian villages. Clinical Infectious Diseases2018;67(6):817-26. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Tripura 2018 KHM</a>; and 13 to 18 months after MDA only in <a href="./references#CD008846-bbs2-0007" title="MorrisU , MsellemM , MkaliH , IslamA , Aydin-SchmidtB , JovelI , et al. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission. BMC Medicine2018;16:215. [DOI: 10.1186/s12916-018-1202-8]">Morris 2018 TZA</a>. All studies monitored adverse effects. </p> <p><a href="./references#CD008846-bbs2-0010" title="ShekalagheSA , DrakeleyC , vanden BoschS , ter BraakR , vanden BikilaardtW , MwanzivaC , et al. A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania. Malaria Journal2011;10:247. ShekalagheSA , ter BraakR , DaouM , KavisheR , vanden BijilaardtW , vanden BoschS , et al. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A) individuals. Antimicrobial Agents and Chemotherapy2010;54(5):1762-8. ">Shekalaghe 2011 TZA</a> reported parasitaemia prevalence by microscopy and quantitative nucleic acid sequence‐based amplification  (QT‐NASBA), confirmed malaria illness incidence, and gametocytaemia prevalence by microscopy in all ages prior to and after MDA up to four months, but these data were omitted from quantitative synthesis at all time points due to either zero events pre‐MDA (outcomes by microscopy) or unclear timing of post‐MDA events (outcomes by QT‐NASBA). </p> <p><i>P vivax</i> parasitaemia prevalence was reported by <a href="./references#CD008846-bbs2-0004" title="LandierJ , KajeechiwaL , ThwinMM , ParkerDM , ChaumeauV , WiladphaingernJ , et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar. Wellcome Open Research2017;2:81. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Landier 2017 MMRa</a>, <a href="./references#CD008846-bbs2-0005" title="HeatonJ , McCleanA , SweMM , SoeK , IndrasutaC , KhantZS , et al. Speeding up malaria elimination; a cluster randomized controlled trial of mass drug administration in Southeast Myanmar, an area with artemisinin resistance. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):411. McLeanAR , IndrasutaC , KhantZS , PhyoAK , MaungSM , HeatonJ , et al. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infectious Diseases 2021 June 17 [Epub ahead of print]. [DOI: 10.1016/S1473-3099(20)30997-X]">McLean 2021 MMR</a>, <a href="./references#CD008846-bbs2-0008" title="PongvongsaT , PhommasoneK , AdhikariB , HenriquesG , ChotivanichK , HanboonkunupakarnB , et al. The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin-piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos. Malaria Journal2018;17(1):405. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Pongvongsa 2018 LAO</a>, <a href="./references#CD008846-bbs2-0011" title="TripuraR , PetoTJ , CheaN , ChanD , MukakaM , SirithiranontP , et al. A controlled trial of mass drug administration to interrupt transmission of multidrug-resistant falciparum malaria in Cambodian villages. Clinical Infectious Diseases2018;67(6):817-26. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Tripura 2018 KHM</a>, and <a href="./references#CD008846-bbs2-0013" title="vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">von Seidlein 2019 VNM</a>, and included the same pre‐MDA and post‐MDA follow‐up time points, detection method, and population sampled as <i>P falciparum</i> parasitaemia. Confirmed malaria illness incidence for <i>P vivax</i> was reported prior to MDA in <a href="./references#CD008846-bbs2-0011" title="TripuraR , PetoTJ , CheaN , ChanD , MukakaM , SirithiranontP , et al. A controlled trial of mass drug administration to interrupt transmission of multidrug-resistant falciparum malaria in Cambodian villages. Clinical Infectious Diseases2018;67(6):817-26. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Tripura 2018 KHM</a>, and at 7 to 12 months after MDA in <a href="./references#CD008846-bbs2-0004" title="LandierJ , KajeechiwaL , ThwinMM , ParkerDM , ChaumeauV , WiladphaingernJ , et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar. Wellcome Open Research2017;2:81. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Landier 2017 MMRa</a>; and <a href="./references#CD008846-bbs2-0011" title="TripuraR , PetoTJ , CheaN , ChanD , MukakaM , SirithiranontP , et al. A controlled trial of mass drug administration to interrupt transmission of multidrug-resistant falciparum malaria in Cambodian villages. Clinical Infectious Diseases2018;67(6):817-26. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Tripura 2018 KHM</a>. </p> </section> </section> </section> <section id="CD008846-sec-0059"> <h5 class="title">Non‐randomized controlled studies</h5> <p>We included three CBA studies in qualitative syntheses. All studies were conducted in areas of moderate to high endemicity (moderate: <a href="./references#CD008846-bbs2-0009" title="RobertsJM . Pyrimethamine (Daraprim) in the control of epidemic malaria. American Journal of Tropical Medicine and Hygiene1956;59(9):201-8. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part I. Before the campaign. American Journal of Tropical Medicine and Hygiene1964;67(7):161-8. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part II. The campaign. American Journal of Tropical Medicine and Hygiene1964;67(8):191-9. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part III. After the campaign. American Journal of Tropical Medicine and Hygiene1964;67(9):230-7. ">Roberts 1964 KEN</a>; high: <a href="./references#CD008846-bbs2-0003" title="EscudieA , HamonJ , SchneiderJ . Results of mass antimalarial chemoprophylaxis with a combination of 4-aminoquinoline and 8-aminoquinoline under rural African conditions in the region of Bobo-Dioulasso (Upper Volta) 1960. Comparative study in a zone treated with DDT and outside this zone. Medecine Tropicale1962;22(2):268-305. SchneiderJ , EscudieA , HamonJ . Eradication of malaria and chemotherapy. Results obtained with the association amino-4 quinoline + amino-8 quinoline in the pilot area of Bobo-Dioulasso (Haute- Volta) [Eradication du paludismeet chimiotherapie resultats d’un essai de l’association:amino–4 quinoleine/amino–8 quinoleine dans la zonepilote de Bobo–Dioulasso (Haute Volta)]. Bulletin de la Societe de Pathologie Exotique1961;54(5):1012-25. ">Escudie 1962 BFA</a>; <a href="./references#CD008846-bbs2-0006" title="BroggerRC , MathewsHM , StoreyJ , AshkarTS , BroggerS , MolineauxL . Changing patterns in the humoral immune response to malaria before, during and after the application of control measures: a longitudinal study in the West African savanna. Bulletin of the World Health Organization1978;56(4):579-600. MolineauxL , BroggerRC , MathewsHM , StoreyJ , AshkarTS . Longitudinal serological study of malaria in infants in the West African savanna. Comparisons in infants exposed to, or protected from, transmission from birth. Bulletin of the World Health Organisation1978;56(4):573-8. MolineauxL , GramicciaG . The Garki Project. Research on the epidemiology and control of malaria in the Sudan Savanna of West Africa. 1980. https://apps.who.int/iris/handle/10665/40316 (accessed prior to 8 July 2021). MolineauxL , StoreyJ , CohenJE , ThomasA . A longitudinal study of human malaria in the West African savanna in the absence of control measures: relationships between different Plasmodium species, in particular P. falciparum and P. malariae. American Journal of Tropical Medicine and Hygiene1980;29(5):725-37. ">Molineaux 1980 NGA</a>). All studies were conducted in sub‐Saharan Africa in the countries of Burkina Faso (<a href="./references#CD008846-bbs2-0003" title="EscudieA , HamonJ , SchneiderJ . Results of mass antimalarial chemoprophylaxis with a combination of 4-aminoquinoline and 8-aminoquinoline under rural African conditions in the region of Bobo-Dioulasso (Upper Volta) 1960. Comparative study in a zone treated with DDT and outside this zone. Medecine Tropicale1962;22(2):268-305. SchneiderJ , EscudieA , HamonJ . Eradication of malaria and chemotherapy. Results obtained with the association amino-4 quinoline + amino-8 quinoline in the pilot area of Bobo-Dioulasso (Haute- Volta) [Eradication du paludismeet chimiotherapie resultats d’un essai de l’association:amino–4 quinoleine/amino–8 quinoleine dans la zonepilote de Bobo–Dioulasso (Haute Volta)]. Bulletin de la Societe de Pathologie Exotique1961;54(5):1012-25. ">Escudie 1962 BFA</a>), Kenya (<a href="./references#CD008846-bbs2-0009" title="RobertsJM . Pyrimethamine (Daraprim) in the control of epidemic malaria. American Journal of Tropical Medicine and Hygiene1956;59(9):201-8. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part I. Before the campaign. American Journal of Tropical Medicine and Hygiene1964;67(7):161-8. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part II. The campaign. American Journal of Tropical Medicine and Hygiene1964;67(8):191-9. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part III. After the campaign. American Journal of Tropical Medicine and Hygiene1964;67(9):230-7. ">Roberts 1964 KEN</a>), and Nigeria (<a href="./references#CD008846-bbs2-0006" title="BroggerRC , MathewsHM , StoreyJ , AshkarTS , BroggerS , MolineauxL . Changing patterns in the humoral immune response to malaria before, during and after the application of control measures: a longitudinal study in the West African savanna. Bulletin of the World Health Organization1978;56(4):579-600. MolineauxL , BroggerRC , MathewsHM , StoreyJ , AshkarTS . Longitudinal serological study of malaria in infants in the West African savanna. Comparisons in infants exposed to, or protected from, transmission from birth. Bulletin of the World Health Organisation1978;56(4):573-8. MolineauxL , GramicciaG . The Garki Project. Research on the epidemiology and control of malaria in the Sudan Savanna of West Africa. 1980. https://apps.who.int/iris/handle/10665/40316 (accessed prior to 8 July 2021). MolineauxL , StoreyJ , CohenJE , ThomasA . A longitudinal study of human malaria in the West African savanna in the absence of control measures: relationships between different Plasmodium species, in particular P. falciparum and P. malariae. American Journal of Tropical Medicine and Hygiene1980;29(5):725-37. ">Molineaux 1980 NGA</a>). </p> <p><a href="./references#CD008846-bbs2-0003" title="EscudieA , HamonJ , SchneiderJ . Results of mass antimalarial chemoprophylaxis with a combination of 4-aminoquinoline and 8-aminoquinoline under rural African conditions in the region of Bobo-Dioulasso (Upper Volta) 1960. Comparative study in a zone treated with DDT and outside this zone. Medecine Tropicale1962;22(2):268-305. SchneiderJ , EscudieA , HamonJ . Eradication of malaria and chemotherapy. Results obtained with the association amino-4 quinoline + amino-8 quinoline in the pilot area of Bobo-Dioulasso (Haute- Volta) [Eradication du paludismeet chimiotherapie resultats d’un essai de l’association:amino–4 quinoleine/amino–8 quinoleine dans la zonepilote de Bobo–Dioulasso (Haute Volta)]. Bulletin de la Societe de Pathologie Exotique1961;54(5):1012-25. ">Escudie 1962 BFA</a> included six arms (chloroquine plus primaquine or amodiaquine plus primaquine every four weeks; chloroquine plus primaquine or amodiaquine plus primaquine every two weeks; chloroquine plus primaquine or amodiaquine plus primaquine every four weeks with IRS; chloroquine plus primaquine or amodiaquine plus primaquine every two weeks with IRS; IRS only; non‐IRS control). Of these six arms, three arms with two comparisons contributed to this review: chloroquine plus primaquine or amodiaquine plus primaquine every four weeks ('low frequency'); chloroquine plus primaquine or amodiaquine plus primaquine every two weeks ('high frequency'); and non‐IRS control. Given similar mechanisms of antimalarial action for chloroquine and amodiaquine, and the combined reporting of outcomes at post‐MDA time points, these drugs were not analysed as separate groups within the six arms described. Of the four arms included in <a href="./references#CD008846-bbs2-0006" title="BroggerRC , MathewsHM , StoreyJ , AshkarTS , BroggerS , MolineauxL . Changing patterns in the humoral immune response to malaria before, during and after the application of control measures: a longitudinal study in the West African savanna. Bulletin of the World Health Organization1978;56(4):579-600. MolineauxL , BroggerRC , MathewsHM , StoreyJ , AshkarTS . Longitudinal serological study of malaria in infants in the West African savanna. Comparisons in infants exposed to, or protected from, transmission from birth. Bulletin of the World Health Organisation1978;56(4):573-8. MolineauxL , GramicciaG . The Garki Project. Research on the epidemiology and control of malaria in the Sudan Savanna of West Africa. 1980. https://apps.who.int/iris/handle/10665/40316 (accessed prior to 8 July 2021). MolineauxL , StoreyJ , CohenJE , ThomasA . A longitudinal study of human malaria in the West African savanna in the absence of control measures: relationships between different Plasmodium species, in particular P. falciparum and P. malariae. American Journal of Tropical Medicine and Hygiene1980;29(5):725-37. ">Molineaux 1980 NGA</a> (low frequency MDA plus IRS, high frequency MDA plus IRS, IRS only, and no intervention), we included three arms with two comparisons in this review: low frequency MDA plus IRS, high frequency MDA plus IRS, and IRS only). <a href="./references#CD008846-bbs2-0009" title="RobertsJM . Pyrimethamine (Daraprim) in the control of epidemic malaria. American Journal of Tropical Medicine and Hygiene1956;59(9):201-8. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part I. Before the campaign. American Journal of Tropical Medicine and Hygiene1964;67(7):161-8. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part II. The campaign. American Journal of Tropical Medicine and Hygiene1964;67(8):191-9. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part III. After the campaign. American Journal of Tropical Medicine and Hygiene1964;67(9):230-7. ">Roberts 1964 KEN</a> compared MDA to no MDA and all data provided comparisons for this review. </p> <section id="CD008846-sec-0060"> <h6 class="title">Interventions</h6> <p>Characteristics of the intervention have been summarized in <a href="#CD008846-tbl-0006">Table 1</a>. </p> <p>All studies administered multiple rounds of MDA using different antimalarials and at different frequencies of MDA rounds. <a href="./references#CD008846-bbs2-0003" title="EscudieA , HamonJ , SchneiderJ . Results of mass antimalarial chemoprophylaxis with a combination of 4-aminoquinoline and 8-aminoquinoline under rural African conditions in the region of Bobo-Dioulasso (Upper Volta) 1960. Comparative study in a zone treated with DDT and outside this zone. Medecine Tropicale1962;22(2):268-305. SchneiderJ , EscudieA , HamonJ . Eradication of malaria and chemotherapy. Results obtained with the association amino-4 quinoline + amino-8 quinoline in the pilot area of Bobo-Dioulasso (Haute- Volta) [Eradication du paludismeet chimiotherapie resultats d’un essai de l’association:amino–4 quinoleine/amino–8 quinoleine dans la zonepilote de Bobo–Dioulasso (Haute Volta)]. Bulletin de la Societe de Pathologie Exotique1961;54(5):1012-25. ">Escudie 1962 BFA</a> administered MDA with a single dose of chloroquine plus primaquine or amodiaquine plus primaquine every four weeks for seven rounds, or every two weeks for 15 rounds to the entire population (all ages). MDA coverage ranged from 75% to 91% per round in the four‐week low frequency MDA arm and 84% to 97% per round in the two‐week high frequency MDA arm. <a href="./references#CD008846-bbs2-0006" title="BroggerRC , MathewsHM , StoreyJ , AshkarTS , BroggerS , MolineauxL . Changing patterns in the humoral immune response to malaria before, during and after the application of control measures: a longitudinal study in the West African savanna. Bulletin of the World Health Organization1978;56(4):579-600. MolineauxL , BroggerRC , MathewsHM , StoreyJ , AshkarTS . Longitudinal serological study of malaria in infants in the West African savanna. Comparisons in infants exposed to, or protected from, transmission from birth. Bulletin of the World Health Organisation1978;56(4):573-8. MolineauxL , GramicciaG . The Garki Project. Research on the epidemiology and control of malaria in the Sudan Savanna of West Africa. 1980. https://apps.who.int/iris/handle/10665/40316 (accessed prior to 8 July 2021). MolineauxL , StoreyJ , CohenJE , ThomasA . A longitudinal study of human malaria in the West African savanna in the absence of control measures: relationships between different Plasmodium species, in particular P. falciparum and P. malariae. American Journal of Tropical Medicine and Hygiene1980;29(5):725-37. ">Molineaux 1980 NGA</a> administered MDA with sulfalene‐pyrimethamine either every 10 weeks ('low frequency MDA') or every 2 weeks during the wet season and every 10 weeks during the dry season ('high frequency MDA') to all ages except infants prior to their first malaria episode. MDA coverage was similar across arms, ranging from 73% to 92% per round in the low frequency MDA arm and 72% to 91% in the high frequency MDA arm. In <a href="./references#CD008846-bbs2-0009" title="RobertsJM . Pyrimethamine (Daraprim) in the control of epidemic malaria. American Journal of Tropical Medicine and Hygiene1956;59(9):201-8. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part I. Before the campaign. American Journal of Tropical Medicine and Hygiene1964;67(7):161-8. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part II. The campaign. American Journal of Tropical Medicine and Hygiene1964;67(8):191-9. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part III. After the campaign. American Journal of Tropical Medicine and Hygiene1964;67(9):230-7. ">Roberts 1964 KEN</a>, two rounds of MDA with pyrimethamine were administered once a year (at the start of the rainy season) to all ages with coverage of 95% in round one and 93% in round two. </p> <p><a href="./references#CD008846-bbs2-0006" title="BroggerRC , MathewsHM , StoreyJ , AshkarTS , BroggerS , MolineauxL . Changing patterns in the humoral immune response to malaria before, during and after the application of control measures: a longitudinal study in the West African savanna. Bulletin of the World Health Organization1978;56(4):579-600. MolineauxL , BroggerRC , MathewsHM , StoreyJ , AshkarTS . Longitudinal serological study of malaria in infants in the West African savanna. Comparisons in infants exposed to, or protected from, transmission from birth. Bulletin of the World Health Organisation1978;56(4):573-8. MolineauxL , GramicciaG . The Garki Project. Research on the epidemiology and control of malaria in the Sudan Savanna of West Africa. 1980. https://apps.who.int/iris/handle/10665/40316 (accessed prior to 8 July 2021). MolineauxL , StoreyJ , CohenJE , ThomasA . A longitudinal study of human malaria in the West African savanna in the absence of control measures: relationships between different Plasmodium species, in particular P. falciparum and P. malariae. American Journal of Tropical Medicine and Hygiene1980;29(5):725-37. ">Molineaux 1980 NGA</a> administered IRS using propoxur for three to four rounds per year in all arms, but there were no co‐interventions in the other two studies. </p> </section> <section id="CD008846-sec-0061"> <h6 class="title">Outcomes</h6> <p>Outcome data are summarized in <a href="#CD008846-tbl-0007">Table 2</a>. </p> <p>All outcomes reported were for <i>P falciparum.</i> All studies reported parasitaemia prevalence by microscopy at pre‐MDA and during‐MDA time points, but outcomes were assessed for different lengths of post‐MDA follow‐up and in different age groups. <a href="./references#CD008846-bbs2-0006" title="BroggerRC , MathewsHM , StoreyJ , AshkarTS , BroggerS , MolineauxL . Changing patterns in the humoral immune response to malaria before, during and after the application of control measures: a longitudinal study in the West African savanna. Bulletin of the World Health Organization1978;56(4):579-600. MolineauxL , BroggerRC , MathewsHM , StoreyJ , AshkarTS . Longitudinal serological study of malaria in infants in the West African savanna. Comparisons in infants exposed to, or protected from, transmission from birth. Bulletin of the World Health Organisation1978;56(4):573-8. MolineauxL , GramicciaG . The Garki Project. Research on the epidemiology and control of malaria in the Sudan Savanna of West Africa. 1980. https://apps.who.int/iris/handle/10665/40316 (accessed prior to 8 July 2021). MolineauxL , StoreyJ , CohenJE , ThomasA . A longitudinal study of human malaria in the West African savanna in the absence of control measures: relationships between different Plasmodium species, in particular P. falciparum and P. malariae. American Journal of Tropical Medicine and Hygiene1980;29(5):725-37. ">Molineaux 1980 NGA</a> provided no post‐MDA data, <a href="./references#CD008846-bbs2-0003" title="EscudieA , HamonJ , SchneiderJ . Results of mass antimalarial chemoprophylaxis with a combination of 4-aminoquinoline and 8-aminoquinoline under rural African conditions in the region of Bobo-Dioulasso (Upper Volta) 1960. Comparative study in a zone treated with DDT and outside this zone. Medecine Tropicale1962;22(2):268-305. SchneiderJ , EscudieA , HamonJ . Eradication of malaria and chemotherapy. Results obtained with the association amino-4 quinoline + amino-8 quinoline in the pilot area of Bobo-Dioulasso (Haute- Volta) [Eradication du paludismeet chimiotherapie resultats d’un essai de l’association:amino–4 quinoleine/amino–8 quinoleine dans la zonepilote de Bobo–Dioulasso (Haute Volta)]. Bulletin de la Societe de Pathologie Exotique1961;54(5):1012-25. ">Escudie 1962 BFA</a> reported parasitaemia prevalence at one to three months after MDA, and <a href="./references#CD008846-bbs2-0009" title="RobertsJM . Pyrimethamine (Daraprim) in the control of epidemic malaria. American Journal of Tropical Medicine and Hygiene1956;59(9):201-8. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part I. Before the campaign. American Journal of Tropical Medicine and Hygiene1964;67(7):161-8. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part II. The campaign. American Journal of Tropical Medicine and Hygiene1964;67(8):191-9. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part III. After the campaign. American Journal of Tropical Medicine and Hygiene1964;67(9):230-7. ">Roberts 1964 KEN</a> provided parasitaemia prevalence at time points up to 7 to 12 months after MDA. Two studies assessed parasitaemia prevalence in all age groups (<a href="./references#CD008846-bbs2-0006" title="BroggerRC , MathewsHM , StoreyJ , AshkarTS , BroggerS , MolineauxL . Changing patterns in the humoral immune response to malaria before, during and after the application of control measures: a longitudinal study in the West African savanna. Bulletin of the World Health Organization1978;56(4):579-600. MolineauxL , BroggerRC , MathewsHM , StoreyJ , AshkarTS . Longitudinal serological study of malaria in infants in the West African savanna. Comparisons in infants exposed to, or protected from, transmission from birth. Bulletin of the World Health Organisation1978;56(4):573-8. MolineauxL , GramicciaG . The Garki Project. Research on the epidemiology and control of malaria in the Sudan Savanna of West Africa. 1980. https://apps.who.int/iris/handle/10665/40316 (accessed prior to 8 July 2021). MolineauxL , StoreyJ , CohenJE , ThomasA . A longitudinal study of human malaria in the West African savanna in the absence of control measures: relationships between different Plasmodium species, in particular P. falciparum and P. malariae. American Journal of Tropical Medicine and Hygiene1980;29(5):725-37. ">Molineaux 1980 NGA</a>; <a href="./references#CD008846-bbs2-0009" title="RobertsJM . Pyrimethamine (Daraprim) in the control of epidemic malaria. American Journal of Tropical Medicine and Hygiene1956;59(9):201-8. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part I. Before the campaign. American Journal of Tropical Medicine and Hygiene1964;67(7):161-8. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part II. The campaign. American Journal of Tropical Medicine and Hygiene1964;67(8):191-9. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part III. After the campaign. American Journal of Tropical Medicine and Hygiene1964;67(9):230-7. ">Roberts 1964 KEN</a>), and <a href="./references#CD008846-bbs2-0003" title="EscudieA , HamonJ , SchneiderJ . Results of mass antimalarial chemoprophylaxis with a combination of 4-aminoquinoline and 8-aminoquinoline under rural African conditions in the region of Bobo-Dioulasso (Upper Volta) 1960. Comparative study in a zone treated with DDT and outside this zone. Medecine Tropicale1962;22(2):268-305. SchneiderJ , EscudieA , HamonJ . Eradication of malaria and chemotherapy. Results obtained with the association amino-4 quinoline + amino-8 quinoline in the pilot area of Bobo-Dioulasso (Haute- Volta) [Eradication du paludismeet chimiotherapie resultats d’un essai de l’association:amino–4 quinoleine/amino–8 quinoleine dans la zonepilote de Bobo–Dioulasso (Haute Volta)]. Bulletin de la Societe de Pathologie Exotique1961;54(5):1012-25. ">Escudie 1962 BFA</a> assessed parasitaemia prevalence only in children aged two to nine years. Gametocytaemia prevalence was reported by <a href="./references#CD008846-bbs2-0003" title="EscudieA , HamonJ , SchneiderJ . Results of mass antimalarial chemoprophylaxis with a combination of 4-aminoquinoline and 8-aminoquinoline under rural African conditions in the region of Bobo-Dioulasso (Upper Volta) 1960. Comparative study in a zone treated with DDT and outside this zone. Medecine Tropicale1962;22(2):268-305. SchneiderJ , EscudieA , HamonJ . Eradication of malaria and chemotherapy. Results obtained with the association amino-4 quinoline + amino-8 quinoline in the pilot area of Bobo-Dioulasso (Haute- Volta) [Eradication du paludismeet chimiotherapie resultats d’un essai de l’association:amino–4 quinoleine/amino–8 quinoleine dans la zonepilote de Bobo–Dioulasso (Haute Volta)]. Bulletin de la Societe de Pathologie Exotique1961;54(5):1012-25. ">Escudie 1962 BFA</a> in children aged two to nine years prior to MDA, during MDA, and one to three months after MDA, and by <a href="./references#CD008846-bbs2-0006" title="BroggerRC , MathewsHM , StoreyJ , AshkarTS , BroggerS , MolineauxL . Changing patterns in the humoral immune response to malaria before, during and after the application of control measures: a longitudinal study in the West African savanna. Bulletin of the World Health Organization1978;56(4):579-600. MolineauxL , BroggerRC , MathewsHM , StoreyJ , AshkarTS . Longitudinal serological study of malaria in infants in the West African savanna. Comparisons in infants exposed to, or protected from, transmission from birth. Bulletin of the World Health Organisation1978;56(4):573-8. MolineauxL , GramicciaG . The Garki Project. Research on the epidemiology and control of malaria in the Sudan Savanna of West Africa. 1980. https://apps.who.int/iris/handle/10665/40316 (accessed prior to 8 July 2021). MolineauxL , StoreyJ , CohenJE , ThomasA . A longitudinal study of human malaria in the West African savanna in the absence of control measures: relationships between different Plasmodium species, in particular P. falciparum and P. malariae. American Journal of Tropical Medicine and Hygiene1980;29(5):725-37. ">Molineaux 1980 NGA</a> in all ages, prior to MDA and during MDA (no post‐MDA time points). No other outcomes, including adverse effects, were reported by these studies. </p> </section> </section> </section> <section id="CD008846-sec-0062"> <h4 class="title">Excluded studies</h4> <p>We excluded 25 articles for the following reasons: 13 were duplicates (cross‐referenced articles of another study); 10 failed to meet the study design inclusion criteria; and two were the incorrect intervention or inadequate treatment dose. We have provided detailed reasons in the <a href="./references#CD008846-sec-0127" title="">Characteristics of excluded studies</a>. </p> <p>Two additional excluded studies were unpublished trials that are awaiting classification (<a href="./references#CD008846-sec-0128" title="">Characteristics of studies awaiting classification</a>). We made several attempts to contact <a href="./references#CD008846-bbs2-0028" title="ChiCTR-POC-16009019. Protocol of study on the therapeutic tolerability of Artequick/Femse/Togo. chictr.org.cn/showprojen.aspx?proj=15217 (first received 13 August 2016). ">Song TGO</a>, but did not receive a response. We were unable to obtain sufficient information from authors of <a href="./references#CD008846-bbs2-0027" title="NCT00646126. Antimalarial treatments for clearing low density P. falciparum and its impact on malaria transmission. clinicaltrials.gov/ct2/show/NCT00646126 (first received 28 March 2008). ">El‐Sayed SDN</a> to assess the trial for eligibility. However, we plan to screen the study should the authors publish the results.  </p> </section> </section> <section id="CD008846-sec-0063"> <h3 class="title">Risk of bias in included studies</h3> <p>Our summary assessment for risks of bias are shown in <a href="#CD008846-fig-0002">Figure 2</a> and <a href="#CD008846-fig-0003">Figure 3</a>, and details are provided for each study in the <a href="./references#CD008846-sec-0126" title="">Characteristics of included studies</a> tables. </p> <div class="figure" id="CD008846-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD008846-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_n/nCD008846-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <div class="figure" id="CD008846-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD008846-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_n/nCD008846-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <section id="CD008846-sec-0064"> <h4 class="title">Allocation</h4> <p>We assessed nine studies as low risk of bias for random sequence generation due to the use of a computerized randomization algorithm (<a href="./references#CD008846-bbs2-0001" title="BennettA , PorterTR ,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C, et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in Southern Province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in Southern Province, Zambia: An evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. [DOI: 10.1186/s13063-015-0862-3]MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBa</a>; <a href="./references#CD008846-bbs2-0002" title="BennettA , Porter TR,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C,   et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in southern province, Zambia: an evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence  in southern province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of Plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBb</a>; <a href="./references#CD008846-bbs2-0004" title="LandierJ , KajeechiwaL , ThwinMM , ParkerDM , ChaumeauV , WiladphaingernJ , et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar. Wellcome Open Research2017;2:81. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Landier 2017 MMRa</a>; <a href="./references#CD008846-bbs2-0007" title="MorrisU , MsellemM , MkaliH , IslamA , Aydin-SchmidtB , JovelI , et al. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission. BMC Medicine2018;16:215. [DOI: 10.1186/s12916-018-1202-8]">Morris 2018 TZA</a>; <a href="./references#CD008846-bbs2-0008" title="PongvongsaT , PhommasoneK , AdhikariB , HenriquesG , ChotivanichK , HanboonkunupakarnB , et al. The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin-piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos. Malaria Journal2018;17(1):405. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Pongvongsa 2018 LAO</a>; <a href="./references#CD008846-bbs2-0010" title="ShekalagheSA , DrakeleyC , vanden BoschS , ter BraakR , vanden BikilaardtW , MwanzivaC , et al. A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania. Malaria Journal2011;10:247. ShekalagheSA , ter BraakR , DaouM , KavisheR , vanden BijilaardtW , vanden BoschS , et al. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A) individuals. Antimicrobial Agents and Chemotherapy2010;54(5):1762-8. ">Shekalaghe 2011 TZA</a>; <a href="./references#CD008846-bbs2-0011" title="TripuraR , PetoTJ , CheaN , ChanD , MukakaM , SirithiranontP , et al. A controlled trial of mass drug administration to interrupt transmission of multidrug-resistant falciparum malaria in Cambodian villages. Clinical Infectious Diseases2018;67(6):817-26. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Tripura 2018 KHM</a>; <a href="./references#CD008846-bbs2-0012" title="De MartinS , vonSeidleinL , DeenJL , PinderM , WalravenG , GreenwoodB . Community perceptions of a mass administration of an antimalarial drug combination in The Gambia. Tropical Medicine &amp; International Health2001;6(6):442-8. vonSeidleinL , WalravenG , MilliganPJ , AlexanderN , MannehF , DeenJL , et al. The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia. Transactions of the Royal Society of Tropical Medicine &amp; Hygiene2003;97(2):217-25. ">von Seidlein 2003 GMB</a>; <a href="./references#CD008846-bbs2-0013" title="vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">von Seidlein 2019 VNM</a>). We assessed the remaining four studies as high risk of bias, due to lack of randomization (<a href="./references#CD008846-bbs2-0003" title="EscudieA , HamonJ , SchneiderJ . Results of mass antimalarial chemoprophylaxis with a combination of 4-aminoquinoline and 8-aminoquinoline under rural African conditions in the region of Bobo-Dioulasso (Upper Volta) 1960. Comparative study in a zone treated with DDT and outside this zone. Medecine Tropicale1962;22(2):268-305. SchneiderJ , EscudieA , HamonJ . Eradication of malaria and chemotherapy. Results obtained with the association amino-4 quinoline + amino-8 quinoline in the pilot area of Bobo-Dioulasso (Haute- Volta) [Eradication du paludismeet chimiotherapie resultats d’un essai de l’association:amino–4 quinoleine/amino–8 quinoleine dans la zonepilote de Bobo–Dioulasso (Haute Volta)]. Bulletin de la Societe de Pathologie Exotique1961;54(5):1012-25. ">Escudie 1962 BFA</a>; <a href="./references#CD008846-bbs2-0006" title="BroggerRC , MathewsHM , StoreyJ , AshkarTS , BroggerS , MolineauxL . Changing patterns in the humoral immune response to malaria before, during and after the application of control measures: a longitudinal study in the West African savanna. Bulletin of the World Health Organization1978;56(4):579-600. MolineauxL , BroggerRC , MathewsHM , StoreyJ , AshkarTS . Longitudinal serological study of malaria in infants in the West African savanna. Comparisons in infants exposed to, or protected from, transmission from birth. Bulletin of the World Health Organisation1978;56(4):573-8. MolineauxL , GramicciaG . The Garki Project. Research on the epidemiology and control of malaria in the Sudan Savanna of West Africa. 1980. https://apps.who.int/iris/handle/10665/40316 (accessed prior to 8 July 2021). MolineauxL , StoreyJ , CohenJE , ThomasA . A longitudinal study of human malaria in the West African savanna in the absence of control measures: relationships between different Plasmodium species, in particular P. falciparum and P. malariae. American Journal of Tropical Medicine and Hygiene1980;29(5):725-37. ">Molineaux 1980 NGA</a>; <a href="./references#CD008846-bbs2-0009" title="RobertsJM . Pyrimethamine (Daraprim) in the control of epidemic malaria. American Journal of Tropical Medicine and Hygiene1956;59(9):201-8. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part I. Before the campaign. American Journal of Tropical Medicine and Hygiene1964;67(7):161-8. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part II. The campaign. American Journal of Tropical Medicine and Hygiene1964;67(8):191-9. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part III. After the campaign. American Journal of Tropical Medicine and Hygiene1964;67(9):230-7. ">Roberts 1964 KEN</a>), or the use of a non‐computerized randomization method (<a href="./references#CD008846-bbs2-0005" title="HeatonJ , McCleanA , SweMM , SoeK , IndrasutaC , KhantZS , et al. Speeding up malaria elimination; a cluster randomized controlled trial of mass drug administration in Southeast Myanmar, an area with artemisinin resistance. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):411. McLeanAR , IndrasutaC , KhantZS , PhyoAK , MaungSM , HeatonJ , et al. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infectious Diseases 2021 June 17 [Epub ahead of print]. [DOI: 10.1016/S1473-3099(20)30997-X]">McLean 2021 MMR</a>). We judged all 10 cRCTs to be at low risk for bias related to allocation concealment since allocation was performed by an institution, and all non‐randomized studies to be at high risk of bias for allocation concealment. </p> </section> <section id="CD008846-sec-0065"> <h4 class="title">Blinding</h4> <section id="CD008846-sec-0066"> <h5 class="title">Parasitaemia prevalence</h5> <p>We assessed two placebo‐controlled studies as low risk for performance bias since participants and study staff were blinded (<a href="./references#CD008846-bbs2-0010" title="ShekalagheSA , DrakeleyC , vanden BoschS , ter BraakR , vanden BikilaardtW , MwanzivaC , et al. A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania. Malaria Journal2011;10:247. ShekalagheSA , ter BraakR , DaouM , KavisheR , vanden BijilaardtW , vanden BoschS , et al. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A) individuals. Antimicrobial Agents and Chemotherapy2010;54(5):1762-8. ">Shekalaghe 2011 TZA</a>; <a href="./references#CD008846-bbs2-0012" title="De MartinS , vonSeidleinL , DeenJL , PinderM , WalravenG , GreenwoodB . Community perceptions of a mass administration of an antimalarial drug combination in The Gambia. Tropical Medicine &amp; International Health2001;6(6):442-8. vonSeidleinL , WalravenG , MilliganPJ , AlexanderN , MannehF , DeenJL , et al. The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia. Transactions of the Royal Society of Tropical Medicine &amp; Hygiene2003;97(2):217-25. ">von Seidlein 2003 GMB</a>). We judged all other studies, which included non‐MDA control groups, as unclear risk for performance bias since participants were not blinded and it was unclear whether or how this could affect this outcome. </p> <p>Outcome assessment by laboratory staff was blinded to study arm in nine studies, and we judged these as low risk (<a href="./references#CD008846-bbs2-0004" title="LandierJ , KajeechiwaL , ThwinMM , ParkerDM , ChaumeauV , WiladphaingernJ , et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar. Wellcome Open Research2017;2:81. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Landier 2017 MMRa</a>; <a href="./references#CD008846-bbs2-0005" title="HeatonJ , McCleanA , SweMM , SoeK , IndrasutaC , KhantZS , et al. Speeding up malaria elimination; a cluster randomized controlled trial of mass drug administration in Southeast Myanmar, an area with artemisinin resistance. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):411. McLeanAR , IndrasutaC , KhantZS , PhyoAK , MaungSM , HeatonJ , et al. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infectious Diseases 2021 June 17 [Epub ahead of print]. [DOI: 10.1016/S1473-3099(20)30997-X]">McLean 2021 MMR</a>; <a href="./references#CD008846-bbs2-0006" title="BroggerRC , MathewsHM , StoreyJ , AshkarTS , BroggerS , MolineauxL . Changing patterns in the humoral immune response to malaria before, during and after the application of control measures: a longitudinal study in the West African savanna. Bulletin of the World Health Organization1978;56(4):579-600. MolineauxL , BroggerRC , MathewsHM , StoreyJ , AshkarTS . Longitudinal serological study of malaria in infants in the West African savanna. Comparisons in infants exposed to, or protected from, transmission from birth. Bulletin of the World Health Organisation1978;56(4):573-8. MolineauxL , GramicciaG . The Garki Project. Research on the epidemiology and control of malaria in the Sudan Savanna of West Africa. 1980. https://apps.who.int/iris/handle/10665/40316 (accessed prior to 8 July 2021). MolineauxL , StoreyJ , CohenJE , ThomasA . A longitudinal study of human malaria in the West African savanna in the absence of control measures: relationships between different Plasmodium species, in particular P. falciparum and P. malariae. American Journal of Tropical Medicine and Hygiene1980;29(5):725-37. ">Molineaux 1980 NGA</a>; <a href="./references#CD008846-bbs2-0007" title="MorrisU , MsellemM , MkaliH , IslamA , Aydin-SchmidtB , JovelI , et al. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission. BMC Medicine2018;16:215. [DOI: 10.1186/s12916-018-1202-8]">Morris 2018 TZA</a>; <a href="./references#CD008846-bbs2-0008" title="PongvongsaT , PhommasoneK , AdhikariB , HenriquesG , ChotivanichK , HanboonkunupakarnB , et al. The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin-piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos. Malaria Journal2018;17(1):405. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Pongvongsa 2018 LAO</a>; <a href="./references#CD008846-bbs2-0010" title="ShekalagheSA , DrakeleyC , vanden BoschS , ter BraakR , vanden BikilaardtW , MwanzivaC , et al. A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania. Malaria Journal2011;10:247. ShekalagheSA , ter BraakR , DaouM , KavisheR , vanden BijilaardtW , vanden BoschS , et al. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A) individuals. Antimicrobial Agents and Chemotherapy2010;54(5):1762-8. ">Shekalaghe 2011 TZA</a>; <a href="./references#CD008846-bbs2-0011" title="TripuraR , PetoTJ , CheaN , ChanD , MukakaM , SirithiranontP , et al. A controlled trial of mass drug administration to interrupt transmission of multidrug-resistant falciparum malaria in Cambodian villages. Clinical Infectious Diseases2018;67(6):817-26. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Tripura 2018 KHM</a>; <a href="./references#CD008846-bbs2-0012" title="De MartinS , vonSeidleinL , DeenJL , PinderM , WalravenG , GreenwoodB . Community perceptions of a mass administration of an antimalarial drug combination in The Gambia. Tropical Medicine &amp; International Health2001;6(6):442-8. vonSeidleinL , WalravenG , MilliganPJ , AlexanderN , MannehF , DeenJL , et al. The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia. Transactions of the Royal Society of Tropical Medicine &amp; Hygiene2003;97(2):217-25. ">von Seidlein 2003 GMB</a>; <a href="./references#CD008846-bbs2-0013" title="vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">von Seidlein 2019 VNM</a>). Three studies did not describe blinding of laboratory staff, and we judged these as unclear risk of detection bias (<a href="./references#CD008846-bbs2-0001" title="BennettA , PorterTR ,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C, et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in Southern Province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in Southern Province, Zambia: An evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. [DOI: 10.1186/s13063-015-0862-3]MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBa</a>; <a href="./references#CD008846-bbs2-0002" title="BennettA , Porter TR,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C,   et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in southern province, Zambia: an evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence  in southern province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of Plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBb</a>; <a href="./references#CD008846-bbs2-0009" title="RobertsJM . Pyrimethamine (Daraprim) in the control of epidemic malaria. American Journal of Tropical Medicine and Hygiene1956;59(9):201-8. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part I. Before the campaign. American Journal of Tropical Medicine and Hygiene1964;67(7):161-8. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part II. The campaign. American Journal of Tropical Medicine and Hygiene1964;67(8):191-9. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part III. After the campaign. American Journal of Tropical Medicine and Hygiene1964;67(9):230-7. ">Roberts 1964 KEN</a>). Outcome assessment in one study was clearly unblinded, and we considered this study as high risk of detection bias (<a href="./references#CD008846-bbs2-0003" title="EscudieA , HamonJ , SchneiderJ . Results of mass antimalarial chemoprophylaxis with a combination of 4-aminoquinoline and 8-aminoquinoline under rural African conditions in the region of Bobo-Dioulasso (Upper Volta) 1960. Comparative study in a zone treated with DDT and outside this zone. Medecine Tropicale1962;22(2):268-305. SchneiderJ , EscudieA , HamonJ . Eradication of malaria and chemotherapy. Results obtained with the association amino-4 quinoline + amino-8 quinoline in the pilot area of Bobo-Dioulasso (Haute- Volta) [Eradication du paludismeet chimiotherapie resultats d’un essai de l’association:amino–4 quinoleine/amino–8 quinoleine dans la zonepilote de Bobo–Dioulasso (Haute Volta)]. Bulletin de la Societe de Pathologie Exotique1961;54(5):1012-25. ">Escudie 1962 BFA</a>). </p> </section> <section id="CD008846-sec-0067"> <h5 class="title">Parasitaemia incidence</h5> <p>We judged all three studies reporting parasitaemia incidence as low risk of both performance and detection bias since this outcome was evaluated through active surveillance, so lack of blinding of participants and study staff was presumed to minimally affect the outcome (<a href="./references#CD008846-bbs2-0001" title="BennettA , PorterTR ,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C, et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in Southern Province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in Southern Province, Zambia: An evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. [DOI: 10.1186/s13063-015-0862-3]MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBa</a>; <a href="./references#CD008846-bbs2-0002" title="BennettA , Porter TR,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C,   et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in southern province, Zambia: an evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence  in southern province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of Plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBb</a>), or the trial was placebo‐controlled (<a href="./references#CD008846-bbs2-0012" title="De MartinS , vonSeidleinL , DeenJL , PinderM , WalravenG , GreenwoodB . Community perceptions of a mass administration of an antimalarial drug combination in The Gambia. Tropical Medicine &amp; International Health2001;6(6):442-8. vonSeidleinL , WalravenG , MilliganPJ , AlexanderN , MannehF , DeenJL , et al. The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia. Transactions of the Royal Society of Tropical Medicine &amp; Hygiene2003;97(2):217-25. ">von Seidlein 2003 GMB</a>). </p> </section> <section id="CD008846-sec-0068"> <h5 class="title">Confirmed malaria illness incidence</h5> <p>We judged one placebo‐controlled trial as having low risk of performance and detection bias due to blinding of participants, study staff, and outcome assessment (<a href="./references#CD008846-bbs2-0010" title="ShekalagheSA , DrakeleyC , vanden BoschS , ter BraakR , vanden BikilaardtW , MwanzivaC , et al. A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania. Malaria Journal2011;10:247. ShekalagheSA , ter BraakR , DaouM , KavisheR , vanden BijilaardtW , vanden BoschS , et al. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A) individuals. Antimicrobial Agents and Chemotherapy2010;54(5):1762-8. ">Shekalaghe 2011 TZA</a>). We judged five studies as having unclear risk since it was unclear how lack of blinding would affect care‐seeking behaviours by participants, or outcome assessment (<a href="./references#CD008846-bbs2-0001" title="BennettA , PorterTR ,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C, et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in Southern Province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in Southern Province, Zambia: An evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. [DOI: 10.1186/s13063-015-0862-3]MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBa</a>; <a href="./references#CD008846-bbs2-0002" title="BennettA , Porter TR,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C,   et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in southern province, Zambia: an evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence  in southern province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of Plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBb</a>; <a href="./references#CD008846-bbs2-0004" title="LandierJ , KajeechiwaL , ThwinMM , ParkerDM , ChaumeauV , WiladphaingernJ , et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar. Wellcome Open Research2017;2:81. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Landier 2017 MMRa</a>; <a href="./references#CD008846-bbs2-0007" title="MorrisU , MsellemM , MkaliH , IslamA , Aydin-SchmidtB , JovelI , et al. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission. BMC Medicine2018;16:215. [DOI: 10.1186/s12916-018-1202-8]">Morris 2018 TZA</a>; <a href="./references#CD008846-bbs2-0011" title="TripuraR , PetoTJ , CheaN , ChanD , MukakaM , SirithiranontP , et al. A controlled trial of mass drug administration to interrupt transmission of multidrug-resistant falciparum malaria in Cambodian villages. Clinical Infectious Diseases2018;67(6):817-26. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Tripura 2018 KHM</a>). </p> </section> </section> <section id="CD008846-sec-0069"> <h4 class="title">Incomplete outcome data</h4> <section id="CD008846-sec-0070"> <h5 class="title">Parasitaemia prevalence</h5> <p>We judged one trial that reported large variations in the size of the population evaluated for parasitaemia prevalence outcomes at different time points as having high risk of bias since, based on the described methodology, the population evaluated should have remained consistent (<a href="./references#CD008846-bbs2-0005" title="HeatonJ , McCleanA , SweMM , SoeK , IndrasutaC , KhantZS , et al. Speeding up malaria elimination; a cluster randomized controlled trial of mass drug administration in Southeast Myanmar, an area with artemisinin resistance. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):411. McLeanAR , IndrasutaC , KhantZS , PhyoAK , MaungSM , HeatonJ , et al. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infectious Diseases 2021 June 17 [Epub ahead of print]. [DOI: 10.1016/S1473-3099(20)30997-X]">McLean 2021 MMR</a>). The remaining eight studies had a low risk of attrition bias. </p> </section> <section id="CD008846-sec-0071"> <h5 class="title">Parasitaemia incidence</h5> <p>We judged one study as high risk of bias due to a large proportion of missed malaria infections (particularly, afebrile or low parasite density malaria infections) due to outcome definitions (<a href="./references#CD008846-bbs2-0012" title="De MartinS , vonSeidleinL , DeenJL , PinderM , WalravenG , GreenwoodB . Community perceptions of a mass administration of an antimalarial drug combination in The Gambia. Tropical Medicine &amp; International Health2001;6(6):442-8. vonSeidleinL , WalravenG , MilliganPJ , AlexanderN , MannehF , DeenJL , et al. The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia. Transactions of the Royal Society of Tropical Medicine &amp; Hygiene2003;97(2):217-25. ">von Seidlein 2003 GMB</a>). We judged two studies as unclear risk of bias since loss to follow‐up was not provided by baseline endemicity strata (<a href="./references#CD008846-bbs2-0001" title="BennettA , PorterTR ,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C, et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in Southern Province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in Southern Province, Zambia: An evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. [DOI: 10.1186/s13063-015-0862-3]MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBa</a>, <a href="./references#CD008846-bbs2-0002" title="BennettA , Porter TR,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C,   et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in southern province, Zambia: an evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence  in southern province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of Plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBb</a>). </p> </section> <section id="CD008846-sec-0072"> <h5 class="title">Confirmed malaria illness incidence</h5> <p>We judged all six studies reporting this outcome as having low risk of bias (<a href="./references#CD008846-bbs2-0001" title="BennettA , PorterTR ,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C, et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in Southern Province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in Southern Province, Zambia: An evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. [DOI: 10.1186/s13063-015-0862-3]MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBa</a>; <a href="./references#CD008846-bbs2-0002" title="BennettA , Porter TR,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C,   et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in southern province, Zambia: an evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence  in southern province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of Plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBb</a>; <a href="./references#CD008846-bbs2-0004" title="LandierJ , KajeechiwaL , ThwinMM , ParkerDM , ChaumeauV , WiladphaingernJ , et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar. Wellcome Open Research2017;2:81. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Landier 2017 MMRa</a>; <a href="./references#CD008846-bbs2-0007" title="MorrisU , MsellemM , MkaliH , IslamA , Aydin-SchmidtB , JovelI , et al. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission. BMC Medicine2018;16:215. [DOI: 10.1186/s12916-018-1202-8]">Morris 2018 TZA</a>; <a href="./references#CD008846-bbs2-0011" title="TripuraR , PetoTJ , CheaN , ChanD , MukakaM , SirithiranontP , et al. A controlled trial of mass drug administration to interrupt transmission of multidrug-resistant falciparum malaria in Cambodian villages. Clinical Infectious Diseases2018;67(6):817-26. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Tripura 2018 KHM</a>; <a href="./references#CD008846-bbs2-0010" title="ShekalagheSA , DrakeleyC , vanden BoschS , ter BraakR , vanden BikilaardtW , MwanzivaC , et al. A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania. Malaria Journal2011;10:247. ShekalagheSA , ter BraakR , DaouM , KavisheR , vanden BijilaardtW , vanden BoschS , et al. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A) individuals. Antimicrobial Agents and Chemotherapy2010;54(5):1762-8. ">Shekalaghe 2011 TZA</a>). </p> </section> </section> <section id="CD008846-sec-0073"> <h4 class="title">Selective reporting</h4> <p>All studies reported the outcomes that were pre‐specified and were judged as having low risk of reporting bias. </p> </section> <section id="CD008846-sec-0074"> <h4 class="title">Other potential sources of bias</h4> <p>No cRCTs were judged to have a high or unclear risk of bias from recruitment, loss of clusters, incorrect analyses, or comparability with individually randomized trials. All studies were judged to be at low risk for other biases. </p> <section id="CD008846-sec-0075"> <h5 class="title">Baseline imbalance</h5> <p>We judged five studies to have high risk of bias due to unbalanced baseline malaria prevalence in intervention and control arms (<a href="./references#CD008846-bbs2-0004" title="LandierJ , KajeechiwaL , ThwinMM , ParkerDM , ChaumeauV , WiladphaingernJ , et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar. Wellcome Open Research2017;2:81. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Landier 2017 MMRa</a>; <a href="./references#CD008846-bbs2-0007" title="MorrisU , MsellemM , MkaliH , IslamA , Aydin-SchmidtB , JovelI , et al. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission. BMC Medicine2018;16:215. [DOI: 10.1186/s12916-018-1202-8]">Morris 2018 TZA</a>; <a href="./references#CD008846-bbs2-0008" title="PongvongsaT , PhommasoneK , AdhikariB , HenriquesG , ChotivanichK , HanboonkunupakarnB , et al. The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin-piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos. Malaria Journal2018;17(1):405. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Pongvongsa 2018 LAO</a>; <a href="./references#CD008846-bbs2-0009" title="RobertsJM . Pyrimethamine (Daraprim) in the control of epidemic malaria. American Journal of Tropical Medicine and Hygiene1956;59(9):201-8. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part I. Before the campaign. American Journal of Tropical Medicine and Hygiene1964;67(7):161-8. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part II. The campaign. American Journal of Tropical Medicine and Hygiene1964;67(8):191-9. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part III. After the campaign. American Journal of Tropical Medicine and Hygiene1964;67(9):230-7. ">Roberts 1964 KEN</a>; <a href="./references#CD008846-bbs2-0011" title="TripuraR , PetoTJ , CheaN , ChanD , MukakaM , SirithiranontP , et al. A controlled trial of mass drug administration to interrupt transmission of multidrug-resistant falciparum malaria in Cambodian villages. Clinical Infectious Diseases2018;67(6):817-26. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Tripura 2018 KHM</a>). Two studies did not report baseline demographic characteristics (other risk factors for malaria), and we judged these to have unclear risk of bias (<a href="./references#CD008846-bbs2-0003" title="EscudieA , HamonJ , SchneiderJ . Results of mass antimalarial chemoprophylaxis with a combination of 4-aminoquinoline and 8-aminoquinoline under rural African conditions in the region of Bobo-Dioulasso (Upper Volta) 1960. Comparative study in a zone treated with DDT and outside this zone. Medecine Tropicale1962;22(2):268-305. SchneiderJ , EscudieA , HamonJ . Eradication of malaria and chemotherapy. Results obtained with the association amino-4 quinoline + amino-8 quinoline in the pilot area of Bobo-Dioulasso (Haute- Volta) [Eradication du paludismeet chimiotherapie resultats d’un essai de l’association:amino–4 quinoleine/amino–8 quinoleine dans la zonepilote de Bobo–Dioulasso (Haute Volta)]. Bulletin de la Societe de Pathologie Exotique1961;54(5):1012-25. ">Escudie 1962 BFA</a>; <a href="./references#CD008846-bbs2-0006" title="BroggerRC , MathewsHM , StoreyJ , AshkarTS , BroggerS , MolineauxL . Changing patterns in the humoral immune response to malaria before, during and after the application of control measures: a longitudinal study in the West African savanna. Bulletin of the World Health Organization1978;56(4):579-600. MolineauxL , BroggerRC , MathewsHM , StoreyJ , AshkarTS . Longitudinal serological study of malaria in infants in the West African savanna. Comparisons in infants exposed to, or protected from, transmission from birth. Bulletin of the World Health Organisation1978;56(4):573-8. MolineauxL , GramicciaG . The Garki Project. Research on the epidemiology and control of malaria in the Sudan Savanna of West Africa. 1980. https://apps.who.int/iris/handle/10665/40316 (accessed prior to 8 July 2021). MolineauxL , StoreyJ , CohenJE , ThomasA . A longitudinal study of human malaria in the West African savanna in the absence of control measures: relationships between different Plasmodium species, in particular P. falciparum and P. malariae. American Journal of Tropical Medicine and Hygiene1980;29(5):725-37. ">Molineaux 1980 NGA</a>). The remaining studies were balanced for malaria and demographic characteristics across arms at baseline. </p> </section> <section id="CD008846-sec-0076"> <h5 class="title">Contamination protection</h5> <p>The study arms for six studies were either paired by geographic proximity or located in close geographic proximity with a high potential for population movement. We judged these studies as having a high risk of contamination bias (<a href="./references#CD008846-bbs2-0004" title="LandierJ , KajeechiwaL , ThwinMM , ParkerDM , ChaumeauV , WiladphaingernJ , et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar. Wellcome Open Research2017;2:81. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Landier 2017 MMRa</a>; <a href="./references#CD008846-bbs2-0005" title="HeatonJ , McCleanA , SweMM , SoeK , IndrasutaC , KhantZS , et al. Speeding up malaria elimination; a cluster randomized controlled trial of mass drug administration in Southeast Myanmar, an area with artemisinin resistance. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):411. McLeanAR , IndrasutaC , KhantZS , PhyoAK , MaungSM , HeatonJ , et al. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infectious Diseases 2021 June 17 [Epub ahead of print]. [DOI: 10.1016/S1473-3099(20)30997-X]">McLean 2021 MMR</a>; <a href="./references#CD008846-bbs2-0008" title="PongvongsaT , PhommasoneK , AdhikariB , HenriquesG , ChotivanichK , HanboonkunupakarnB , et al. The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin-piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos. Malaria Journal2018;17(1):405. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Pongvongsa 2018 LAO</a>; <a href="./references#CD008846-bbs2-0009" title="RobertsJM . Pyrimethamine (Daraprim) in the control of epidemic malaria. American Journal of Tropical Medicine and Hygiene1956;59(9):201-8. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part I. Before the campaign. American Journal of Tropical Medicine and Hygiene1964;67(7):161-8. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part II. The campaign. American Journal of Tropical Medicine and Hygiene1964;67(8):191-9. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part III. After the campaign. American Journal of Tropical Medicine and Hygiene1964;67(9):230-7. ">Roberts 1964 KEN</a>; <a href="./references#CD008846-bbs2-0011" title="TripuraR , PetoTJ , CheaN , ChanD , MukakaM , SirithiranontP , et al. A controlled trial of mass drug administration to interrupt transmission of multidrug-resistant falciparum malaria in Cambodian villages. Clinical Infectious Diseases2018;67(6):817-26. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Tripura 2018 KHM</a>; <a href="./references#CD008846-bbs2-0013" title="vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">von Seidlein 2019 VNM</a>). Two studies did not describe methods for contamination protection, and we judged these as unclear risk (<a href="./references#CD008846-bbs2-0003" title="EscudieA , HamonJ , SchneiderJ . Results of mass antimalarial chemoprophylaxis with a combination of 4-aminoquinoline and 8-aminoquinoline under rural African conditions in the region of Bobo-Dioulasso (Upper Volta) 1960. Comparative study in a zone treated with DDT and outside this zone. Medecine Tropicale1962;22(2):268-305. SchneiderJ , EscudieA , HamonJ . Eradication of malaria and chemotherapy. Results obtained with the association amino-4 quinoline + amino-8 quinoline in the pilot area of Bobo-Dioulasso (Haute- Volta) [Eradication du paludismeet chimiotherapie resultats d’un essai de l’association:amino–4 quinoleine/amino–8 quinoleine dans la zonepilote de Bobo–Dioulasso (Haute Volta)]. Bulletin de la Societe de Pathologie Exotique1961;54(5):1012-25. ">Escudie 1962 BFA</a>; <a href="./references#CD008846-bbs2-0007" title="MorrisU , MsellemM , MkaliH , IslamA , Aydin-SchmidtB , JovelI , et al. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission. BMC Medicine2018;16:215. [DOI: 10.1186/s12916-018-1202-8]">Morris 2018 TZA</a>). The remaining four studies included buffer zones to minimize contamination of outcome assessment, and we judged these as low risk (<a href="./references#CD008846-bbs2-0001" title="BennettA , PorterTR ,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C, et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in Southern Province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in Southern Province, Zambia: An evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. [DOI: 10.1186/s13063-015-0862-3]MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBa</a>; <a href="./references#CD008846-bbs2-0002" title="BennettA , Porter TR,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C,   et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in southern province, Zambia: an evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence  in southern province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of Plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBb</a>; <a href="./references#CD008846-bbs2-0010" title="ShekalagheSA , DrakeleyC , vanden BoschS , ter BraakR , vanden BikilaardtW , MwanzivaC , et al. A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania. Malaria Journal2011;10:247. ShekalagheSA , ter BraakR , DaouM , KavisheR , vanden BijilaardtW , vanden BoschS , et al. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A) individuals. Antimicrobial Agents and Chemotherapy2010;54(5):1762-8. ">Shekalaghe 2011 TZA</a>; <a href="./references#CD008846-bbs2-0012" title="De MartinS , vonSeidleinL , DeenJL , PinderM , WalravenG , GreenwoodB . Community perceptions of a mass administration of an antimalarial drug combination in The Gambia. Tropical Medicine &amp; International Health2001;6(6):442-8. vonSeidleinL , WalravenG , MilliganPJ , AlexanderN , MannehF , DeenJL , et al. The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia. Transactions of the Royal Society of Tropical Medicine &amp; Hygiene2003;97(2):217-25. ">von Seidlein 2003 GMB</a>). </p> </section> </section> </section> <section id="CD008846-sec-0077"> <h3 class="title" id="CD008846-sec-0077">Effects of interventions</h3> <p>See: <a href="./full#CD008846-tbl-0001"><b>Summary of findings 1</b> MDA compared to no MDA for <i>Plasmodium falciparum</i> malaria (moderate to high endemicity, short‐term follow‐up)</a>; <a href="./full#CD008846-tbl-0002"><b>Summary of findings 2</b> MDA compared to no MDA for <i>Plasmodium falciparum</i> malaria (very low to low endemicity, short‐term follow‐up)</a>; <a href="./full#CD008846-tbl-0003"><b>Summary of findings 3</b> MDA compared to no MDA for <i>Plasmodium falciparum</i> malaria (very low to low endemicity, long‐term follow‐up)</a>; <a href="./full#CD008846-tbl-0004"><b>Summary of findings 4</b> MDA compared to no MDA for <i>P vivax</i> malaria (very low to low endemicity, short‐term follow‐up)</a>; <a href="./full#CD008846-tbl-0005"><b>Summary of findings 5</b> MDA compared to no MDA for <i>P vivax</i> malaria (very low to low endemicity, long‐term follow‐up)</a> </p> <section id="CD008846-sec-0078"> <h4 class="title">Cluster‐randomized trials</h4> <section id="CD008846-sec-0079"> <h5 class="title">Moderate‐ to high‐transmission areas</h5> <section id="CD008846-sec-0080"> <h6 class="title">Effects reported on <i>P falciparum</i> outcomes </h6> <section id="CD008846-sec-0081"> <p><b>At one to three months after MDA</b></p> <p><a href="./references#CD008846-bbs2-0002" title="BennettA , Porter TR,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C,   et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in southern province, Zambia: an evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence  in southern province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of Plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBb</a> found a non‐significant increase in <i>P falciparum</i> parasitaemia prevalence (RR 1.76, 95% CI 0.58 to 5.36; 1 study; <a href="./references#CD008846-fig-0004" title="">Analysis 1.1</a>), a significant reduction in parasitaemia incidence by 39% (rate ratio 0.61, 95% CI 0.40 to 0.92; 1 study; <a href="./references#CD008846-fig-0005" title="">Analysis 1.2</a>), and a non‐significant reduction in confirmed malaria illness incidence by 59% (RR 0.41, 95% CI 0.04 to 4.51; 1 study; <a href="./references#CD008846-fig-0006" title="">Analysis 1.3</a>) in MDA compared to non‐MDA clusters at one to three months after MDA. </p> </section> <section id="CD008846-sec-0082"> <p><b>At four to six months after MDA</b></p> <p>As reported by <a href="./references#CD008846-bbs2-0012" title="De MartinS , vonSeidleinL , DeenJL , PinderM , WalravenG , GreenwoodB . Community perceptions of a mass administration of an antimalarial drug combination in The Gambia. Tropical Medicine &amp; International Health2001;6(6):442-8. vonSeidleinL , WalravenG , MilliganPJ , AlexanderN , MannehF , DeenJL , et al. The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia. Transactions of the Royal Society of Tropical Medicine &amp; Hygiene2003;97(2):217-25. ">von Seidlein 2003 GMB</a>, at four to six months after MDA, MDA did not reduce <i>P falciparum</i> parasitaemia prevalence (RR 1.18, 95% CI 0.89 to 1.56; 1 study; <a href="./references#CD008846-fig-0004" title="">Analysis 1.1</a>), and also did not reduce the secondary outcomes of <i>P falciparum</i> gametocytaemia prevalence (RR 1.13, 95% CI 0.20 to 6.54; 1 study; <a href="./references#CD008846-fig-0007" title="">Analysis 1.4</a>), and malaria‐specific mortality (RR 1.42, 95% CI 0.12 to 17.15; 1 study; <a href="./references#CD008846-fig-0008" title="">Analysis 1.5</a>). </p> </section> </section> </section> <section id="CD008846-sec-0083"> <h5 class="title">Very low‐ to low‐transmission areas</h5> <section id="CD008846-sec-0084"> <h6 class="title">Effects reported on <i>P falciparum</i> outcomes </h6> <section id="CD008846-sec-0085"> <p><b>At less than one month after MDA</b></p> <p><a href="./references#CD008846-bbs2-0005" title="HeatonJ , McCleanA , SweMM , SoeK , IndrasutaC , KhantZS , et al. Speeding up malaria elimination; a cluster randomized controlled trial of mass drug administration in Southeast Myanmar, an area with artemisinin resistance. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):411. McLeanAR , IndrasutaC , KhantZS , PhyoAK , MaungSM , HeatonJ , et al. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infectious Diseases 2021 June 17 [Epub ahead of print]. [DOI: 10.1016/S1473-3099(20)30997-X]">McLean 2021 MMR</a> reported that MDA reduced <i>P falciparum</i> parasitaemia prevalence by 88% immediately (less than one month) after MDA (RR 0.12, 95% CI 0.03 to 0.52; 1 study; <a href="./references#CD008846-fig-0009" title="">Analysis 2.1</a>). </p> </section> <section id="CD008846-sec-0086"> <p><b>At one to three months after MDA</b></p> <p>Based on results from seven studies, MDA significantly reduced <i>P falciparum</i> parasitaemia prevalence by 75% one to three months after MDA (RR 0.25, 95% 0.15 to 0.41; 7 studies; <a href="./references#CD008846-fig-0009" title="">Analysis 2.1</a>). The largest reduction was observed by <a href="./references#CD008846-bbs2-0004" title="LandierJ , KajeechiwaL , ThwinMM , ParkerDM , ChaumeauV , WiladphaingernJ , et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar. Wellcome Open Research2017;2:81. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Landier 2017 MMRa</a> in Myanmar (RR 0.06, 95% CI 0.01 to 0.45; 1 study; <a href="./references#CD008846-fig-0009" title="">Analysis 2.1</a>), while the opposite effect was found by <a href="./references#CD008846-bbs2-0007" title="MorrisU , MsellemM , MkaliH , IslamA , Aydin-SchmidtB , JovelI , et al. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission. BMC Medicine2018;16:215. [DOI: 10.1186/s12916-018-1202-8]">Morris 2018 TZA</a> in Zanzibar (RR 1.34, 95% CI 0.30 to 5.92; <a href="./references#CD008846-fig-0009" title="">Analysis 2.1</a>). Although the I<sup>2</sup> value(31%) did not indicate inconsistency in the results, we explored differences in malaria epidemiology by continent as a cause of heterogeneity in this effect. When the effects were sub‐grouped by continent (Africa and Asia) in post‐hoc analysis (<a href="./references#CD008846-fig-0014" title="">Analysis 4.1</a>), there was no effect of MDA in two studies in sub‐Saharan Africa (pooled RR 0.97, 95% CI 0.32 to 2.98; <a href="./references#CD008846-bbs2-0001" title="BennettA , PorterTR ,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C, et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in Southern Province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in Southern Province, Zambia: An evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. [DOI: 10.1186/s13063-015-0862-3]MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBa</a>; <a href="./references#CD008846-bbs2-0007" title="MorrisU , MsellemM , MkaliH , IslamA , Aydin-SchmidtB , JovelI , et al. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission. BMC Medicine2018;16:215. [DOI: 10.1186/s12916-018-1202-8]">Morris 2018 TZA</a>), but a larger reduction in the five studies in Southeast Asia (RR 0.19, 95% CI 0.11 to 0.33; <a href="./references#CD008846-bbs2-0004" title="LandierJ , KajeechiwaL , ThwinMM , ParkerDM , ChaumeauV , WiladphaingernJ , et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar. Wellcome Open Research2017;2:81. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Landier 2017 MMRa</a>; <a href="./references#CD008846-bbs2-0005" title="HeatonJ , McCleanA , SweMM , SoeK , IndrasutaC , KhantZS , et al. Speeding up malaria elimination; a cluster randomized controlled trial of mass drug administration in Southeast Myanmar, an area with artemisinin resistance. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):411. McLeanAR , IndrasutaC , KhantZS , PhyoAK , MaungSM , HeatonJ , et al. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infectious Diseases 2021 June 17 [Epub ahead of print]. [DOI: 10.1016/S1473-3099(20)30997-X]">McLean 2021 MMR</a>; <a href="./references#CD008846-bbs2-0008" title="PongvongsaT , PhommasoneK , AdhikariB , HenriquesG , ChotivanichK , HanboonkunupakarnB , et al. The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin-piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos. Malaria Journal2018;17(1):405. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Pongvongsa 2018 LAO</a>; <a href="./references#CD008846-bbs2-0011" title="TripuraR , PetoTJ , CheaN , ChanD , MukakaM , SirithiranontP , et al. A controlled trial of mass drug administration to interrupt transmission of multidrug-resistant falciparum malaria in Cambodian villages. Clinical Infectious Diseases2018;67(6):817-26. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Tripura 2018 KHM</a>; <a href="./references#CD008846-bbs2-0013" title="vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">von Seidlein 2019 VNM</a>). </p> <p><a href="./references#CD008846-bbs2-0001" title="BennettA , PorterTR ,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C, et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in Southern Province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in Southern Province, Zambia: An evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. [DOI: 10.1186/s13063-015-0862-3]MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBa</a> measured the effect of MDA compared to no MDA on <i>P falciparum</i> parasitaemia incidence in very low‐ to low‐endemicity areas, and found a statistically significant 63% reduction one to three months after MDA (rate ratio 0.37, 95% CI 0.21 to 0.66; 1 study; <a href="./references#CD008846-fig-0010" title="">Analysis 2.2</a>). </p> <p>MDA also reduced confirmed malaria illness incidence (rate ratio 0.58, 95% CI 0.12 to 2.73, 2 studies; <a href="./references#CD008846-fig-0011" title="">Analysis 2.3</a>). However, the effect was imprecise and not statistically significant. </p> </section> <section id="CD008846-sec-0087"> <p><b>At four to six months after MDA</b></p> <p>Based on findings from four studies in Southeast Asia, at four to six months after MDA, there was a non‐significant reduction in <i>P falciparum</i> parasitaemia prevalence by 37% (RR 0.63, 95% CI 0.36 to 1.12; 4 studies; <a href="./references#CD008846-fig-0009" title="">Analysis 2.1</a>) in MDA compared to non‐MDA clusters. Effects across studies included few malaria cases and were therefore very imprecise. The strongest reduction was observed by <a href="./references#CD008846-bbs2-0008" title="PongvongsaT , PhommasoneK , AdhikariB , HenriquesG , ChotivanichK , HanboonkunupakarnB , et al. The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin-piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos. Malaria Journal2018;17(1):405. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Pongvongsa 2018 LAO</a> in Laos (RR 0.07, 95% CI 0 to 1.31; <a href="./references#CD008846-fig-0009" title="">Analysis 2.1</a>), while the weakest effect was found by <a href="./references#CD008846-bbs2-0004" title="LandierJ , KajeechiwaL , ThwinMM , ParkerDM , ChaumeauV , WiladphaingernJ , et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar. Wellcome Open Research2017;2:81. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Landier 2017 MMRa</a> in Myanmar (RR 0.89, 95% CI 0.27 to 2.95; <a href="./references#CD008846-fig-0009" title="">Analysis 2.1</a>). </p> <p>There was no effect of MDA on confirmed malaria illness incidence four to six months after MDA as reported by a single study, <a href="./references#CD008846-bbs2-0007" title="MorrisU , MsellemM , MkaliH , IslamA , Aydin-SchmidtB , JovelI , et al. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission. BMC Medicine2018;16:215. [DOI: 10.1186/s12916-018-1202-8]">Morris 2018 TZA</a> (rate ratio 0.93, 95% CI 0.07 to 12.43; <a href="./references#CD008846-fig-0011" title="">Analysis 2.3</a>). </p> </section> <section id="CD008846-sec-0088"> <p><b>At 7 to 12 months after MDA</b></p> <p>At 7 to 12 months after MDA, there was a small but non‐significant reduction in <i>P falciparum</i> parasitaemia prevalence (RR 0.86, 95% CI 0.55 to 1.36; 5 studies; <a href="./references#CD008846-fig-0009" title="">Analysis 2.1</a>) in MDA compared to non‐MDA clusters. Due to few malaria cases, the effect estimates across studies were very imprecise. Additionally, the direction of effect was inconsistent across studies, with two studies showing a non‐significant increase in <i>P falciparum</i> parasitaemia prevalence in the MDA compared to no‐MDA arm (<a href="./references#CD008846-bbs2-0004" title="LandierJ , KajeechiwaL , ThwinMM , ParkerDM , ChaumeauV , WiladphaingernJ , et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar. Wellcome Open Research2017;2:81. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Landier 2017 MMRa</a>; <a href="./references#CD008846-bbs2-0013" title="vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">von Seidlein 2019 VNM</a>), while three studies found that MDA reduced parasitaemia prevalence (<a href="./references#CD008846-bbs2-0005" title="HeatonJ , McCleanA , SweMM , SoeK , IndrasutaC , KhantZS , et al. Speeding up malaria elimination; a cluster randomized controlled trial of mass drug administration in Southeast Myanmar, an area with artemisinin resistance. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):411. McLeanAR , IndrasutaC , KhantZS , PhyoAK , MaungSM , HeatonJ , et al. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infectious Diseases 2021 June 17 [Epub ahead of print]. [DOI: 10.1016/S1473-3099(20)30997-X]">McLean 2021 MMR</a>; <a href="./references#CD008846-bbs2-0008" title="PongvongsaT , PhommasoneK , AdhikariB , HenriquesG , ChotivanichK , HanboonkunupakarnB , et al. The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin-piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos. Malaria Journal2018;17(1):405. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Pongvongsa 2018 LAO</a>; <a href="./references#CD008846-bbs2-0011" title="TripuraR , PetoTJ , CheaN , ChanD , MukakaM , SirithiranontP , et al. A controlled trial of mass drug administration to interrupt transmission of multidrug-resistant falciparum malaria in Cambodian villages. Clinical Infectious Diseases2018;67(6):817-26. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Tripura 2018 KHM</a>). </p> <p>MDA reduced confirmed malaria illness incidence 7 to 12 months after MDA (rate ratio 0.47, 95% CI 0.21 to 1.03; 3 studies; <a href="./references#CD008846-fig-0011" title="">Analysis 2.3</a>). However, the effect was not statistically significant and there was substantial heterogeneity (I<sup>2</sup>=72%, <a href="./references#CD008846-fig-0011" title="">Analysis 2.3</a>). </p> </section> <section id="CD008846-sec-0089"> <p><b>At longer time periods (&gt; 12 months) after MDA</b></p> <p>At 13 to 18 months after MDA, MDA did not significantly reduce <i>P falciparum</i> parasitaemia prevalence in <a href="./references#CD008846-bbs2-0005" title="HeatonJ , McCleanA , SweMM , SoeK , IndrasutaC , KhantZS , et al. Speeding up malaria elimination; a cluster randomized controlled trial of mass drug administration in Southeast Myanmar, an area with artemisinin resistance. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):411. McLeanAR , IndrasutaC , KhantZS , PhyoAK , MaungSM , HeatonJ , et al. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infectious Diseases 2021 June 17 [Epub ahead of print]. [DOI: 10.1016/S1473-3099(20)30997-X]">McLean 2021 MMR</a> (RR 0.82, 95% CI 0.20 to 3.34; 1 study; <a href="./references#CD008846-fig-0009" title="">Analysis 2.1</a>) or confirmed malaria illness incidence in <a href="./references#CD008846-bbs2-0007" title="MorrisU , MsellemM , MkaliH , IslamA , Aydin-SchmidtB , JovelI , et al. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission. BMC Medicine2018;16:215. [DOI: 10.1186/s12916-018-1202-8]">Morris 2018 TZA</a> (rate ratio 0.77, 95% CI 0.2 to 3.03; 1 study; <a href="./references#CD008846-fig-0011" title="">Analysis 2.3</a>). <a href="./references#CD008846-bbs2-0005" title="HeatonJ , McCleanA , SweMM , SoeK , IndrasutaC , KhantZS , et al. Speeding up malaria elimination; a cluster randomized controlled trial of mass drug administration in Southeast Myanmar, an area with artemisinin resistance. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):411. McLeanAR , IndrasutaC , KhantZS , PhyoAK , MaungSM , HeatonJ , et al. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infectious Diseases 2021 June 17 [Epub ahead of print]. [DOI: 10.1016/S1473-3099(20)30997-X]">McLean 2021 MMR</a> reported no effect on parasitaemia prevalence at 19 to 24 months, 25 to 30 months and 31 to 36 months after MDA (<a href="./references#CD008846-fig-0009" title="">Analysis 2.1</a>). </p> </section> </section> <section id="CD008846-sec-0090"> <h6 class="title">Effects reported on <i>P vivax</i> outcomes </h6> <section id="CD008846-sec-0091"> <p><b>At less than one month after MDA</b></p> <p><a href="./references#CD008846-bbs2-0005" title="HeatonJ , McCleanA , SweMM , SoeK , IndrasutaC , KhantZS , et al. Speeding up malaria elimination; a cluster randomized controlled trial of mass drug administration in Southeast Myanmar, an area with artemisinin resistance. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):411. McLeanAR , IndrasutaC , KhantZS , PhyoAK , MaungSM , HeatonJ , et al. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infectious Diseases 2021 June 17 [Epub ahead of print]. [DOI: 10.1016/S1473-3099(20)30997-X]">McLean 2021 MMR</a> showed that MDA had an immediate and large reduction on <i>P vivax</i> parasitaemia prevalence at less than one month after MDA (RR 0.18, 95% CI 0.08‐0.40; 1 study; <a href="./references#CD008846-fig-0012" title="">Analysis 3.1</a>). </p> </section> <section id="CD008846-sec-0092"> <p><b>At one to three months after MDA</b></p> <p>Although there was considerable heterogeneity across five studies (I<sup>2</sup> = 84%) in the effect of MDA on <i>P vivax</i> parasitaemia prevalence one to three months after MDA, we meta‐analysed the results since the direction of effect was consistent and all reported effect estimates were very imprecise due to a small number of malaria events. At one to three months after MDA, MDA significantly reduced <i>P vivax</i> parasitaemia prevalence by 85% (RR 0.15, 95% CI 0.10 to 0.24; 5 studies; <a href="./references#CD008846-fig-0012" title="">Analysis 3.1</a>). </p> </section> <section id="CD008846-sec-0093"> <p><b>At four to six months after MDA</b></p> <p>MDA significantly reduced <i>P vivax</i> parasitaemia prevalence by 22% at four to six months after MDA (RR 0.78, 95% CI 0.63 to 0.95; 4 studies; <a href="./references#CD008846-fig-0012" title="">Analysis 3.1</a>). </p> </section> <section id="CD008846-sec-0094"> <p><b>At 7 to 12 months after MDA</b></p> <p>At 7 to 12 months after MDA, MDA did not reduce <i>P vivax</i> parasitaemia prevalence (RR 1.12, 95% CI 0.94 to 1.34; 5 studies; <a href="./references#CD008846-fig-0012" title="">Analysis 3.1</a>). There was a non‐significant increase in confirmed malaria illness incidence (pooled rate ratio 1.38, 95% CI 0.97 to 1.95; 2 studies; <a href="./references#CD008846-fig-0013" title="">Analysis 3.2</a>) in MDA compared to non‐MDA clusters. </p> </section> <section id="CD008846-sec-0095"> <p><b>At longer time periods (&gt; 12 months) after MDA</b></p> <p><a href="./references#CD008846-bbs2-0005" title="HeatonJ , McCleanA , SweMM , SoeK , IndrasutaC , KhantZS , et al. Speeding up malaria elimination; a cluster randomized controlled trial of mass drug administration in Southeast Myanmar, an area with artemisinin resistance. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):411. McLeanAR , IndrasutaC , KhantZS , PhyoAK , MaungSM , HeatonJ , et al. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infectious Diseases 2021 June 17 [Epub ahead of print]. [DOI: 10.1016/S1473-3099(20)30997-X]">McLean 2021 MMR</a> reported that MDA did not reduce parasitaemia prevalence at 13 to 18 months, 19 to 24 months, 25 to 30 months, and 31 to 36 months after MDA (<a href="./references#CD008846-fig-0012" title="">Analysis 3.1</a>). </p> </section> </section> </section> <section id="CD008846-sec-0096"> <h5 class="title">Adverse effects</h5> <p>Adverse effects (AEs) of MDA were reported by all ten cRCTs included in qualitative synthesis (<a href="./references#CD008846-bbs2-0001" title="BennettA , PorterTR ,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C, et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in Southern Province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in Southern Province, Zambia: An evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. [DOI: 10.1186/s13063-015-0862-3]MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBa</a>; <a href="./references#CD008846-bbs2-0002" title="BennettA , Porter TR,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C,   et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in southern province, Zambia: an evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence  in southern province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of Plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBb</a>; <a href="./references#CD008846-bbs2-0004" title="LandierJ , KajeechiwaL , ThwinMM , ParkerDM , ChaumeauV , WiladphaingernJ , et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar. Wellcome Open Research2017;2:81. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Landier 2017 MMRa</a>; <a href="./references#CD008846-bbs2-0005" title="HeatonJ , McCleanA , SweMM , SoeK , IndrasutaC , KhantZS , et al. Speeding up malaria elimination; a cluster randomized controlled trial of mass drug administration in Southeast Myanmar, an area with artemisinin resistance. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):411. McLeanAR , IndrasutaC , KhantZS , PhyoAK , MaungSM , HeatonJ , et al. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infectious Diseases 2021 June 17 [Epub ahead of print]. [DOI: 10.1016/S1473-3099(20)30997-X]">McLean 2021 MMR</a>; <a href="./references#CD008846-bbs2-0007" title="MorrisU , MsellemM , MkaliH , IslamA , Aydin-SchmidtB , JovelI , et al. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission. BMC Medicine2018;16:215. [DOI: 10.1186/s12916-018-1202-8]">Morris 2018 TZA</a>; <a href="./references#CD008846-bbs2-0008" title="PongvongsaT , PhommasoneK , AdhikariB , HenriquesG , ChotivanichK , HanboonkunupakarnB , et al. The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin-piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos. Malaria Journal2018;17(1):405. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Pongvongsa 2018 LAO</a>; <a href="./references#CD008846-bbs2-0010" title="ShekalagheSA , DrakeleyC , vanden BoschS , ter BraakR , vanden BikilaardtW , MwanzivaC , et al. A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania. Malaria Journal2011;10:247. ShekalagheSA , ter BraakR , DaouM , KavisheR , vanden BijilaardtW , vanden BoschS , et al. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A) individuals. Antimicrobial Agents and Chemotherapy2010;54(5):1762-8. ">Shekalaghe 2011 TZA</a>; <a href="./references#CD008846-bbs2-0011" title="TripuraR , PetoTJ , CheaN , ChanD , MukakaM , SirithiranontP , et al. A controlled trial of mass drug administration to interrupt transmission of multidrug-resistant falciparum malaria in Cambodian villages. Clinical Infectious Diseases2018;67(6):817-26. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Tripura 2018 KHM</a>; <a href="./references#CD008846-bbs2-0012" title="De MartinS , vonSeidleinL , DeenJL , PinderM , WalravenG , GreenwoodB . Community perceptions of a mass administration of an antimalarial drug combination in The Gambia. Tropical Medicine &amp; International Health2001;6(6):442-8. vonSeidleinL , WalravenG , MilliganPJ , AlexanderN , MannehF , DeenJL , et al. The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia. Transactions of the Royal Society of Tropical Medicine &amp; Hygiene2003;97(2):217-25. ">von Seidlein 2003 GMB</a>; <a href="./references#CD008846-bbs2-0013" title="vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">von Seidlein 2019 VNM</a>). We have provided details by study in the <a href="./references#CD008846-sec-0126" title="">Characteristics of included studies</a> tables. <a href="./references#CD008846-bbs2-0005" title="HeatonJ , McCleanA , SweMM , SoeK , IndrasutaC , KhantZS , et al. Speeding up malaria elimination; a cluster randomized controlled trial of mass drug administration in Southeast Myanmar, an area with artemisinin resistance. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):411. McLeanAR , IndrasutaC , KhantZS , PhyoAK , MaungSM , HeatonJ , et al. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infectious Diseases 2021 June 17 [Epub ahead of print]. [DOI: 10.1016/S1473-3099(20)30997-X]">McLean 2021 MMR</a> reported AEs by relatedness to MDA drug, but did not provide diagnoses of AEs. <a href="./references#CD008846-bbs2-0001" title="BennettA , PorterTR ,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C, et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in Southern Province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in Southern Province, Zambia: An evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. [DOI: 10.1186/s13063-015-0862-3]MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBa</a> and <a href="./references#CD008846-bbs2-0002" title="BennettA , Porter TR,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C,   et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in southern province, Zambia: an evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence  in southern province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of Plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBb</a> reported AEs by MDA and fMDA arms combined and in aggregate across low‐ and high‐transmission strata clusters. </p> <p>Two studies reported one serious AE with MDA using dihydroartemisinin piperaquine (<a href="./references#CD008846-bbs2-0001" title="BennettA , PorterTR ,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C, et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in Southern Province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in Southern Province, Zambia: An evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. [DOI: 10.1186/s13063-015-0862-3]MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBa</a> or <a href="./references#CD008846-bbs2-0002" title="BennettA , Porter TR,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C,   et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in southern province, Zambia: an evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence  in southern province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of Plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBb</a>), or dihydroartemisinin piperaquine plus primaquine (<a href="./references#CD008846-bbs2-0005" title="HeatonJ , McCleanA , SweMM , SoeK , IndrasutaC , KhantZS , et al. Speeding up malaria elimination; a cluster randomized controlled trial of mass drug administration in Southeast Myanmar, an area with artemisinin resistance. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):411. McLeanAR , IndrasutaC , KhantZS , PhyoAK , MaungSM , HeatonJ , et al. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infectious Diseases 2021 June 17 [Epub ahead of print]. [DOI: 10.1016/S1473-3099(20)30997-X]">McLean 2021 MMR</a>). One study reported that 0.5% of all AEs reported after MDA with dihydroartemisinin piperaquine plus primaquine were perceived as serious by participants (<a href="./references#CD008846-bbs2-0007" title="MorrisU , MsellemM , MkaliH , IslamA , Aydin-SchmidtB , JovelI , et al. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission. BMC Medicine2018;16:215. [DOI: 10.1186/s12916-018-1202-8]">Morris 2018 TZA</a>). Two studies administering dihydroartemisinin piperaquine plus primaquine reported multiple serious AEs that were not drug‐related (<a href="./references#CD008846-bbs2-0004" title="LandierJ , KajeechiwaL , ThwinMM , ParkerDM , ChaumeauV , WiladphaingernJ , et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar. Wellcome Open Research2017;2:81. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Landier 2017 MMRa</a>; <a href="./references#CD008846-bbs2-0013" title="vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">von Seidlein 2019 VNM</a>). <a href="./references#CD008846-bbs2-0004" title="LandierJ , KajeechiwaL , ThwinMM , ParkerDM , ChaumeauV , WiladphaingernJ , et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar. Wellcome Open Research2017;2:81. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Landier 2017 MMRa</a> also reported three cases of black urine. One study reported a possibly drug‐related severe skin reaction following administration of MDA using sulfadoxine‐pyrimethamine plus artesunate with primaquine (<a href="./references#CD008846-bbs2-0010" title="ShekalagheSA , DrakeleyC , vanden BoschS , ter BraakR , vanden BikilaardtW , MwanzivaC , et al. A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania. Malaria Journal2011;10:247. ShekalagheSA , ter BraakR , DaouM , KavisheR , vanden BijilaardtW , vanden BoschS , et al. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A) individuals. Antimicrobial Agents and Chemotherapy2010;54(5):1762-8. ">Shekalaghe 2011 TZA</a>). </p> <p>Four studies indicated stomach pains or diarrhoea and vomiting as commonly reported AEs to MDA with dihydroartemisinin piperaquine (<a href="./references#CD008846-bbs2-0001" title="BennettA , PorterTR ,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C, et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in Southern Province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in Southern Province, Zambia: An evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. [DOI: 10.1186/s13063-015-0862-3]MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBa</a>; <a href="./references#CD008846-bbs2-0002" title="BennettA , Porter TR,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C,   et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in southern province, Zambia: an evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence  in southern province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of Plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBb</a>), dihydroartemisinin piperaquine plus primaquine (<a href="./references#CD008846-bbs2-0007" title="MorrisU , MsellemM , MkaliH , IslamA , Aydin-SchmidtB , JovelI , et al. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission. BMC Medicine2018;16:215. [DOI: 10.1186/s12916-018-1202-8]">Morris 2018 TZA</a>, <a href="./references#CD008846-bbs2-0008" title="PongvongsaT , PhommasoneK , AdhikariB , HenriquesG , ChotivanichK , HanboonkunupakarnB , et al. The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin-piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos. Malaria Journal2018;17(1):405. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Pongvongsa 2018 LAO</a>, <a href="./references#CD008846-bbs2-0013" title="vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">von Seidlein 2019 VNM</a>), and sulfadoxine‐pyrimethamine plus artesunate (<a href="./references#CD008846-bbs2-0012" title="De MartinS , vonSeidleinL , DeenJL , PinderM , WalravenG , GreenwoodB . Community perceptions of a mass administration of an antimalarial drug combination in The Gambia. Tropical Medicine &amp; International Health2001;6(6):442-8. vonSeidleinL , WalravenG , MilliganPJ , AlexanderN , MannehF , DeenJL , et al. The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia. Transactions of the Royal Society of Tropical Medicine &amp; Hygiene2003;97(2):217-25. ">von Seidlein 2003 GMB</a>). Dizziness and fever were mentioned as minor AEs to MDA with dihydroartemisinin piperaquine (<a href="./references#CD008846-bbs2-0007" title="MorrisU , MsellemM , MkaliH , IslamA , Aydin-SchmidtB , JovelI , et al. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission. BMC Medicine2018;16:215. [DOI: 10.1186/s12916-018-1202-8]">Morris 2018 TZA</a>, <a href="./references#CD008846-bbs2-0011" title="TripuraR , PetoTJ , CheaN , ChanD , MukakaM , SirithiranontP , et al. A controlled trial of mass drug administration to interrupt transmission of multidrug-resistant falciparum malaria in Cambodian villages. Clinical Infectious Diseases2018;67(6):817-26. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Tripura 2018 KHM</a>) and sulfadoxine‐pyrimethamine plus artesunate (<a href="./references#CD008846-bbs2-0012" title="De MartinS , vonSeidleinL , DeenJL , PinderM , WalravenG , GreenwoodB . Community perceptions of a mass administration of an antimalarial drug combination in The Gambia. Tropical Medicine &amp; International Health2001;6(6):442-8. vonSeidleinL , WalravenG , MilliganPJ , AlexanderN , MannehF , DeenJL , et al. The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia. Transactions of the Royal Society of Tropical Medicine &amp; Hygiene2003;97(2):217-25. ">von Seidlein 2003 GMB</a>). Dizziness was also a common AE in two studies with MDA using dihydroartemisinin piperaquine plus primaquine (<a href="./references#CD008846-bbs2-0004" title="LandierJ , KajeechiwaL , ThwinMM , ParkerDM , ChaumeauV , WiladphaingernJ , et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar. Wellcome Open Research2017;2:81. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Landier 2017 MMRa</a>, <a href="./references#CD008846-bbs2-0008" title="PongvongsaT , PhommasoneK , AdhikariB , HenriquesG , ChotivanichK , HanboonkunupakarnB , et al. The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin-piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos. Malaria Journal2018;17(1):405. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Pongvongsa 2018 LAO</a>). Three studies also indicated complaints of nausea, headache, and fatigue in relation to MDA with dihydroartemisinin piperaquine plus primaquine (<a href="./references#CD008846-bbs2-0007" title="MorrisU , MsellemM , MkaliH , IslamA , Aydin-SchmidtB , JovelI , et al. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission. BMC Medicine2018;16:215. [DOI: 10.1186/s12916-018-1202-8]">Morris 2018 TZA</a>, <a href="./references#CD008846-bbs2-0013" title="vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">von Seidlein 2019 VNM</a>), or dihydroartemisinin piperaquine alone (<a href="./references#CD008846-bbs2-0011" title="TripuraR , PetoTJ , CheaN , ChanD , MukakaM , SirithiranontP , et al. A controlled trial of mass drug administration to interrupt transmission of multidrug-resistant falciparum malaria in Cambodian villages. Clinical Infectious Diseases2018;67(6):817-26. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Tripura 2018 KHM</a>). Pruritis or itching were reported by studies administering dihydroartemisinin piperaquine plus primaquine (<a href="./references#CD008846-bbs2-0004" title="LandierJ , KajeechiwaL , ThwinMM , ParkerDM , ChaumeauV , WiladphaingernJ , et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar. Wellcome Open Research2017;2:81. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Landier 2017 MMRa</a>; <a href="./references#CD008846-bbs2-0008" title="PongvongsaT , PhommasoneK , AdhikariB , HenriquesG , ChotivanichK , HanboonkunupakarnB , et al. The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin-piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos. Malaria Journal2018;17(1):405. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Pongvongsa 2018 LAO</a>) and a study administering MDA with sulfadoxine‐pyrimethamine plus amodiaquine (<a href="./references#CD008846-bbs2-0012" title="De MartinS , vonSeidleinL , DeenJL , PinderM , WalravenG , GreenwoodB . Community perceptions of a mass administration of an antimalarial drug combination in The Gambia. Tropical Medicine &amp; International Health2001;6(6):442-8. vonSeidleinL , WalravenG , MilliganPJ , AlexanderN , MannehF , DeenJL , et al. The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia. Transactions of the Royal Society of Tropical Medicine &amp; Hygiene2003;97(2):217-25. ">von Seidlein 2003 GMB</a>). Common cold or dry cough was reported as a common minor AE in two studies using MDA with dihydroartemisinin piperaquine (<a href="./references#CD008846-bbs2-0001" title="BennettA , PorterTR ,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C, et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in Southern Province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in Southern Province, Zambia: An evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. [DOI: 10.1186/s13063-015-0862-3]MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBa</a>; <a href="./references#CD008846-bbs2-0002" title="BennettA , Porter TR,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C,   et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in southern province, Zambia: an evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence  in southern province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of Plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBb</a>), or MDA with dihydroartemisinin piperaquine plus primaquine (<a href="./references#CD008846-bbs2-0008" title="PongvongsaT , PhommasoneK , AdhikariB , HenriquesG , ChotivanichK , HanboonkunupakarnB , et al. The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin-piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos. Malaria Journal2018;17(1):405. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Pongvongsa 2018 LAO</a>). </p> <p>Among the four studies that reported the distribution of AEs (as either percentage of participants or percentage of doses with an AE), the frequency of at least one AE report was highest in MDA with sulfadoxine‐pyrimethamine plus amodiaquine (33% of participants, <a href="./references#CD008846-bbs2-0012" title="De MartinS , vonSeidleinL , DeenJL , PinderM , WalravenG , GreenwoodB . Community perceptions of a mass administration of an antimalarial drug combination in The Gambia. Tropical Medicine &amp; International Health2001;6(6):442-8. vonSeidleinL , WalravenG , MilliganPJ , AlexanderN , MannehF , DeenJL , et al. The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia. Transactions of the Royal Society of Tropical Medicine &amp; Hygiene2003;97(2):217-25. ">von Seidlein 2003 GMB</a>), and lower in MDA with dihydroartemisinin piperaquine (0.24% (<a href="./references#CD008846-bbs2-0001" title="BennettA , PorterTR ,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C, et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in Southern Province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in Southern Province, Zambia: An evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. [DOI: 10.1186/s13063-015-0862-3]MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBa</a> or <a href="./references#CD008846-bbs2-0002" title="BennettA , Porter TR,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C,   et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in southern province, Zambia: an evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence  in southern province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of Plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBb</a>) to 11.6% (<a href="./references#CD008846-bbs2-0007" title="MorrisU , MsellemM , MkaliH , IslamA , Aydin-SchmidtB , JovelI , et al. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission. BMC Medicine2018;16:215. [DOI: 10.1186/s12916-018-1202-8]">Morris 2018 TZA</a>) of participants) or dihydroartemisinin piperaquine plus primaquine (3.6% of participants in <a href="./references#CD008846-bbs2-0005" title="HeatonJ , McCleanA , SweMM , SoeK , IndrasutaC , KhantZS , et al. Speeding up malaria elimination; a cluster randomized controlled trial of mass drug administration in Southeast Myanmar, an area with artemisinin resistance. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):411. McLeanAR , IndrasutaC , KhantZS , PhyoAK , MaungSM , HeatonJ , et al. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infectious Diseases 2021 June 17 [Epub ahead of print]. [DOI: 10.1016/S1473-3099(20)30997-X]">McLean 2021 MMR</a>). </p> </section> </section> <section id="CD008846-sec-0097"> <h4 class="title">Non‐randomized studies</h4> <section id="CD008846-sec-0098"> <h5 class="title"><i>P falciparum</i> parasitaemia prevalence </h5> <p>In the three non‐randomized trials, we summarized changes in parasitaemia prevalence from baseline to during‐MDA or post‐MDA, in MDA compared to no‐MDA groups, using a DiD analysis (<a href="#CD008846-tbl-0008">Table 3</a>). </p> <div class="table" id="CD008846-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Difference‐in‐differences analysis of P falciparum parasitaemia prevalence in non‐randomized studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="center" class="headercell" colspan="5" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention, % (n)</b> </p> </th> <th align="center" class="headercell" colspan="5" rowspan="1" scope="col" valign="bottom"> <p><b>Control % (n)</b> </p> </th> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign="bottom"> <p><b>Difference‐in‐differences, percentage points<sup>a</sup> </b> </p> </th> </tr> <tr> <th align="center" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Pre‐MDA</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>During MDA</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Post‐MDA</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Pre‐MDA</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>During MDA</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Post‐MDA</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>During MDA</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Post‐MDA</b> </p> </th> </tr> <tr> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>1 to 3 months</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>4 to 6 months</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>7 to 12 months</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>1 to 3 months</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>4 to 6 months</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>7 to 12 months</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>1 to 3 months</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>4 to 6 months</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>7 to 12 months</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="15" rowspan="1" valign="top"> <p><a href="./references#CD008846-bbs2-0003" title="EscudieA , HamonJ , SchneiderJ . Results of mass antimalarial chemoprophylaxis with a combination of 4-aminoquinoline and 8-aminoquinoline under rural African conditions in the region of Bobo-Dioulasso (Upper Volta) 1960. Comparative study in a zone treated with DDT and outside this zone. Medecine Tropicale1962;22(2):268-305. SchneiderJ , EscudieA , HamonJ . Eradication of malaria and chemotherapy. Results obtained with the association amino-4 quinoline + amino-8 quinoline in the pilot area of Bobo-Dioulasso (Haute- Volta) [Eradication du paludismeet chimiotherapie resultats d’un essai de l’association:amino–4 quinoleine/amino–8 quinoleine dans la zonepilote de Bobo–Dioulasso (Haute Volta)]. Bulletin de la Societe de Pathologie Exotique1961;54(5):1012-25. ">Escudie 1962 BFA</a><sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low frequency MDA with AQ‐PQ or CQ‐PQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67.6 (190)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.6 (75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.3 (105)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59.4 (129)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74.8 (517)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>386 (72.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐61.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐42.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High frequency MDA with AQ‐PQ or CQ‐PQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.6 (131)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.6 (59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.4 (286)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59.4 (129)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74.8 (517)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>386 (72.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐36.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="15" rowspan="1" valign="top"> <p><a href="./references#CD008846-bbs2-0006" title="BroggerRC , MathewsHM , StoreyJ , AshkarTS , BroggerS , MolineauxL . Changing patterns in the humoral immune response to malaria before, during and after the application of control measures: a longitudinal study in the West African savanna. Bulletin of the World Health Organization1978;56(4):579-600. MolineauxL , BroggerRC , MathewsHM , StoreyJ , AshkarTS . Longitudinal serological study of malaria in infants in the West African savanna. Comparisons in infants exposed to, or protected from, transmission from birth. Bulletin of the World Health Organisation1978;56(4):573-8. MolineauxL , GramicciaG . The Garki Project. Research on the epidemiology and control of malaria in the Sudan Savanna of West Africa. 1980. https://apps.who.int/iris/handle/10665/40316 (accessed prior to 8 July 2021). MolineauxL , StoreyJ , CohenJE , ThomasA . A longitudinal study of human malaria in the West African savanna in the absence of control measures: relationships between different Plasmodium species, in particular P. falciparum and P. malariae. American Journal of Tropical Medicine and Hygiene1980;29(5):725-37. ">Molineaux 1980 NGA</a><sup>c</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low frequency MDA with SP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.8 (525)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9 (40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49.1 (493)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.5 (380)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐23.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High frequency MDA with SP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44.9 (754)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.3 (109)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49.1 (493)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.5 (380)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐20.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="15" rowspan="1" valign="top"> <p><a href="./references#CD008846-bbs2-0009" title="RobertsJM . Pyrimethamine (Daraprim) in the control of epidemic malaria. American Journal of Tropical Medicine and Hygiene1956;59(9):201-8. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part I. Before the campaign. American Journal of Tropical Medicine and Hygiene1964;67(7):161-8. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part II. The campaign. American Journal of Tropical Medicine and Hygiene1964;67(8):191-9. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part III. After the campaign. American Journal of Tropical Medicine and Hygiene1964;67(9):230-7. ">Roberts 1964 KEN</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MDA with pyrimethamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.3 (25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (188)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.9 (26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(27) (4.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(15) (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 (154)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.4 (723)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.7 (366)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 (222)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 (78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐15.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐28.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐22.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐11.3</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AQ = amodiaquine, CQ = chloroquine, MDA = mass drug administration, ND = no data, PQ = primaquine, SP = sulfalene‐pyrimethamine </p> <p><sup>a</sup>Calculated as difference in proportion at the time period of during MDA or post‐MDA minus the proportion at pre‐MDA in the intervention and control separately and the difference in these two proportion differences between the intervention and control groups.<br/><sup>b</sup>MDA with AQ‐PQ or CQ‐PQ either every 4 weeks ('low frequency MDA') or every 2 weeks ('high frequency MDA').<br/><sup>c</sup>MDA with sulfalene‐pyrimethamine either every 10 weeks (low frequency MDA') or every 2 weeks during the wet season and every 10 weeks during the dry season ('high frequency MDA') to all ages except infants prior to their first malaria episode. </p> </div> </div> <p>MDA appeared to reduce parasitaemia prevalence in all studies during MDA compared to pre‐MDA, with a wide range of DiD percentage point reductions from ‐15.8 (<a href="./references#CD008846-bbs2-0009" title="RobertsJM . Pyrimethamine (Daraprim) in the control of epidemic malaria. American Journal of Tropical Medicine and Hygiene1956;59(9):201-8. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part I. Before the campaign. American Journal of Tropical Medicine and Hygiene1964;67(7):161-8. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part II. The campaign. American Journal of Tropical Medicine and Hygiene1964;67(8):191-9. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part III. After the campaign. American Journal of Tropical Medicine and Hygiene1964;67(9):230-7. ">Roberts 1964 KEN</a>), to ‐61.4 (<a href="./references#CD008846-bbs2-0003" title="EscudieA , HamonJ , SchneiderJ . Results of mass antimalarial chemoprophylaxis with a combination of 4-aminoquinoline and 8-aminoquinoline under rural African conditions in the region of Bobo-Dioulasso (Upper Volta) 1960. Comparative study in a zone treated with DDT and outside this zone. Medecine Tropicale1962;22(2):268-305. SchneiderJ , EscudieA , HamonJ . Eradication of malaria and chemotherapy. Results obtained with the association amino-4 quinoline + amino-8 quinoline in the pilot area of Bobo-Dioulasso (Haute- Volta) [Eradication du paludismeet chimiotherapie resultats d’un essai de l’association:amino–4 quinoleine/amino–8 quinoleine dans la zonepilote de Bobo–Dioulasso (Haute Volta)]. Bulletin de la Societe de Pathologie Exotique1961;54(5):1012-25. ">Escudie 1962 BFA</a>). The smallest reduction was observed in <a href="./references#CD008846-bbs2-0009" title="RobertsJM . Pyrimethamine (Daraprim) in the control of epidemic malaria. American Journal of Tropical Medicine and Hygiene1956;59(9):201-8. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part I. Before the campaign. American Journal of Tropical Medicine and Hygiene1964;67(7):161-8. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part II. The campaign. American Journal of Tropical Medicine and Hygiene1964;67(8):191-9. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part III. After the campaign. American Journal of Tropical Medicine and Hygiene1964;67(9):230-7. ">Roberts 1964 KEN</a>, in which two rounds of MDA using pyrimethamine were administered one year apart and, therefore, the during‐MDA time period included multiple surveys between the two rounds. Similar percentage point reductions from baseline were observed between both the low‐frequency MDA plus IRS (‐23.2 percentage points) and high frequency MDA plus IRS (‐20.9 percentage points) compared to the control (IRS only) group in <a href="./references#CD008846-bbs2-0006" title="BroggerRC , MathewsHM , StoreyJ , AshkarTS , BroggerS , MolineauxL . Changing patterns in the humoral immune response to malaria before, during and after the application of control measures: a longitudinal study in the West African savanna. Bulletin of the World Health Organization1978;56(4):579-600. MolineauxL , BroggerRC , MathewsHM , StoreyJ , AshkarTS . Longitudinal serological study of malaria in infants in the West African savanna. Comparisons in infants exposed to, or protected from, transmission from birth. Bulletin of the World Health Organisation1978;56(4):573-8. MolineauxL , GramicciaG . The Garki Project. Research on the epidemiology and control of malaria in the Sudan Savanna of West Africa. 1980. https://apps.who.int/iris/handle/10665/40316 (accessed prior to 8 July 2021). MolineauxL , StoreyJ , CohenJE , ThomasA . A longitudinal study of human malaria in the West African savanna in the absence of control measures: relationships between different Plasmodium species, in particular P. falciparum and P. malariae. American Journal of Tropical Medicine and Hygiene1980;29(5):725-37. ">Molineaux 1980 NGA</a> during the period that MDA was administered with sulfalene‐pyrimethamine. In <a href="./references#CD008846-bbs2-0003" title="EscudieA , HamonJ , SchneiderJ . Results of mass antimalarial chemoprophylaxis with a combination of 4-aminoquinoline and 8-aminoquinoline under rural African conditions in the region of Bobo-Dioulasso (Upper Volta) 1960. Comparative study in a zone treated with DDT and outside this zone. Medecine Tropicale1962;22(2):268-305. SchneiderJ , EscudieA , HamonJ . Eradication of malaria and chemotherapy. Results obtained with the association amino-4 quinoline + amino-8 quinoline in the pilot area of Bobo-Dioulasso (Haute- Volta) [Eradication du paludismeet chimiotherapie resultats d’un essai de l’association:amino–4 quinoleine/amino–8 quinoleine dans la zonepilote de Bobo–Dioulasso (Haute Volta)]. Bulletin de la Societe de Pathologie Exotique1961;54(5):1012-25. ">Escudie 1962 BFA</a>, there was a substantially greater DiD reduction in parasitaemia prevalence in the low‐frequency MDA group (amodiaquine plus primaquine or chloroquine plus primaquine every four weeks, ‐61.4 percentage points) compared to the high‐frequency MDA group (amodiaquine plus primaquine or chloroquine plus primaquine every two weeks; ‐36.3 percentage points) at during‐MDA compared to pre‐MDA time periods. </p> <p>At one to three months after MDA, parasitaemia prevalence was reduced in the low‐frequency MDA arm of <a href="./references#CD008846-bbs2-0003" title="EscudieA , HamonJ , SchneiderJ . Results of mass antimalarial chemoprophylaxis with a combination of 4-aminoquinoline and 8-aminoquinoline under rural African conditions in the region of Bobo-Dioulasso (Upper Volta) 1960. Comparative study in a zone treated with DDT and outside this zone. Medecine Tropicale1962;22(2):268-305. SchneiderJ , EscudieA , HamonJ . Eradication of malaria and chemotherapy. Results obtained with the association amino-4 quinoline + amino-8 quinoline in the pilot area of Bobo-Dioulasso (Haute- Volta) [Eradication du paludismeet chimiotherapie resultats d’un essai de l’association:amino–4 quinoleine/amino–8 quinoleine dans la zonepilote de Bobo–Dioulasso (Haute Volta)]. Bulletin de la Societe de Pathologie Exotique1961;54(5):1012-25. ">Escudie 1962 BFA</a> by ‐42.1 percentage points, but there was an increase in parasitaemia prevalence in the high‐frequency MDA arm compared to control, as reflected by a +14.9 percentage point DiD. There was an initial reduction in parasitaemia prevalence (‐28.1 percentage points) found in <a href="./references#CD008846-bbs2-0009" title="RobertsJM . Pyrimethamine (Daraprim) in the control of epidemic malaria. American Journal of Tropical Medicine and Hygiene1956;59(9):201-8. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part I. Before the campaign. American Journal of Tropical Medicine and Hygiene1964;67(7):161-8. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part II. The campaign. American Journal of Tropical Medicine and Hygiene1964;67(8):191-9. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part III. After the campaign. American Journal of Tropical Medicine and Hygiene1964;67(9):230-7. ">Roberts 1964 KEN</a> at one to three months after MDA, which decreased over time to ‐22.8 percentage points at four to six months after MDA, and to ‐11.3 percentage points at 7 to 12 months after MDA. Given the introduction of new interventions in <a href="./references#CD008846-bbs2-0006" title="BroggerRC , MathewsHM , StoreyJ , AshkarTS , BroggerS , MolineauxL . Changing patterns in the humoral immune response to malaria before, during and after the application of control measures: a longitudinal study in the West African savanna. Bulletin of the World Health Organization1978;56(4):579-600. MolineauxL , BroggerRC , MathewsHM , StoreyJ , AshkarTS . Longitudinal serological study of malaria in infants in the West African savanna. Comparisons in infants exposed to, or protected from, transmission from birth. Bulletin of the World Health Organisation1978;56(4):573-8. MolineauxL , GramicciaG . The Garki Project. Research on the epidemiology and control of malaria in the Sudan Savanna of West Africa. 1980. https://apps.who.int/iris/handle/10665/40316 (accessed prior to 8 July 2021). MolineauxL , StoreyJ , CohenJE , ThomasA . A longitudinal study of human malaria in the West African savanna in the absence of control measures: relationships between different Plasmodium species, in particular P. falciparum and P. malariae. American Journal of Tropical Medicine and Hygiene1980;29(5):725-37. ">Molineaux 1980 NGA</a> immediately following MDA, there were no post‐MDA data available. </p> </section> <section id="CD008846-sec-0099"> <h5 class="title"><i>P falciparum</i> gametocytaemia prevalence </h5> <p>In the two non‐randomized trials reporting gametocytaemia prevalence, we summarized changes in the effect of MDA from baseline to during‐MDA or post‐MDA using DiD analysis (<a href="#CD008846-tbl-0009">Table 4</a>). </p> <div class="table" id="CD008846-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Difference‐in‐differences analysis of P falciparum gametocytaemia prevalence in non‐randomized studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention, % (n)</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Control, % (n)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Difference‐in‐differences</b> </p> <p><b>percentage point<sup>a</sup> </b> </p> </th> </tr> <tr> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Pre‐MDA</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>During MDA</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Post‐MDA</b> </p> <p><b>1 to 3 months</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Pre‐MDA</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>During MDA</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Post‐MDA</b> </p> <p><b>1 to 3 months</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>During MDA</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Post‐MDA</b> </p> <p><b>1 to 3 months</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><a href="./references#CD008846-bbs2-0003" title="EscudieA , HamonJ , SchneiderJ . Results of mass antimalarial chemoprophylaxis with a combination of 4-aminoquinoline and 8-aminoquinoline under rural African conditions in the region of Bobo-Dioulasso (Upper Volta) 1960. Comparative study in a zone treated with DDT and outside this zone. Medecine Tropicale1962;22(2):268-305. SchneiderJ , EscudieA , HamonJ . Eradication of malaria and chemotherapy. Results obtained with the association amino-4 quinoline + amino-8 quinoline in the pilot area of Bobo-Dioulasso (Haute- Volta) [Eradication du paludismeet chimiotherapie resultats d’un essai de l’association:amino–4 quinoleine/amino–8 quinoleine dans la zonepilote de Bobo–Dioulasso (Haute Volta)]. Bulletin de la Societe de Pathologie Exotique1961;54(5):1012-25. ">Escudie 1962 BFA</a><sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low frequency MDA with AQ‐PQ or CQ‐PQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.3 (57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.3 (35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.4 (42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.1 (102)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐14.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High frequency MDA with AQ‐PQ or CQ‐PQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.2 (32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9 (9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.4 (107)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.4 (42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.1 (102)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><a href="./references#CD008846-bbs2-0006" title="BroggerRC , MathewsHM , StoreyJ , AshkarTS , BroggerS , MolineauxL . Changing patterns in the humoral immune response to malaria before, during and after the application of control measures: a longitudinal study in the West African savanna. Bulletin of the World Health Organization1978;56(4):579-600. MolineauxL , BroggerRC , MathewsHM , StoreyJ , AshkarTS . Longitudinal serological study of malaria in infants in the West African savanna. Comparisons in infants exposed to, or protected from, transmission from birth. Bulletin of the World Health Organisation1978;56(4):573-8. MolineauxL , GramicciaG . The Garki Project. Research on the epidemiology and control of malaria in the Sudan Savanna of West Africa. 1980. https://apps.who.int/iris/handle/10665/40316 (accessed prior to 8 July 2021). MolineauxL , StoreyJ , CohenJE , ThomasA . A longitudinal study of human malaria in the West African savanna in the absence of control measures: relationships between different Plasmodium species, in particular P. falciparum and P. malariae. American Journal of Tropical Medicine and Hygiene1980;29(5):725-37. ">Molineaux 1980 NGA</a><sup>c</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low frequency MDA with SP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.1 (127)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.6 (12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.4 (124)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.9 (92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High frequency MDA with SP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.4 (208)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.2 (48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.4 (124)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.9 (92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐4.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AQ = amodiaquine, CQ = chloroquine, MDA = mass drug administration, ND = no data, SP = sulfalene‐pyrimethamine </p> <p><sup>a</sup>Calculated as difference in proportion at the time period of during MDA or post‐MDA minus the proportion at pre‐MDA in the intervention and control separately and the difference in these two proportion differences between the intervention and control groups.<br/><sup>b</sup>MDA with AQ‐PQ or CQ‐PQ either every 4 weeks ('low frequency MDA') or every 2 weeks ('high frequency MDA').<br/><sup>c</sup>MDA with sulfalene‐pyrimethamine either every 10 weeks ('low frequency MDA') or every 2 weeks during the wet season and every 10 weeks during the dry season ('high frequency MDA') to all ages except infants prior to their first malaria episode. </p> </div> </div> <p>From pre‐MDA to during‐MDA, with the exception of the low‐frequency MDA arm in <a href="./references#CD008846-bbs2-0003" title="EscudieA , HamonJ , SchneiderJ . Results of mass antimalarial chemoprophylaxis with a combination of 4-aminoquinoline and 8-aminoquinoline under rural African conditions in the region of Bobo-Dioulasso (Upper Volta) 1960. Comparative study in a zone treated with DDT and outside this zone. Medecine Tropicale1962;22(2):268-305. SchneiderJ , EscudieA , HamonJ . Eradication of malaria and chemotherapy. Results obtained with the association amino-4 quinoline + amino-8 quinoline in the pilot area of Bobo-Dioulasso (Haute- Volta) [Eradication du paludismeet chimiotherapie resultats d’un essai de l’association:amino–4 quinoleine/amino–8 quinoleine dans la zonepilote de Bobo–Dioulasso (Haute Volta)]. Bulletin de la Societe de Pathologie Exotique1961;54(5):1012-25. ">Escudie 1962 BFA</a>, there was a small DiD reduction on gametocytaemia prevalence, ranging from ‐1 percentage point (<a href="./references#CD008846-bbs2-0003" title="EscudieA , HamonJ , SchneiderJ . Results of mass antimalarial chemoprophylaxis with a combination of 4-aminoquinoline and 8-aminoquinoline under rural African conditions in the region of Bobo-Dioulasso (Upper Volta) 1960. Comparative study in a zone treated with DDT and outside this zone. Medecine Tropicale1962;22(2):268-305. SchneiderJ , EscudieA , HamonJ . Eradication of malaria and chemotherapy. Results obtained with the association amino-4 quinoline + amino-8 quinoline in the pilot area of Bobo-Dioulasso (Haute- Volta) [Eradication du paludismeet chimiotherapie resultats d’un essai de l’association:amino–4 quinoleine/amino–8 quinoleine dans la zonepilote de Bobo–Dioulasso (Haute Volta)]. Bulletin de la Societe de Pathologie Exotique1961;54(5):1012-25. ">Escudie 1962 BFA</a> high‐frequency MDA) to ‐5.0 percentage points in both arms of <a href="./references#CD008846-bbs2-0006" title="BroggerRC , MathewsHM , StoreyJ , AshkarTS , BroggerS , MolineauxL . Changing patterns in the humoral immune response to malaria before, during and after the application of control measures: a longitudinal study in the West African savanna. Bulletin of the World Health Organization1978;56(4):579-600. MolineauxL , BroggerRC , MathewsHM , StoreyJ , AshkarTS . Longitudinal serological study of malaria in infants in the West African savanna. Comparisons in infants exposed to, or protected from, transmission from birth. Bulletin of the World Health Organisation1978;56(4):573-8. MolineauxL , GramicciaG . The Garki Project. Research on the epidemiology and control of malaria in the Sudan Savanna of West Africa. 1980. https://apps.who.int/iris/handle/10665/40316 (accessed prior to 8 July 2021). MolineauxL , StoreyJ , CohenJE , ThomasA . A longitudinal study of human malaria in the West African savanna in the absence of control measures: relationships between different Plasmodium species, in particular P. falciparum and P. malariae. American Journal of Tropical Medicine and Hygiene1980;29(5):725-37. ">Molineaux 1980 NGA</a>. A large reduction from pre‐MDA (‐14.1 percentage points) was observed in the low‐frequency MDA arm of <a href="./references#CD008846-bbs2-0003" title="EscudieA , HamonJ , SchneiderJ . Results of mass antimalarial chemoprophylaxis with a combination of 4-aminoquinoline and 8-aminoquinoline under rural African conditions in the region of Bobo-Dioulasso (Upper Volta) 1960. Comparative study in a zone treated with DDT and outside this zone. Medecine Tropicale1962;22(2):268-305. SchneiderJ , EscudieA , HamonJ . Eradication of malaria and chemotherapy. Results obtained with the association amino-4 quinoline + amino-8 quinoline in the pilot area of Bobo-Dioulasso (Haute- Volta) [Eradication du paludismeet chimiotherapie resultats d’un essai de l’association:amino–4 quinoleine/amino–8 quinoleine dans la zonepilote de Bobo–Dioulasso (Haute Volta)]. Bulletin de la Societe de Pathologie Exotique1961;54(5):1012-25. ">Escudie 1962 BFA</a> during MDA. However, compared to the pre‐MDA period, gametocytaemia prevalence at one to three months after MDA was increased in both the low‐frequency MDA arm (18.3 percentage points) and high‐frequency MDA arm (53.4 percentage points) in <a href="./references#CD008846-bbs2-0003" title="EscudieA , HamonJ , SchneiderJ . Results of mass antimalarial chemoprophylaxis with a combination of 4-aminoquinoline and 8-aminoquinoline under rural African conditions in the region of Bobo-Dioulasso (Upper Volta) 1960. Comparative study in a zone treated with DDT and outside this zone. Medecine Tropicale1962;22(2):268-305. SchneiderJ , EscudieA , HamonJ . Eradication of malaria and chemotherapy. Results obtained with the association amino-4 quinoline + amino-8 quinoline in the pilot area of Bobo-Dioulasso (Haute- Volta) [Eradication du paludismeet chimiotherapie resultats d’un essai de l’association:amino–4 quinoleine/amino–8 quinoleine dans la zonepilote de Bobo–Dioulasso (Haute Volta)]. Bulletin de la Societe de Pathologie Exotique1961;54(5):1012-25. ">Escudie 1962 BFA</a> compared to no MDA. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008846-sec-0100" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008846-sec-0100"></div> <section id="CD008846-sec-0101"> <h3 class="title" id="CD008846-sec-0101">Summary of main results</h3> <p>We included 13 studies in this review: 10 cRCTs, of which two were from areas of moderate to high transmission, and eight were from areas of very low to low endemicity; and three CBAs, all from settings of moderate to high transmission. </p> <section id="CD008846-sec-0102"> <h4 class="title">Areas of moderate‐ to high‐endemicity (cRCTs)</h4> <p>The two included studies were both conducted in sub‐Saharan Africa. We included MDA versus no‐MDA comparisons from <a href="./references#CD008846-bbs2-0012" title="De MartinS , vonSeidleinL , DeenJL , PinderM , WalravenG , GreenwoodB . Community perceptions of a mass administration of an antimalarial drug combination in The Gambia. Tropical Medicine &amp; International Health2001;6(6):442-8. vonSeidleinL , WalravenG , MilliganPJ , AlexanderN , MannehF , DeenJL , et al. The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia. Transactions of the Royal Society of Tropical Medicine &amp; Hygiene2003;97(2):217-25. ">von Seidlein 2003 GMB</a>, which examined the effect of one round of MDA with sulfadoxine‐pyrimethamine plus artesunate, and from <a href="./references#CD008846-bbs2-0002" title="BennettA , Porter TR,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C,   et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in southern province, Zambia: an evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence  in southern province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of Plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBb</a>, which examined the effect of four rounds of MDA with dihydroartemisinin piperaquine. No co‐interventions were implemented in the <a href="./references#CD008846-bbs2-0012" title="De MartinS , vonSeidleinL , DeenJL , PinderM , WalravenG , GreenwoodB . Community perceptions of a mass administration of an antimalarial drug combination in The Gambia. Tropical Medicine &amp; International Health2001;6(6):442-8. vonSeidleinL , WalravenG , MilliganPJ , AlexanderN , MannehF , DeenJL , et al. The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia. Transactions of the Royal Society of Tropical Medicine &amp; Hygiene2003;97(2):217-25. ">von Seidlein 2003 GMB</a> study, but IRS, ITNs, and enhanced community case management practices were included in all arms of <a href="./references#CD008846-bbs2-0002" title="BennettA , Porter TR,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C,   et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in southern province, Zambia: an evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence  in southern province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of Plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBb</a>. </p> <p>Based on these data, in comparison to no‐MDA:</p> <p> <ul id="CD008846-list-0024"> <li> <p>at one to three months after MDA, <i>P falciparum</i> parasitaemia prevalence may be higher (low‐certainty evidence), parasitaemia incidence is probably lower (moderate‐certainty evidence), and confirmed malaria illness incidence may be lower (low‐certainty evidence) in MDA compared to no‐MDA, as reported by a single study (<a href="./references#CD008846-bbs2-0002" title="BennettA , Porter TR,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C,   et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in southern province, Zambia: an evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence  in southern province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of Plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBb</a>); </p> </li> <li> <p>at four to six months after MDA, MDA probably leads to little or no effect on <i>P falciparum</i> parasitaemia prevalence (moderate‐certainty evidence) and we do not know the effect on parasitaemia incidence (very low‐certainty evidence) as reported by a single study (<a href="./references#CD008846-bbs2-0012" title="De MartinS , vonSeidleinL , DeenJL , PinderM , WalravenG , GreenwoodB . Community perceptions of a mass administration of an antimalarial drug combination in The Gambia. Tropical Medicine &amp; International Health2001;6(6):442-8. vonSeidleinL , WalravenG , MilliganPJ , AlexanderN , MannehF , DeenJL , et al. The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia. Transactions of the Royal Society of Tropical Medicine &amp; Hygiene2003;97(2):217-25. ">von Seidlein 2003 GMB</a>). </p> </li> </ul> </p> <p>Longer‐term effects of MDA on outcomes were not reported by any included studies in moderate‐ to high‐transmission settings. </p> </section> <section id="CD008846-sec-0103"> <h4 class="title">Areas of very low‐ to low‐endemicity (cRCTs)</h4> <p>Of the eight studies included in qualitative synthesis, three were carried out in sub‐Saharan Africa and five were conducted in Southeast Asia. One study that administered one round of MDA with sulfadoxine‐pyrimethamine plus artesunate plus primaquine was excluded from quantitative synthesis due to insufficient data (<a href="./references#CD008846-bbs2-0010" title="ShekalagheSA , DrakeleyC , vanden BoschS , ter BraakR , vanden BikilaardtW , MwanzivaC , et al. A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania. Malaria Journal2011;10:247. ShekalagheSA , ter BraakR , DaouM , KavisheR , vanden BijilaardtW , vanden BoschS , et al. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A) individuals. Antimicrobial Agents and Chemotherapy2010;54(5):1762-8. ">Shekalaghe 2011 TZA</a>). Of the remaining seven trials, we included one comparison (multiple rounds of MDA with dihydroartemisinin piperaquine plus primaquine) each from <a href="./references#CD008846-bbs2-0004" title="LandierJ , KajeechiwaL , ThwinMM , ParkerDM , ChaumeauV , WiladphaingernJ , et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar. Wellcome Open Research2017;2:81. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Landier 2017 MMRa</a>, <a href="./references#CD008846-bbs2-0005" title="HeatonJ , McCleanA , SweMM , SoeK , IndrasutaC , KhantZS , et al. Speeding up malaria elimination; a cluster randomized controlled trial of mass drug administration in Southeast Myanmar, an area with artemisinin resistance. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):411. McLeanAR , IndrasutaC , KhantZS , PhyoAK , MaungSM , HeatonJ , et al. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infectious Diseases 2021 June 17 [Epub ahead of print]. [DOI: 10.1016/S1473-3099(20)30997-X]">McLean 2021 MMR</a>, <a href="./references#CD008846-bbs2-0007" title="MorrisU , MsellemM , MkaliH , IslamA , Aydin-SchmidtB , JovelI , et al. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission. BMC Medicine2018;16:215. [DOI: 10.1186/s12916-018-1202-8]">Morris 2018 TZA</a>, <a href="./references#CD008846-bbs2-0008" title="PongvongsaT , PhommasoneK , AdhikariB , HenriquesG , ChotivanichK , HanboonkunupakarnB , et al. The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin-piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos. Malaria Journal2018;17(1):405. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Pongvongsa 2018 LAO</a>, and <a href="./references#CD008846-bbs2-0013" title="vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">von Seidlein 2019 VNM</a>; and one comparison (multiple rounds of MDA with dihydroartemisinin piperaquine) each from <a href="./references#CD008846-bbs2-0001" title="BennettA , PorterTR ,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C, et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in Southern Province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in Southern Province, Zambia: An evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. [DOI: 10.1186/s13063-015-0862-3]MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBa</a> and <a href="./references#CD008846-bbs2-0011" title="TripuraR , PetoTJ , CheaN , ChanD , MukakaM , SirithiranontP , et al. A controlled trial of mass drug administration to interrupt transmission of multidrug-resistant falciparum malaria in Cambodian villages. Clinical Infectious Diseases2018;67(6):817-26. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Tripura 2018 KHM</a>. All studies implemented ITNs, while <a href="./references#CD008846-bbs2-0007" title="MorrisU , MsellemM , MkaliH , IslamA , Aydin-SchmidtB , JovelI , et al. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission. BMC Medicine2018;16:215. [DOI: 10.1186/s12916-018-1202-8]">Morris 2018 TZA</a> and <a href="./references#CD008846-bbs2-0001" title="BennettA , PorterTR ,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C, et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in Southern Province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in Southern Province, Zambia: An evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. [DOI: 10.1186/s13063-015-0862-3]MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBa</a> also included IRS in both intervention and control arms. </p> <p>Based on these data, in comparison to no‐MDA:</p> <p> <ul id="CD008846-list-0025"> <li> <p>at less than one month after MDA, <i>P falciparum</i> parasitaemia prevalence may be lower in MDA compared to no‐MDA (low‐certainty evidence<i>);</i> </p> </li> <li> <p>at one to three months after MDA, MDA probably reduces <i>P falciparum</i> parasitaemia incidence (moderate‐certainty evidence) and may reduce <i>P falciparum</i> parasitaemia prevalence (low‐certainty evidence), but we do not know if MDA has an effect on confirmed malaria illness incidence (very low‐certainty evidence); </p> </li> <li> <p>at 4 to 6 months and 7 to 12 months after MDA, we do not know the effect of MDA on <i>P falciparum</i> parasitaemia prevalence and confirmed malaria illness incidence (very low‐certainty evidence); </p> </li> <li> <p>as reported by a single study (<a href="./references#CD008846-bbs2-0005" title="HeatonJ , McCleanA , SweMM , SoeK , IndrasutaC , KhantZS , et al. Speeding up malaria elimination; a cluster randomized controlled trial of mass drug administration in Southeast Myanmar, an area with artemisinin resistance. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):411. McLeanAR , IndrasutaC , KhantZS , PhyoAK , MaungSM , HeatonJ , et al. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infectious Diseases 2021 June 17 [Epub ahead of print]. [DOI: 10.1016/S1473-3099(20)30997-X]">McLean 2021 MMR</a>), we do not know if MDA has an effect on <i>P falciparum</i> parasitaemia prevalence at longer‐term follow‐up periods (13 to 36 months, very low‐certainty evidence). </p> </li> </ul> </p> <p>Despite the very low‐certainty evidence available for outcomes after four months post‐MDA, there was a general trend of a substantial reduction in <i>P falciparum</i> parasitaemia prevalence immediately following MDA and the strength of the reduction declined over time. </p> <p>Five studies provided data for comparison of <i>P vivax</i> outcomes: </p> <p> <ul id="CD008846-list-0026"> <li> <p>at less than one month after MDA, <i>P vivax</i> parasitaemia prevalence may be lower in MDA compared to no‐MDA (low‐certainty evidence); </p> </li> <li> <p>at one to three months after MDA, <i>P vivax</i> parasitaemia prevalence may be lower in MDA compared to no‐MDA (low‐certainty evidence); </p> </li> <li> <p>at four to six months after MDA, we do not know if MDA reduces <i>P vivax</i> parasitaemia prevalence (very low‐certainty evidence); </p> </li> <li> <p>at 7 to 12 months after MDA, we do not know the effect of MDA on <i>P vivax</i> parasitaemia prevalence and confirmed malaria illness incidence (very low‐certainty evidence); </p> </li> <li> <p>as reported by a single study (<a href="./references#CD008846-bbs2-0005" title="HeatonJ , McCleanA , SweMM , SoeK , IndrasutaC , KhantZS , et al. Speeding up malaria elimination; a cluster randomized controlled trial of mass drug administration in Southeast Myanmar, an area with artemisinin resistance. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):411. McLeanAR , IndrasutaC , KhantZS , PhyoAK , MaungSM , HeatonJ , et al. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infectious Diseases 2021 June 17 [Epub ahead of print]. [DOI: 10.1016/S1473-3099(20)30997-X]">McLean 2021 MMR</a>), we do not know if MDA has an effect on <i>P vivax</i> parasitaemia prevalence at longer‐term follow‐up periods (13 to 36 months, very low‐certainty evidence). </p> </li> </ul> </p> <p>Very low‐certainty evidence was available for multiple outcomes. However, similar to <i>P falciparum</i> outcomes in this setting<i>,</i> there was a general trend of a large and immediate reduction in <i>P vivax</i> parasitaemia prevalence following MDA that waned over time. </p> <p>In relation to the <a href="#CD008846-sec-0014">Objectives</a> of this review: </p> <p> <ul id="CD008846-list-0027"> <li> <p>in moderate‐ to high‐transmission settings, no studies provided data at longer‐term time periods to observe a 50% reduction in median malaria parasite prevalence or incidence, or both, at 12 months after MDA. However, the available studies showed a reduction in parasitaemia incidence, but not parasitaemia prevalence, at time periods prior to six months after MDA; </p> </li> <li> <p>in very low‐ to low‐transmission settings, there was a strong reduction in <i>P falciparum</i> and <i>P vivax</i> parasitaemia prevalence immediately following MDA, that decreased over time. However, there was no evidence of interruption of transmission, defined as a reduction in number of indigenous malaria infections to zero at six months after MDA. </p> </li> </ul> </p> </section> </section> <section id="CD008846-sec-0104"> <h3 class="title" id="CD008846-sec-0104">Overall completeness and applicability of evidence</h3> <p>This review highlights a renewed interest in MDA as a strategy to accelerate progress towards malaria elimination, given the more recent studies conducted since the previous review on this topic (<a href="./references#CD008846-bbs2-0062" title="PoirotE , SkarbinskiJ , SinclairD , KachurSP , SlutskerL , HwangJ . Mass drug administration for malaria. Cochrane Database of Systematic Reviews2013, Issue 12 10.1002/14651858.CD008846.pub2 10.1002/14651858.CD008846.pub2. Art. No: CD008846. [DOI: 10.1002/14651858.CD008846.pub2]">Poirot 2013</a>). In areas of moderate to high transmission, no studies reported outcomes under six months after MDA, but available evidence from earlier post‐MDA time periods showed that MDA decreased parasitaemia incidence, but not parasitaemia prevalence. In very low‐ to low‐transmission areas, several studies found substantial short‐term reductions in parasitaemia prevalence following MDA that were not sustained longer‐term. None of these studies found a reduction to zero indigenous malaria cases at any post‐MDA time period. </p> <p>In both malaria transmission settings, we found that MDA compared to no MDA led to significant reductions in <i>P falciparum</i> parasitaemia incidence at one to three months after MDA, and in very low‐ to low‐transmission settings, correspondingly large and statistically significant reductions in parasitaemia prevalence at less than one month after MDA (one study) and at one to three months after MDA (seven studies). However, in moderate‐ to high‐transmission settings, this trend was not mirrored by a reduction in parasitaemia prevalence, based on a single study reporting at one to three months and four to six months after MDA. We believe one explanation for this counterintuitive finding of a reduction in incidence but not prevalence is due to differences in the study design and populations used to measure these outcomes. Studies measured incidence in a fixed cohort and prevalence in a random sample of the population in cross‐sectional surveys. Since the inclusion criteria for cohort studies typically requires establishment of a period of residency in the study area, cohort participants may also be more likely to receive at least one round of MDA compared to a cross‐section of the population that can include individuals who recently moved to the study area after the MDA round (i.e. did not receive the intervention) but prior to the survey. This distinction also raises the concern about risk of re‐introduction of malaria. It is possible that we found no effect of MDA on several outcomes due to the high risk of re‐introduction in the study areas of included studies, possibly due to a combination of high levels of migration and low effective MDA coverage (i.e. the proportion of the population that received at least one round of MDA). </p> <p>In an area of moderate to high transmission, <a href="./references#CD008846-bbs2-0002" title="BennettA , Porter TR,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C,   et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in southern province, Zambia: an evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence  in southern province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of Plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBb</a> found an unexpected increase in parasitaemia prevalence in the MDA arm compared to no‐MDA control at one to three months, following four rounds of MDA. Although the effect estimate was very imprecise, it is worth noting that parasitaemia prevalence decreased overall in the entire study area (both the lower‐ and higher‐transmission strata) and specifically in the moderate‐ to high‐transmission control clusters, from above 50% at baseline to below 10% following four rounds of MDA. Other interventions such as ITNs, IRS and enhanced community case management were implemented at high coverage in intervention and control arms at the start of the study and may have contributed to the overall decline in malaria transmission in the study area. This finding may also highlight the importance of implementing MDA as a component of a package of malaria control interventions to achieve reductions in malaria transmission. </p> <p>Although not an important cause of heterogeneity in our analysis, the short‐term effects of MDA in studies conducted in very low‐ to low‐ transmission settings differed by geography. Trials conducted in Southeast Asia generally found a large reduction in parasitaemia prevalence at one to three months after MDA (<a href="./references#CD008846-bbs2-0004" title="LandierJ , KajeechiwaL , ThwinMM , ParkerDM , ChaumeauV , WiladphaingernJ , et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar. Wellcome Open Research2017;2:81. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Landier 2017 MMRa</a>; <a href="./references#CD008846-bbs2-0005" title="HeatonJ , McCleanA , SweMM , SoeK , IndrasutaC , KhantZS , et al. Speeding up malaria elimination; a cluster randomized controlled trial of mass drug administration in Southeast Myanmar, an area with artemisinin resistance. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):411. McLeanAR , IndrasutaC , KhantZS , PhyoAK , MaungSM , HeatonJ , et al. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infectious Diseases 2021 June 17 [Epub ahead of print]. [DOI: 10.1016/S1473-3099(20)30997-X]">McLean 2021 MMR</a>; <a href="./references#CD008846-bbs2-0008" title="PongvongsaT , PhommasoneK , AdhikariB , HenriquesG , ChotivanichK , HanboonkunupakarnB , et al. The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin-piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos. Malaria Journal2018;17(1):405. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Pongvongsa 2018 LAO</a>; <a href="./references#CD008846-bbs2-0011" title="TripuraR , PetoTJ , CheaN , ChanD , MukakaM , SirithiranontP , et al. A controlled trial of mass drug administration to interrupt transmission of multidrug-resistant falciparum malaria in Cambodian villages. Clinical Infectious Diseases2018;67(6):817-26. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Tripura 2018 KHM</a>; <a href="./references#CD008846-bbs2-0013" title="vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">von Seidlein 2019 VNM</a>), while the two studies in Africa showed a smaller or no reduction (<a href="./references#CD008846-bbs2-0001" title="BennettA , PorterTR ,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C, et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in Southern Province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in Southern Province, Zambia: An evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. [DOI: 10.1186/s13063-015-0862-3]MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBa</a>; <a href="./references#CD008846-bbs2-0007" title="MorrisU , MsellemM , MkaliH , IslamA , Aydin-SchmidtB , JovelI , et al. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission. BMC Medicine2018;16:215. [DOI: 10.1186/s12916-018-1202-8]">Morris 2018 TZA</a>). All studies administered MDA with dihydroartemisinin piperaquine (primaquine was included in most Southeast Asia trials and the Zanzibar study), implemented multiple rounds of MDA, and had similar levels of coverage. Trials in Africa included substantially larger MDA target populations (&gt; 10,000 in Zanzibar; &gt; 37,000 in Zambia) compared to Southeast Asia (&lt; 5000) and implemented additional co‐interventions (mainly, IRS) across arms. Although not measured directly, differences in underlying malaria epidemiology, population movement and risk of re‐introduction, and implementation of the intervention (more resource‐intensive in larger trials) could have contributed to variations in the short‐term effects by geography. </p> <p>Of note, the certainty of evidence for outcomes in this review was based on a small number of included studies that, after stratification by endemicity and post‐MDA time period, often resulted in limited evidence. We assessed studies from very low‐ to low‐endemicity settings as high risk of bias for several criteria, and the certainty of evidence from studies from all endemicities was affected by imprecision. This highlights the need for additional studies with high‐quality evidence (both randomized and non‐randomized designs) and with sufficient sample sizes to account for the correlation due to clustering. Finally, we excluded many studies due to reasons such as imbalanced co‐interventions across arms or insufficient time points before and after MDA to conduct interrupted time series (ITS) analyses. Although these studies did not meet our criteria for inclusion, they may provide information useful for policymakers. </p> </section> <section id="CD008846-sec-0105"> <h3 class="title" id="CD008846-sec-0105">Quality of the evidence</h3> <p>In settings of moderate to high transmission, we judged the two trials as having low risk of bias (<a href="#CD008846-fig-0002">Figure 2</a>), and <a href="./full#CD008846-tbl-0001">summary of findings Table 1</a> describes our assessment of the certainty of evidence available. No pooled effect estimates were provided for outcomes in moderate‐ to high‐transmission settings due to a single study reporting after stratification by post‐MDA time period. </p> <p>We judged most studies from very low‐ to low‐endemicity settings to be at high risk or unclear risk of bias for some criteria (<a href="#CD008846-fig-0002">Figure 2</a>), and our assessment of the certainty of evidence available for important short‐term outcomes is provided in <a href="./full#CD008846-tbl-0002">summary of findings Table 2</a>, <a href="./full#CD008846-tbl-0003">summary of findings Table 3</a>, <a href="./full#CD008846-tbl-0004">summary of findings Table 4</a>, and <a href="./full#CD008846-tbl-0005">summary of findings Table 5</a>. Studies in this setting were generally underpowered and there were only a few malaria events across arms, resulting in imprecise estimates of effect. Many outcomes were downgraded by one or two levels due to imprecision after adjustment for clustering. All parasitaemia prevalence outcomes at longer‐term post‐MDA time periods were downgraded by one or two levels due to risk of bias, mainly due to baseline imbalance or biased sampling approaches for cross‐sectional parasitaemia surveys. </p> </section> <section id="CD008846-sec-0106"> <h3 class="title" id="CD008846-sec-0106">Potential biases in the review process</h3> <p>Although we sought to examine short‐ and longer‐term effects of MDA over a range of follow‐up time periods, there were few studies available within each follow‐up time period. Therefore, we were unable to examine whether variables, such as type of antimalarial drug, MDA coverage or number of rounds, and co‐interventions, modified the effect of MDA compared to no MDA. </p> </section> <section id="CD008846-sec-0107"> <h3 class="title" id="CD008846-sec-0107">Agreements and disagreements with other studies or reviews</h3> <p>Previous reviews on this topic described substantial but temporary reductions in malaria burden immediately following MDA (in both low‐ and high‐transmission settings) (<a href="./references#CD008846-bbs2-0039" title="GreenwoodB . The use of anti-malarial drugs to prevent malaria in the population of malaria-endemic areas. American Journal of Tropical Medicine and Hygiene2004;70(1):1-7.">Greenwood 2004</a>; <a href="./references#CD008846-bbs2-0048" title="NewbyG , HwangJ , KoitaK , ChenI , GreenwoodB , vonSeidleinL , et al. Review of mass drug administration for malaria and its operational challenges. American Journal of Tropical Medicine and Hygiene2015;93(1):125-134.">Newby 2015</a>; <a href="./references#CD008846-bbs2-0062" title="PoirotE , SkarbinskiJ , SinclairD , KachurSP , SlutskerL , HwangJ . Mass drug administration for malaria. Cochrane Database of Systematic Reviews2013, Issue 12 10.1002/14651858.CD008846.pub2 10.1002/14651858.CD008846.pub2. Art. No: CD008846. [DOI: 10.1002/14651858.CD008846.pub2]">Poirot 2013</a>; <a href="./references#CD008846-bbs2-0054" title="vonSeidleinL , GreenwoodBM . Mass administration of antimalaria drugs. Trends in Parasitology2003;19(10):452-60.">von Seidlein 2003</a>). Our review provides evidence of short‐term reductions in parasitaemia incidence in both transmission settings and evidence of short‐term reductions in parasitaemia prevalence in very low‐ to low‐endemicity areas, but not in moderate‐ to high‐endemicity areas. This difference is possibly due to the limited number of studies in moderate‐ to high‐transmission settings included in this review (two trials), different study design, or differences in malaria context between older and newer studies. Many older studies included in previous reviews were conducted in settings prior to scale‐up of vector control measures (e.g. ITNs), improvements in case management (i.e. RDTs and ACTs), and potentially less population movement to limit risk of re‐introduction. This may have resulted in a larger effect of MDA, which is supported by our results from non‐randomized studies that showed large short‐term reductions in parasitaemia prevalence in older studies conducted in settings of moderate to high endemicity. Additionally, it is possible that our inclusion of more rigorous study designs provided less biased comparisons for evaluating the effect of MDA. </p> <p>The 2013 Cochrane Review on this topic highlighted a few studies on small islands or in highland settings in which malaria transmission was interrupted by MDA (<a href="./references#CD008846-bbs2-0062" title="PoirotE , SkarbinskiJ , SinclairD , KachurSP , SlutskerL , HwangJ . Mass drug administration for malaria. Cochrane Database of Systematic Reviews2013, Issue 12 10.1002/14651858.CD008846.pub2 10.1002/14651858.CD008846.pub2. Art. No: CD008846. [DOI: 10.1002/14651858.CD008846.pub2]">Poirot 2013</a>), but these studies did not meet inclusion criteria for our updated review. Although MDA has been attributed to successful elimination of malaria in Vanuatu (<a href="./references#CD008846-bbs2-0022" title="KanekoA , ChanC , IsozumiR , KalkoaM , ChavesLF , WatanabeN , et al. Sustainable malaria elimination on Aneityum Island, Vanuatu, 1991-2014. American Journal of Tropical Medicine and Hygiene2014;91(5 Supplement 1):197. KanekoA , ChanC , TaleoG , WatanabeN , KalkoaM , IamarS , et al. Community-directed malaria freedom on Aneityum Island, Vanuatu, 1991-2014. Malaria Journal2014;13(Supplement 1):P50. KanekoA , TaleoG , KalkoaM , YamarS , KobayakawaT , BjorkmanA . Malaria eradication on islands. Lancet2000;356(9241):1560-4. ">Kaneko 2000 VUT</a>), we excluded this study due to an imbalance in co‐interventions, since MDA was administered in combination with ITNs and larvivorous fish, while the no‐MDA control arm received delayed ITNs and no additional interventions. Additionally, more recent studies from island settings did not meet our inclusion criteria: ITNs were introduced concurrently with MDA in a recent study conducted in Grande Comore, Comoros (<a href="./references#CD008846-bbs2-0014" title="ChakirI , SaidAI , AffaneB , JambouR . Control of malaria in the Comoro Islands over the past century. Malaria Journal2017;16(1):387. [DOI: 10.1186/s12936-017-2027-1]">Affane 2012 COM</a>), and there were insufficient data points collected to adequately account for trends in malaria seasonality using the ITS design in a study conducted on Anjouan island, Comoros (<a href="./references#CD008846-bbs2-0016" title="DengC , HuangB , WangQ , WuW , ZhengS , ZhangH , et al. Large-scale artemisinin–piperaquine mass drug administration with or without primaquine dramatically reduces malaria in a highly endemic region of Africa. Clinical Infectious Diseases2018;67(11):1670-6. ">Deng 2018 COM</a>). </p> <p>Finally, the previous Cochrane Review also highlighted a paucity of data to assess whether a reduction by MDA was sustained (<a href="./references#CD008846-bbs2-0062" title="PoirotE , SkarbinskiJ , SinclairD , KachurSP , SlutskerL , HwangJ . Mass drug administration for malaria. Cochrane Database of Systematic Reviews2013, Issue 12 10.1002/14651858.CD008846.pub2 10.1002/14651858.CD008846.pub2. Art. No: CD008846. [DOI: 10.1002/14651858.CD008846.pub2]">Poirot 2013</a>). Our findings address some of the knowledge gaps from the previous review with the availability of longer‐term follow‐up data post‐MDA for parasitaemia prevalence, and confirmed malaria illness incidence from several studies in very low‐ to low‐transmission settings. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008846-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/urn:x-wiley:14651858:media:CD008846:CD008846-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD008846-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_n/nCD008846-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_t/tCD008846-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/full#CD008846-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_n/nCD008846-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008846-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/urn:x-wiley:14651858:media:CD008846:CD008846-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD008846-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_n/nCD008846-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_t/tCD008846-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/full#CD008846-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_n/nCD008846-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008846-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/urn:x-wiley:14651858:media:CD008846:CD008846-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD008846-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_n/nCD008846-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_t/tCD008846-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/full#CD008846-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_n/nCD008846-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008846-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/urn:x-wiley:14651858:media:CD008846:CD008846-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: MDA versus no MDA in moderate to high endemicity (cRCTs) on P falciparum outcomes, Outcome 1: Parasitaemia prevalence (P falciparum)" data-id="CD008846-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_n/nCD008846-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_t/tCD008846-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: MDA versus no MDA in moderate to high endemicity (cRCTs) on <i>P falciparum</i> outcomes, Outcome 1: Parasitaemia prevalence (<i>P falciparum)</i> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/references#CD008846-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_n/nCD008846-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008846-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/urn:x-wiley:14651858:media:CD008846:CD008846-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: MDA versus no MDA in moderate to high endemicity (cRCTs) on P falciparum outcomes, Outcome 2: Parasitaemia incidence (P falciparum)" data-id="CD008846-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_n/nCD008846-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_t/tCD008846-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: MDA versus no MDA in moderate to high endemicity (cRCTs) on <i>P falciparum</i> outcomes, Outcome 2: Parasitaemia incidence (<i>P falciparum)</i> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/references#CD008846-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_n/nCD008846-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008846-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/urn:x-wiley:14651858:media:CD008846:CD008846-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: MDA versus no MDA in moderate to high endemicity (cRCTs) on P falciparum outcomes, Outcome 3: Confirmed malaria illness incidence (P falciparum)" data-id="CD008846-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_n/nCD008846-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_t/tCD008846-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: MDA versus no MDA in moderate to high endemicity (cRCTs) on <i>P falciparum</i> outcomes, Outcome 3: Confirmed malaria illness incidence (<i>P falciparum)</i> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/references#CD008846-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_n/nCD008846-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008846-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/urn:x-wiley:14651858:media:CD008846:CD008846-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: MDA versus no MDA in moderate to high endemicity (cRCTs) on P falciparum outcomes, Outcome 4: Gametocytaemia prevalence (P falciparum)" data-id="CD008846-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_n/nCD008846-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_t/tCD008846-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: MDA versus no MDA in moderate to high endemicity (cRCTs) on <i>P falciparum</i> outcomes, Outcome 4: Gametocytaemia prevalence (<i>P falciparum)</i> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/references#CD008846-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_n/nCD008846-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008846-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/urn:x-wiley:14651858:media:CD008846:CD008846-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: MDA versus no MDA in moderate to high endemicity (cRCTs) on P falciparum outcomes, Outcome 5: Malaria‐specific mortality" data-id="CD008846-fig-0008" src="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_n/nCD008846-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_t/tCD008846-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: MDA versus no MDA in moderate to high endemicity (cRCTs) on <i>P falciparum</i> outcomes, Outcome 5: Malaria‐specific mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/references#CD008846-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_n/nCD008846-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008846-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/urn:x-wiley:14651858:media:CD008846:CD008846-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: MDA versus no MDA in very low to low endemicity (cRCTs) on P falciparum outcomes, Outcome 1: Parasitaemia prevalence (P falciparum)" data-id="CD008846-fig-0009" src="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_n/nCD008846-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_t/tCD008846-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: MDA versus no MDA in very low to low endemicity (cRCTs) on <i>P falciparum</i> outcomes, Outcome 1: Parasitaemia prevalence (<i>P falciparum)</i> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/references#CD008846-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_n/nCD008846-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008846-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/urn:x-wiley:14651858:media:CD008846:CD008846-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: MDA versus no MDA in very low to low endemicity (cRCTs) on P falciparum outcomes, Outcome 2: Parasitaemia incidence (P falciparum)" data-id="CD008846-fig-0010" src="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_n/nCD008846-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_t/tCD008846-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: MDA versus no MDA in very low to low endemicity (cRCTs) on <i>P falciparum</i> outcomes, Outcome 2: Parasitaemia incidence (<i>P falciparum)</i> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/references#CD008846-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_n/nCD008846-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008846-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/urn:x-wiley:14651858:media:CD008846:CD008846-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: MDA versus no MDA in very low to low endemicity (cRCTs) on P falciparum outcomes, Outcome 3: Confirmed malaria illness incidence (P falciparum)" data-id="CD008846-fig-0011" src="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_n/nCD008846-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_t/tCD008846-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: MDA versus no MDA in very low to low endemicity (cRCTs) on <i>P falciparum</i> outcomes, Outcome 3: Confirmed malaria illness incidence (<i>P falciparum)</i> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/references#CD008846-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_n/nCD008846-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008846-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/urn:x-wiley:14651858:media:CD008846:CD008846-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: MDA versus no MDA in very low to low endemicity (cRCTs) on P vivax outcomes, Outcome 1: Parasitaemia prevalence (P vivax)" data-id="CD008846-fig-0012" src="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_n/nCD008846-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_t/tCD008846-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: MDA versus no MDA in very low to low endemicity (cRCTs) on <i>P vivax</i> outcomes, Outcome 1: Parasitaemia prevalence (<i>P vivax)</i> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/references#CD008846-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_n/nCD008846-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008846-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/urn:x-wiley:14651858:media:CD008846:CD008846-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: MDA versus no MDA in very low to low endemicity (cRCTs) on P vivax outcomes, Outcome 2: Confirmed malaria illness incidence (P vivax)" data-id="CD008846-fig-0013" src="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_n/nCD008846-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_t/tCD008846-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: MDA versus no MDA in very low to low endemicity (cRCTs) on <i>P vivax</i> outcomes, Outcome 2: Confirmed malaria illness incidence (<i>P vivax)</i> </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/references#CD008846-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_n/nCD008846-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008846-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/urn:x-wiley:14651858:media:CD008846:CD008846-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Supplemental analysis: post‐hoc subgroup analysis by continent, Outcome 1: Plasmodium falciparum parasitaemia prevalence post‐MDA 1‐3 months" data-id="CD008846-fig-0014" src="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_n/nCD008846-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_t/tCD008846-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Supplemental analysis: post‐hoc subgroup analysis by continent, Outcome 1: <i>Plasmodium falciparum</i> parasitaemia prevalence post‐MDA 1‐3 months </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/references#CD008846-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/media/CDSR/CD008846/image_n/nCD008846-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008846-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">MDA compared to no MDA for Plasmodium falciparum malaria (moderate to high endemicity, short‐term follow‐up)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> People of all ages living in an area with moderate to high endemicity of <i>P falciparum</i> malaria (≥ 10% prevalence)<br/><b>Setting:</b> Moderate to high endemicity defined as ≥10% prevalence of <i>P falciparum</i><br/><b>Intervention:</b> MDA<br/><b>Comparison:</b> Control (no MDA or placebo) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with no MDA</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with MDA</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Follow‐up: 1 to 3 months</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parasitaemia prevalence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 100<br/>(3 to 27) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.76<br/>(0.58 to 5.36) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>786<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b,c</sup> </p> <p>Due to imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 1‐3 months post‐MDA, parasite prevalence may increase in MDA compared no MDA. However, the effects vary and it is possible that MDA makes little or no difference on parasitaemia prevalence. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parasitaemia incidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>68 events per 100 person‐years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>42 events per 100 person‐years<br/>(27 to 63) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio 0.61<br/>(0.40 to 0.92) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>739<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a,b,d</sup> </p> <p>Due to imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 1‐3 months post‐MDA, there is probably a reduction in parasitaemia incidence in MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confirmed malaria illness incidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000 population</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000 population<br/>(1 to 122) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio 0.41<br/>(0.04 to 4.42) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>144,422<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b,c</sup> </p> <p>Due to imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 1‐3 months post‐MDA, there may be a reduction in confirmed malaria illness incidence in MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Follow‐up: 4 to 6 months</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parasitaemia prevalence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>55 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>65 per 100<br/>(49 to 86) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.18<br/>(0.89 to 1.56) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1414<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a,b,d</sup> </p> <p>Due to imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 4‐6 months post‐MDA, there is probably little or no effect on parasitaemia prevalence in MDA compared to no MDA </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parasitaemia incidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>129 events per 100 person‐years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>118 events per 100 person‐years<br/>(71 to 194) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio 0.91<br/>(0.55 to 1.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1376<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a,b,d,e</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if MDA has an effect on parasitaemia incidence at 4‐6 months post‐MDA</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>cRCT:</b> cluster‐randomized controlled trial; <b>MDA:</b> mass drug administration; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Not downgraded for inconsistency; the comparison presented is reported from a single study.<br/><sup>b</sup>Not downgraded for indirectness; outcome was evaluated in all ages or assessed in children (considered the most appropriate population to measure malaria transmission in moderate‐ to high‐endemicity areas).<br/><sup>c</sup>Downgraded 2 levels for imprecision due to very wide CIs.<br/><sup>d</sup>Downgraded 1 level for imprecision due to wide CIs.<br/><sup>e</sup>Downgraded 2 levels for risk of bias since malaria cases in outcome were defined as fever plus parasitaemia &gt; 5000, which excludes all afebrile and low density infections and results in an underestimate of the outcome. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">MDA compared to no MDA for Plasmodium falciparum malaria (moderate to high endemicity, short‐term follow‐up)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/full#CD008846-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008846-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">MDA compared to no MDA for Plasmodium falciparum malaria (very low to low endemicity, short‐term follow‐up)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> People of all ages living in an area with very low to low endemicity of <i>P falciparum</i> malaria (&lt; 10% prevalence)<br/><b>Setting:</b> Very low to low endemicity defined as &lt; 10% prevalence of <i>P falciparum</i><br/><b>Intervention:</b> MDA<br/><b>Comparison:</b> Control (no MDA or placebo) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with MDA</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Follow‐up: &lt; 1 month</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parasitaemia prevalence<br/>follow up: range &lt; 1 month </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 100<br/>(0 to 6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.12<br/>(0.03 to 0.52) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1232<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a‐d</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At &lt; 1 month post‐MDA, there may a reduction in parasitaemia prevalence in MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Follow‐up: 1 to 3 months</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parasitaemia prevalence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 100</p> <p>(0 to 1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR: 0.25</p> <p>(0.15 to 0.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17,454<br/>(7 RCTs)<sup>5</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>e‐i</sup> </p> <p>Due to risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 1‐3 months post‐MDA, there may a reduction in parasitaemia prevalence in MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parasitaemia incidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 events per 100 person‐years</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 events per 100 person‐years<br/>(3 to 10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio 0.37<br/>(0.21 to 0.66) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>736<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>b,d,,j</sup> </p> <p>Due to imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 1‐3 months post‐MDA, there is probably a reduction in parasitaemia incidence in MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confirmed malaria illness incidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000 population</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000 population<br/>(1 to 17) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio: 0.58</p> <p>(0.12 to 2.73)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130,651<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a,j‐l</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if MDA has an effect on confirmed malaria illness incidence at 1‐3 months post‐MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Follow‐up: 4 to 6 months</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parasitaemia prevalence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 100</p> <p>(2 to 6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR: 0.63</p> <p>(0.36 to 1.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5670</p> <p>(4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>c,d,f,l</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if MDA has an effect on parasitaemia prevalence at 4‐6 months post‐MDA compared to no MDA. </p> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confirmed malaria illness incidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000 population</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 1000 population<br/>(0 to 53) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio 0.93<br/>(0.07 to 12.43) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23,251<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a,b,k,l</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if MDA has an effect on confirmed malaria illness incidence at 4‐6 months post‐MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Follow‐up: 7 to 12 months</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parasitaemia prevalence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 100</p> <p>(3 to 6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR: 0.86</p> <p>(0.55 to 1.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7760</p> <p>(5 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>c,d,l,m</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if MDA has an effect on parasitaemia prevalence at 7‐12 months post‐MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confirmed malaria illness incidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 1000 population</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 1000 population (2 to 12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio 0.47</p> <p>(0.21 to 1.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26,576<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>d,f,j,l</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if MDA has an effect on confirmed malaria illness incidence at 7‐12 months post‐MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>cRCT:</b> cluster‐randomized controlled trial; <b>MDA:</b> mass drug administration; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded 1 level for risk of bias due to several criteria scored as high or unclear risk of bias.<br/><sup>b</sup>Not downgraded for inconsistency; the comparison presented is reported from a single study.<br/><sup>c</sup>Not downgraded for indirectness; all ages are at similar risk of malaria transmission, given the local epidemiology of malaria in this study setting and the outcomes were assessed by a highly sensitive diagnostic method (ultrasensitive PCR).<br/><sup>d</sup>Downgraded 1 level for imprecision due to wide CIs.<br/><sup>e</sup>Eight included studies reported parasitaemia prevalence during the 1‐3 month post‐MDA follow‐up period; however, one study did not contribute data in the meta‐analysis due to no events at baseline before MDA or at any follow‐up time points.<br/><sup>f</sup>Downgraded 2 levels for risk of bias due to several criteria scored as high or unclear risk of bias, including baseline imbalance and high risk of contamination in several studies.<br/><sup>g</sup>Not downgraded for inconsistency based on I<sup>2</sup> statistic; however, reasons for heterogeneity explored in post‐hoc sub‐group analysis by continent (sub‐Saharan Africa and Southeast Asia; <a href="./references#CD008846-fig-0014" title="">Analysis 4.1</a>).<br/><sup>h</sup>Not downgraded for indirectness; all ages are at similar risk of malaria transmission, given the local epidemiology of malaria in this study setting so there is no concern with assessing this outcome in different age groups across studies.<br/><sup>i</sup>Not downgraded for imprecision due to appreciable benefit of pooled effect as reported by seven studies.<br/><sup>j</sup>Not downgraded for indirectness since outcome was assessed in all ages and by routine detection methods.<br/><sup>k</sup>Downgraded 2 levels for imprecision due to very wide CIs.<br/><sup>l</sup>Not downgraded for inconsistency based on I<sup>2</sup> statistic.<br/><sup>m</sup>Downgraded 2 levels for risk of bias due to several criteria scored as high or unclear risk of bias, including baseline imbalance, high risk of contamination, and a large unexplained increase in sampled population in the MDA group at this time point.<br/>  </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">MDA compared to no MDA for Plasmodium falciparum malaria (very low to low endemicity, short‐term follow‐up)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/full#CD008846-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008846-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">MDA compared to no MDA for Plasmodium falciparum malaria (very low to low endemicity, long‐term follow‐up)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> People of all ages living in an area with very low to low endemicity of <i>P falciparum</i> malaria ( &lt; 10% prevalence)<br/><b>Setting:</b> Very low to low endemicity defined as &lt; 10% prevalence of <i>P falciparum</i><br/><b>Intervention:</b> MDA<br/><b>Comparison:</b> Control (no MDA or placebo) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with Control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with MDA</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Follow‐up: 13 to 18 months</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parasitaemia prevalence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 100<br/>(1 to 14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.82<br/>(0.20 to 3.34) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1537<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a‐d</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if MDA has an effect on parasitaemia prevalence at 13‐18 months post‐MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confirmed malaria illness incidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000 population</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 1000 population<br/>(3 to 51) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio 0.77<br/>(0.20 to 3.03) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23,251<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>b,d‐f</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if MDA has an effect on confirmed malaria illness incidence at 13‐18 months post‐MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Follow‐up: 19 to 24 months</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parasitaemia prevalence<br/>follow‐up: range 19 to 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 100<br/>(0 to 6) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.34<br/>(0.06 to 1.97) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1393<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a‐d</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if MDA has an effect on parasitaemia prevalence at 19‐24 months post‐MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Follow‐up: 25 months and above</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parasitaemia prevalence<br/>follow‐up: range 25 to 30 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 100<br/>(1 to 12) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.89<br/>(0.22 to 3.62) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1521<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a‐d</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if MDA has an effect on parasitaemia prevalence at 25‐30 months post‐MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parasitaemia prevalence<br/>follow‐up: range 31 to 36 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 per 100<br/>(1 to 19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.25<br/>(0.25 to 6.31) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1679<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a‐d</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if MDA has an effect on parasitaemia prevalence at 31‐36 months post‐MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>cRCT:</b> cluster‐randomized controlled trial; <b>MDA:</b> mass drug administration; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded 2 levels for risk of bias due to several criteria scored as high or unclear risk of bias, including baseline imbalance, high risk of contamination, and a large unexplained increase in sampled population in the MDA group at this time point.<br/><sup>b</sup>Not downgraded for inconsistency; the comparison presented is reported from a single study.<br/><sup>c</sup>Not downgraded for indirectness; all ages are at similar risk of malaria transmission, given the local epidemiology of malaria in this study setting and the outcomes were assessed by a highly sensitive diagnostic method (ultrasensitive PCR).<br/><sup>d</sup>Downgraded 2 levels for imprecision due to very wide CIs.<br/><sup>e</sup>Downgraded 1 level for risk of bias due to several criteria scored as high or unclear risk of bias.<br/><sup>f</sup>Not downgraded for indirectness since outcome was assessed in all ages and by routine detection methods. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">MDA compared to no MDA for Plasmodium falciparum malaria (very low to low endemicity, long‐term follow‐up)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/full#CD008846-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008846-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">MDA compared to no MDA for P vivax malaria (very low to low endemicity, short‐term follow‐up)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> People of all ages living in an area with very low to low endemicity of <i>P vivax</i> malaria (&lt; 10% prevalence)<br/><b>Setting:</b> Very low to low endemicity defined as &lt; 10% prevalence of <i>P vivax</i><br/><b>Intervention:</b> MDA<br/><b>Comparison:</b> Control (no MDA or placebo) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with MDA</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Follow‐up: &lt; 1 month</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parasitaemia prevalence<br/>follow up: range &lt; 1 month </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 per 100<br/>(2 to 11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.18<br/>(0.08 to 0.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1232<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a‐d</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At &lt; 1 month post‐MDA, there may a reduction in parasitaemia prevalence in MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Follow‐up: 1 to 3 months</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parasitaemia prevalence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>2 per 100</p> <p>(1 to 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR: 0.15</p> <p>(0.10 to 0.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6896</p> <p>(5 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>c,e‐g</sup> </p> <p>Due to risk of bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 1‐3 months post‐MDA, there may a reduction in parasitaemia prevalence in MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Follow‐up: 4 to 6 months</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parasitaemia prevalence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 100</p> <p>(7 to 10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR: 0.78</p> <p>(0.63 to 0.95)</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5670</p> <p>(4 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>c,d,f,h</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if MDA reduces parasitaemia prevalence at 4‐6 months post‐MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>Follow‐up: 7 to 12 months</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parasitaemia prevalence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 100</p> <p>(9 to 13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR: 1.12</p> <p>(0.94 to 1.34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7760</p> <p>(5 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>c,d,h,i</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if MDA has an effect on parasitaemia prevalence at 7‐12 months post‐MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confirmed malaria illness incidence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41 per 1000 population</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>57 per 1000 population (40 to 80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate ratio: 1.38</p> <p>(0.97 to 1.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3325</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>d,f,h,j</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if MDA has an effect on confirmed malaria illness incidence at 7‐12 months post‐MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>cRCT:</b> cluster‐randomized controlled trial; <b>MDA:</b> mass drug administration; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded 1 level for risk of bias due to several criteria scored as high or unclear risk of bias.<br/><sup>b</sup>Not downgraded for inconsistency; the comparison presented is reported from a single study.<br/><sup>c</sup>Not downgraded for indirectness; all ages are at similar risk of malaria transmission, given the local epidemiology of malaria in this study setting and the outcomes were assessed by a highly sensitive diagnostic method (ultrasensitive PCR).<br/><sup>d</sup>Downgraded 1 level for imprecision due to wide CIs.<br/><sup>e</sup>Not downgraded for imprecision due to appreciable benefit of pooled effect as reported by five studies.<br/><sup>f</sup>Downgraded 2 levels for risk of bias due to several criteria scored as high or unclear risk of bias, including baseline imbalance and high risk of contamination.<br/><sup>g</sup>Not downgraded for inconsistency despite the large value of the I<sup>2</sup> statistic since the direction of effect was consistent with large imprecision.<br/><sup>h</sup>Not downgraded for inconsistency based on I<sup>2</sup> statistic.<br/><sup>i</sup>Downgraded 2 levels for risk of bias due to several criteria scored as high or unclear risk of bias, including a large unexplained increase in sampled population in the MDA group at this time point.<br/><sup>j</sup>Not downgraded for indirectness since outcome was assessed in all ages and by routine detection methods. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">MDA compared to no MDA for P vivax malaria (very low to low endemicity, short‐term follow‐up)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/full#CD008846-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD008846-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">MDA compared to no MDA for P vivax malaria (very low to low endemicity, long‐term follow‐up)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> People of all ages living in an area with very low to low endemicity of <i>P vivax</i> malaria (&lt; 10% prevalence)<br/><b>Setting:</b> Very low to low endemicity &lt; 10% prevalence of <i>P vivax</i><br/><b>Intervention:</b> MDA<br/><b>Comparison:</b> Control (no MDA or placebo) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with Control</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with MDA</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Follow‐up: 13 to 18 months</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parasitaemia prevalence</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 100<br/>(8 to 25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.81<br/>(0.44 to 1.48) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1537<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a‐d</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if MDA reduces parasitaemia prevalence at 13‐18 months post‐MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Follow‐up: 19 to 24 months</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parasitaemia prevalence<br/>follow‐up: range 19 to 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 100<br/>(4 to 20) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.84<br/>(0.38 to 1.83) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1393<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a‐d</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if MDA reduces parasitaemia prevalence at 19‐24 months post‐MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Follow‐up: 25 months and above</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parasitaemia prevalence<br/>follow‐up: range 25 to 30 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 100<br/>(4 to 21) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.89<br/>(0.41 to 1.94) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1521<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a‐d</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if MDA reduces parasitaemia prevalence at 25‐30 months post‐MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Parasitaemia prevalence<br/>follow‐up: range 31 to 36 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>7 per 100<br/>(3 to 20) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.20<br/>(0.44 to 3.29) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1679<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>a‐c,e</sup> </p> <p>Due to risk of bias and imprecision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if MDA reduces parasitaemia prevalence at 31‐36 months post‐MDA compared to no MDA. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>cRCT:</b> cluster‐randomized controlled trial; <b>MDA:</b> mass drug administration; <b>RCT:</b> randomized controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded 2 levels for risk of bias due to several criteria scored as high or unclear risk of bias, including a large unexplained increase in sampled population in the MDA group at this time point.<br/><sup>b</sup>Not downgraded for inconsistency; the comparison presented is reported from a single study.<br/><sup>c</sup>Not downgraded for indirectness; all ages are at similar risk of malaria transmission, given the local epidemiology of malaria in this study setting and the outcomes were assessed by a highly sensitive diagnostic method (ultrasensitive PCR).<br/><sup>d</sup>Downgraded 1 level for imprecision due to wide CIs.<br/><sup>e</sup>Downgraded 2 levels for imprecision due to very wide CIs. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">MDA compared to no MDA for P vivax malaria (very low to low endemicity, long‐term follow‐up)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/full#CD008846-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008846-tbl-0006"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Description of studies</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study ID (Design)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Year(s) of study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Malaria endemicity<sup>a</sup> </b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b><i>Plasmodium</i> species</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Antimalarial drug resistance</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>MDA group</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Control group</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Co‐intervention(s)</b><sup>b</sup> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes reported (months of follow‐up post‐MDA<sup>c</sup>)</b> </p> </th> </tr> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Drug</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Rounds, interval, and duration implemented</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Population targeted (coverage)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008846-bbs2-0001" title="BennettA , PorterTR ,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C, et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in Southern Province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in Southern Province, Zambia: An evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. [DOI: 10.1186/s13063-015-0862-3]MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBa</a> (cRCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2014‐2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>P falciparum</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Widespread resistance to CQ and SP, but no evidence of resistance to artemisinin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DHAp</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 rounds administered at start of rainy season, during rainy season, during dry season, and at start of rainy season over 15 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37,694</p> <p>(79% in round 1; 63% in round 2; 76% in round 3; 66% in round 4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No drug and no placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IRS, ITNs, and enhanced standard of care</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD008846-list-0010"> <li> <p>Parasitaemia prevalence (2)</p> </li> <li> <p>Parasitaemia incidence (2)</p> </li> <li> <p>Confirmed malaria case incidence (2)</p> </li> <li> <p>Adverse effects</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008846-bbs2-0002" title="BennettA , Porter TR,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C,   et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in southern province, Zambia: an evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence  in southern province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of Plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBb</a> (cRCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2014‐2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>P falciparum</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Widespread resistance to CQ and SP, but no evidence of resistance to artemisinin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DHAp</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 rounds administered at start of rainy season, during rainy season, during dry season, and at start of rainy season over 15 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45,442</p> <p>(79% in round 1; 63% in round 2; 76% in round 3; 66% in round 4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No drug and no placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IRS, ITNs, and enhanced standard of care</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD008846-list-0011"> <li> <p>Parasitaemia prevalence (2)</p> </li> <li> <p>Parasitaemia incidence (2)</p> </li> <li> <p>Confirmed malaria case incidence (2)</p> </li> <li> <p>Adverse effects</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD008846-bbs2-0003" title="EscudieA , HamonJ , SchneiderJ . Results of mass antimalarial chemoprophylaxis with a combination of 4-aminoquinoline and 8-aminoquinoline under rural African conditions in the region of Bobo-Dioulasso (Upper Volta) 1960. Comparative study in a zone treated with DDT and outside this zone. Medecine Tropicale1962;22(2):268-305. SchneiderJ , EscudieA , HamonJ . Eradication of malaria and chemotherapy. Results obtained with the association amino-4 quinoline + amino-8 quinoline in the pilot area of Bobo-Dioulasso (Haute- Volta) [Eradication du paludismeet chimiotherapie resultats d’un essai de l’association:amino–4 quinoleine/amino–8 quinoleine dans la zonepilote de Bobo–Dioulasso (Haute Volta)]. Bulletin de la Societe de Pathologie Exotique1961;54(5):1012-25. ">Escudie 1962 BFA</a> (CBA) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1960‐1961</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><i>P falciparum,</i> </p> <p><i>P ovale,</i> </p> <p><i>P malariae</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>ND</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>AQ‐PQ or CQ‐PQ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(Low frequency MDA)</p> <p>7 rounds administered 28 days apart over 7 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1890</p> <p>(75% to 91% per round)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No drug and no placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>None (IRS arms excluded)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD008846-list-0012"> <li> <p>Parasitaemia prevalence (3)</p> </li> <li> <p>Gametocytaemia prevalence (3)</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(High frequency MDA)</p> <p>15 rounds administered 14 days apart over 7 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2560</p> <p>(84% to 97% per round)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD008846-list-0013"> <li> <p>Parasitaemia prevalence (3)</p> </li> <li> <p>Gametocytaemia prevalence (3)</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008846-bbs2-0004" title="LandierJ , KajeechiwaL , ThwinMM , ParkerDM , ChaumeauV , WiladphaingernJ , et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar. Wellcome Open Research2017;2:81. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Landier 2017 MMRa</a> (cRCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2013‐2015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>P falciparum,</i> </p> <p><i>P vivax</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Artemisinin resistance firmly established</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DHAp with PQ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 rounds administered 1 month apart over 3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1434 (66% in round 1, 56% in round 2, and 65% in round 3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Delayed MDA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITNs, uninterrupted access to case management</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD008846-list-0014"> <li> <p>Parasitaemia prevalence (7)</p> </li> <li> <p>Confirmed malaria illness incidence (7)</p> </li> <li> <p>Adverse effects</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008846-bbs2-0005" title="HeatonJ , McCleanA , SweMM , SoeK , IndrasutaC , KhantZS , et al. Speeding up malaria elimination; a cluster randomized controlled trial of mass drug administration in Southeast Myanmar, an area with artemisinin resistance. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):411. McLeanAR , IndrasutaC , KhantZS , PhyoAK , MaungSM , HeatonJ , et al. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infectious Diseases 2021 June 17 [Epub ahead of print]. [DOI: 10.1016/S1473-3099(20)30997-X]">McLean 2021 MMR</a> (cRCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2014‐2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>P falciparum,</i> </p> <p><i>P vivax</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Artemisinin resistance: Kelch 13 mutation in 57% of samples at baseline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DHAp with PQ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 rounds administered 1 month apart over 3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4622</p> <p>(86% in round 1, 86% in round 2, 88% in round 3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No drug and no placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITNs, routine malaria control by village health workers</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD008846-list-0015"> <li> <p>Parasitaemia prevalence (31)</p> </li> <li> <p>Adverse effects</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD008846-bbs2-0006" title="BroggerRC , MathewsHM , StoreyJ , AshkarTS , BroggerS , MolineauxL . Changing patterns in the humoral immune response to malaria before, during and after the application of control measures: a longitudinal study in the West African savanna. Bulletin of the World Health Organization1978;56(4):579-600. MolineauxL , BroggerRC , MathewsHM , StoreyJ , AshkarTS . Longitudinal serological study of malaria in infants in the West African savanna. Comparisons in infants exposed to, or protected from, transmission from birth. Bulletin of the World Health Organisation1978;56(4):573-8. MolineauxL , GramicciaG . The Garki Project. Research on the epidemiology and control of malaria in the Sudan Savanna of West Africa. 1980. https://apps.who.int/iris/handle/10665/40316 (accessed prior to 8 July 2021). MolineauxL , StoreyJ , CohenJE , ThomasA . A longitudinal study of human malaria in the West African savanna in the absence of control measures: relationships between different Plasmodium species, in particular P. falciparum and P. malariae. American Journal of Tropical Medicine and Hygiene1980;29(5):725-37. ">Molineaux 1980 NGA</a> (CBA) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1970‐1975</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><i>P falciparum,</i> </p> <p><i>P malariae,</i> </p> <p><i>P ovale</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>ND</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>SP</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(Low frequency MDA)</p> <p>9 rounds administered 10 weeks apart over 18 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14,129</p> <p>(73% to 92% per round)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No drug and no placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>IRS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p> <ul id="CD008846-list-0016"> <li> <p>Parasitaemia prevalence (0)</p> </li> <li> <p>Gametocytaemia prevalence (0)</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(High frequency MDA)</p> <p>23 rounds administered 2 weeks apart during the wet seasons and 10 weeks apart during the dry seasons over 18 months </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1810</p> <p>(72% to 91% per round)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008846-bbs2-0007" title="MorrisU , MsellemM , MkaliH , IslamA , Aydin-SchmidtB , JovelI , et al. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission. BMC Medicine2018;16:215. [DOI: 10.1186/s12916-018-1202-8]">Morris 2018 TZA</a> (cRCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2016‐2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>P falciparum,</i> </p> <p><i>P malariae,</i> </p> <p><i>P ovale,</i> and </p> <p><i>P vivax</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No evidence of resistance to first line treatment AS‐AQ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DHAp with PQ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 rounds administered 4 weeks apart over 6 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10,944</p> <p>(91% in round 1, 88% in round 2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No drug and no placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IRS and ITNs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD008846-list-0017"> <li> <p>Parasitaemia prevalence (0)</p> </li> <li> <p>Confirmed malaria illness incidence (14)</p> </li> <li> <p>Adverse effects</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008846-bbs2-0008" title="PongvongsaT , PhommasoneK , AdhikariB , HenriquesG , ChotivanichK , HanboonkunupakarnB , et al. The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin-piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos. Malaria Journal2018;17(1):405. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Pongvongsa 2018 LAO</a> (cRCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2016‐2017</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>P falciparum,</i> </p> <p><i>P vivax</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DHAp with PQ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 rounds administered 1 month apart over 3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1006 (81% in round 1, 80% in round 2, and 82% in round 3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Delayed MDA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITNs, uninterrupted access to case management</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD008846-list-0018"> <li> <p>Parasitaemia prevalence (10)</p> </li> <li> <p>Adverse effects</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008846-bbs2-0009" title="RobertsJM . Pyrimethamine (Daraprim) in the control of epidemic malaria. American Journal of Tropical Medicine and Hygiene1956;59(9):201-8. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part I. Before the campaign. American Journal of Tropical Medicine and Hygiene1964;67(7):161-8. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part II. The campaign. American Journal of Tropical Medicine and Hygiene1964;67(8):191-9. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part III. After the campaign. American Journal of Tropical Medicine and Hygiene1964;67(9):230-7. ">Roberts 1964 KEN</a> (CBA) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1953‐1954</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>P falciparum</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pyrimethamine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 rounds administered 1 year apart over 13 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101,000</p> <p>(95% in round 1, 93% in round 2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No drug and no placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD008846-list-0019"> <li> <p>Parasitaemia prevalence (7)</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008846-bbs2-0010" title="ShekalagheSA , DrakeleyC , vanden BoschS , ter BraakR , vanden BikilaardtW , MwanzivaC , et al. A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania. Malaria Journal2011;10:247. ShekalagheSA , ter BraakR , DaouM , KavisheR , vanden BijilaardtW , vanden BoschS , et al. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A) individuals. Antimicrobial Agents and Chemotherapy2010;54(5):1762-8. ">Shekalaghe 2011 TZA</a> (cRCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2008</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>P falciparum</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SP+AS with PQ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 round over 16 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1110</p> <p>(95%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITNs, single treatment campaign for trachoma with azithromycin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD008846-list-0020"> <li> <p>Parasitaemia prevalence (4)</p> </li> <li> <p>Confirmed malaria illness incidence (4)</p> </li> <li> <p>Gametocytaemia prevalence (4)</p> </li> <li> <p>Adverse effects</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008846-bbs2-0011" title="TripuraR , PetoTJ , CheaN , ChanD , MukakaM , SirithiranontP , et al. A controlled trial of mass drug administration to interrupt transmission of multidrug-resistant falciparum malaria in Cambodian villages. Clinical Infectious Diseases2018;67(6):817-26. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Tripura 2018 KHM</a> (cRCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2014‐2016</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>P falciparum,</i> </p> <p><i>P vivax</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reduced susceptibility to artemisinins and ACT partner drug resistance</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DHAp</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 rounds administered 1 month apart over 3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>858 (74% in round 1, 60% in round 2, and 71% in round 3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Delayed MDA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITNs, uninterrupted access to case management</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD008846-list-0021"> <li> <p>Parasitaemia prevalence (10)</p> </li> <li> <p>Confirmed malaria case incidence (9)</p> </li> <li> <p>Adverse effects</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008846-bbs2-0012" title="De MartinS , vonSeidleinL , DeenJL , PinderM , WalravenG , GreenwoodB . Community perceptions of a mass administration of an antimalarial drug combination in The Gambia. Tropical Medicine &amp; International Health2001;6(6):442-8. vonSeidleinL , WalravenG , MilliganPJ , AlexanderN , MannehF , DeenJL , et al. The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia. Transactions of the Royal Society of Tropical Medicine &amp; Hygiene2003;97(2):217-25. ">von Seidlein 2003 GMB</a> (cRCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1999</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>P falciparum</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SP+AS</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 round over 1 month</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12,331</p> <p>(89%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD008846-list-0022"> <li> <p>Parasitaemia prevalence (5)</p> </li> <li> <p>Parasitaemia incidence (5)</p> </li> <li> <p>Gametocytaemia prevalence (5)</p> </li> <li> <p>Malaria‐specific mortality</p> </li> <li> <p>Adverse effects</p> </li> </ul> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD008846-bbs2-0013" title="vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">von Seidlein 2019 VNM</a> (cRCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2013‐2015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very low</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>P falciparum,</i> </p> <p><i>P vivax</i> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No evidence of resistance to DHAp at the start of study, but treatment failure to DHAp has increased following study </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>DHAp with PQ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 rounds administered 1 month apart over 3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1439 (83% in round 1, 98% in round 2, and 99% in round 3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Delayed MDA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITNs, uninterrupted access to case management</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD008846-list-0023"> <li> <p>Parasitaemia prevalence (10)</p> </li> <li> <p>Adverse effects</p> </li> </ul> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="11"> <div class="table-footnote"> <p>ACT = artemisinin‐based combination therapy, AQ = amodiaquine, AS = artesunate, CBA = controlled before‐and‐after study, CQ = chloroquine, cRCT = cluster‐randomized controlled trial, DHAp = dihydroartemisinin piperaquine, ITNs = insecticide‐treated bed nets, IRS = indoor residual spraying, MDA = mass drug administration, PQ = primaquine, SP = sulfadoxine‐ (or sulfalene‐) pyrimethamine, NA = not applicable, ND = not described. </p> <p><sup>a</sup>Malaria endemicity classified as very low (&gt; 0% to &lt; 1%), low (1% to &lt; 10%), moderate (10% to &lt; 35%) or high (≥ 35%) (<a href="./references#CD008846-bbs2-0058" title="World Health Organization. A framework for malaria elimination; WHO; March 2017. Available at apps.who.int/iris/bitstream/handle/10665/254761/9789241511988-eng.pdf?sequence=1.">WHO 2017</a>).<br/><sup>b</sup>Co‐interventions were balanced across intervention and control groups, as per inclusion criteria.<br/><sup>c</sup>Post‐MDA refers to the length of time, in months, after the last round of MDA that the outcome was evaluated. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Description of studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/full#CD008846-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008846-tbl-0007"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Description of outcomes</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study ID (design)</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Parasitaemia prevalence</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Parasitaemia incidence</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Confirmed malaria illness incidence</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>All‐cause or malaria‐specific mortality</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Gametocytaemia prevalence</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Adverse effects</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008846-bbs2-0001" title="BennettA , PorterTR ,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C, et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in Southern Province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in Southern Province, Zambia: An evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence in Southern Province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. [DOI: 10.1186/s13063-015-0862-3]MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBa</a> (cRCT) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008846-bbs2-0002" title="BennettA , Porter TR,  Mwenda MC,  Yukich JO,  FinnTP ,  Lungu C,   et al. A longitudinal cohort to monitor malaria infection incidence during mass drug administration in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):54-65. [DOI: 10.4269/ajtmh.19-0657]ChalweV , SilumbeK , FinnTP , HamainzaB , PorterT , KamuliwoM , et al. Adverse event reporting from malaria mass drug administration rounds conducted in Southern Zambia. American Journal of Tropical Medicine and Hygiene2016;95(5 Supplement 1):487. ConnerR , MudendaM , HamainzaB , MoongaH , MillerJM , EiseleTP , et al. Programmatic mass drug administration in southern province, Zambia: an evaluation of impact and possible spill-over effects using dhis2 malaria case incidence data. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):501. Eisele TP, Bennett A ,  Silumbe K, FinnTP ,   PorterTR ,  ChalweV ,  et al. Impact of four rounds of mass drug administration with dihydroartemisinin–piperaquine implemented in southern province, Zambia. American Journal of Tropical Medicine and Hygiene2020;103(2_Suppl):7-18. [DOI: 10.4269/ajtmh.19-0659]EiseleTP , BennettA , SilumbeK , FinnT , ChalweV , KamuliwoM , et al. The impact of targeted mass drug administration using dihydroartemisinin-piperaquine in southern province Zambia: initial findings. American Journal of Tropical Medicine and Hygiene2015;93(4 Supplement):83. EiseleTP , BennettA , SilumbeK , FinnTP , ChalweV , KamuliwoM , et al. Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in southern province Zambia: a cluster-randomized controlled trial. Journal of Infectious Diseases2016;214(12):1831-9. EiseleTP , SilumbeK , FinnT , ChalweV , KamuliwoM , HamainzaB , et al. Assessing the effectiveness of household-level focal mass drug administration and community-wide mass drug administration for reducing malaria parasite infection prevalence and incidence  in southern province, Zambia: study protocol for a community randomized controlled trial. Trials2015;16:347. MwendaM , ChishimbaS , MambweB , MulubeC , ChalweV , MoongaH , et al. PCR incidence of Plasmodium falciparum infections in cohort samples over time during a malaria MDA randomized control trial in southern province Zambia. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):593. ">Eisele 2020 ZMBb</a> (cRCT) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008846-bbs2-0003" title="EscudieA , HamonJ , SchneiderJ . Results of mass antimalarial chemoprophylaxis with a combination of 4-aminoquinoline and 8-aminoquinoline under rural African conditions in the region of Bobo-Dioulasso (Upper Volta) 1960. Comparative study in a zone treated with DDT and outside this zone. Medecine Tropicale1962;22(2):268-305. SchneiderJ , EscudieA , HamonJ . Eradication of malaria and chemotherapy. Results obtained with the association amino-4 quinoline + amino-8 quinoline in the pilot area of Bobo-Dioulasso (Haute- Volta) [Eradication du paludismeet chimiotherapie resultats d’un essai de l’association:amino–4 quinoleine/amino–8 quinoleine dans la zonepilote de Bobo–Dioulasso (Haute Volta)]. Bulletin de la Societe de Pathologie Exotique1961;54(5):1012-25. ">Escudie 1962 BFA</a> (CBA) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008846-bbs2-0004" title="LandierJ , KajeechiwaL , ThwinMM , ParkerDM , ChaumeauV , WiladphaingernJ , et al. Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: a pilot trial in four villages of Eastern Myanmar. Wellcome Open Research2017;2:81. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Landier 2017 MMRa</a> (cRCT) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008846-bbs2-0005" title="HeatonJ , McCleanA , SweMM , SoeK , IndrasutaC , KhantZS , et al. Speeding up malaria elimination; a cluster randomized controlled trial of mass drug administration in Southeast Myanmar, an area with artemisinin resistance. American Journal of Tropical Medicine and Hygiene2017;97(5 Supplement 1):411. McLeanAR , IndrasutaC , KhantZS , PhyoAK , MaungSM , HeatonJ , et al. Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infectious Diseases 2021 June 17 [Epub ahead of print]. [DOI: 10.1016/S1473-3099(20)30997-X]">McLean 2021 MMR</a> (cRCT) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008846-bbs2-0006" title="BroggerRC , MathewsHM , StoreyJ , AshkarTS , BroggerS , MolineauxL . Changing patterns in the humoral immune response to malaria before, during and after the application of control measures: a longitudinal study in the West African savanna. Bulletin of the World Health Organization1978;56(4):579-600. MolineauxL , BroggerRC , MathewsHM , StoreyJ , AshkarTS . Longitudinal serological study of malaria in infants in the West African savanna. Comparisons in infants exposed to, or protected from, transmission from birth. Bulletin of the World Health Organisation1978;56(4):573-8. MolineauxL , GramicciaG . The Garki Project. Research on the epidemiology and control of malaria in the Sudan Savanna of West Africa. 1980. https://apps.who.int/iris/handle/10665/40316 (accessed prior to 8 July 2021). MolineauxL , StoreyJ , CohenJE , ThomasA . A longitudinal study of human malaria in the West African savanna in the absence of control measures: relationships between different Plasmodium species, in particular P. falciparum and P. malariae. American Journal of Tropical Medicine and Hygiene1980;29(5):725-37. ">Molineaux 1980 NGA</a> (CBA) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008846-bbs2-0007" title="MorrisU , MsellemM , MkaliH , IslamA , Aydin-SchmidtB , JovelI , et al. A cluster randomised controlled trial of two rounds of mass drug administration in Zanzibar, a malaria pre-elimination setting—high coverage and safety, but no significant impact on transmission. BMC Medicine2018;16:215. [DOI: 10.1186/s12916-018-1202-8]">Morris 2018 TZA</a> (cRCT) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008846-bbs2-0008" title="PongvongsaT , PhommasoneK , AdhikariB , HenriquesG , ChotivanichK , HanboonkunupakarnB , et al. The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin-piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos. Malaria Journal2018;17(1):405. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Pongvongsa 2018 LAO</a> (cRCT) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008846-bbs2-0009" title="RobertsJM . Pyrimethamine (Daraprim) in the control of epidemic malaria. American Journal of Tropical Medicine and Hygiene1956;59(9):201-8. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part I. Before the campaign. American Journal of Tropical Medicine and Hygiene1964;67(7):161-8. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part II. The campaign. American Journal of Tropical Medicine and Hygiene1964;67(8):191-9. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part III. After the campaign. American Journal of Tropical Medicine and Hygiene1964;67(9):230-7. ">Roberts 1964 KEN</a> (CBA) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008846-bbs2-0010" title="ShekalagheSA , DrakeleyC , vanden BoschS , ter BraakR , vanden BikilaardtW , MwanzivaC , et al. A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania. Malaria Journal2011;10:247. ShekalagheSA , ter BraakR , DaouM , KavisheR , vanden BijilaardtW , vanden BoschS , et al. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A) individuals. Antimicrobial Agents and Chemotherapy2010;54(5):1762-8. ">Shekalaghe 2011 TZA</a> (cRCT) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008846-bbs2-0011" title="TripuraR , PetoTJ , CheaN , ChanD , MukakaM , SirithiranontP , et al. A controlled trial of mass drug administration to interrupt transmission of multidrug-resistant falciparum malaria in Cambodian villages. Clinical Infectious Diseases2018;67(6):817-26. vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">Tripura 2018 KHM</a> (cRCT) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008846-bbs2-0012" title="De MartinS , vonSeidleinL , DeenJL , PinderM , WalravenG , GreenwoodB . Community perceptions of a mass administration of an antimalarial drug combination in The Gambia. Tropical Medicine &amp; International Health2001;6(6):442-8. vonSeidleinL , WalravenG , MilliganPJ , AlexanderN , MannehF , DeenJL , et al. The effect of mass administration of sulfadoxine-pyrimethamine combined with artesunate on malaria incidence: a double-blind, community-randomized, placebo-controlled trial in The Gambia. Transactions of the Royal Society of Tropical Medicine &amp; Hygiene2003;97(2):217-25. ">von Seidlein 2003 GMB</a> (cRCT) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD008846-bbs2-0013" title="vonSeidleinL , PetoTJ , LandierJ , NguyenTN , TripuraR , PhommasoneK , et al. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in South-East Asia: a cluster randomised trial. PLoS Medicine2019;16(2):e1002745. ">von Seidlein 2019 VNM</a> (cRCT) </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>CBA = controlled before‐and‐after study, cRCT = cluster‐randomized controlled trial</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Description of outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/full#CD008846-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008846-tbl-0008"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Difference‐in‐differences analysis of P falciparum parasitaemia prevalence in non‐randomized studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="center" class="headercell" colspan="5" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention, % (n)</b> </p> </th> <th align="center" class="headercell" colspan="5" rowspan="1" scope="col" valign="bottom"> <p><b>Control % (n)</b> </p> </th> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign="bottom"> <p><b>Difference‐in‐differences, percentage points<sup>a</sup> </b> </p> </th> </tr> <tr> <th align="center" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Pre‐MDA</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>During MDA</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Post‐MDA</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Pre‐MDA</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>During MDA</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Post‐MDA</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>During MDA</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Post‐MDA</b> </p> </th> </tr> <tr> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>1 to 3 months</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>4 to 6 months</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>7 to 12 months</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>1 to 3 months</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>4 to 6 months</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>7 to 12 months</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>1 to 3 months</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>4 to 6 months</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>7 to 12 months</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="15" rowspan="1" valign="top"> <p><a href="./references#CD008846-bbs2-0003" title="EscudieA , HamonJ , SchneiderJ . Results of mass antimalarial chemoprophylaxis with a combination of 4-aminoquinoline and 8-aminoquinoline under rural African conditions in the region of Bobo-Dioulasso (Upper Volta) 1960. Comparative study in a zone treated with DDT and outside this zone. Medecine Tropicale1962;22(2):268-305. SchneiderJ , EscudieA , HamonJ . Eradication of malaria and chemotherapy. Results obtained with the association amino-4 quinoline + amino-8 quinoline in the pilot area of Bobo-Dioulasso (Haute- Volta) [Eradication du paludismeet chimiotherapie resultats d’un essai de l’association:amino–4 quinoleine/amino–8 quinoleine dans la zonepilote de Bobo–Dioulasso (Haute Volta)]. Bulletin de la Societe de Pathologie Exotique1961;54(5):1012-25. ">Escudie 1962 BFA</a><sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low frequency MDA with AQ‐PQ or CQ‐PQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67.6 (190)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.6 (75)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.3 (105)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59.4 (129)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74.8 (517)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>386 (72.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐61.4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐42.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High frequency MDA with AQ‐PQ or CQ‐PQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.6 (131)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.6 (59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.4 (286)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59.4 (129)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74.8 (517)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>386 (72.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐36.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="15" rowspan="1" valign="top"> <p><a href="./references#CD008846-bbs2-0006" title="BroggerRC , MathewsHM , StoreyJ , AshkarTS , BroggerS , MolineauxL . Changing patterns in the humoral immune response to malaria before, during and after the application of control measures: a longitudinal study in the West African savanna. Bulletin of the World Health Organization1978;56(4):579-600. MolineauxL , BroggerRC , MathewsHM , StoreyJ , AshkarTS . Longitudinal serological study of malaria in infants in the West African savanna. Comparisons in infants exposed to, or protected from, transmission from birth. Bulletin of the World Health Organisation1978;56(4):573-8. MolineauxL , GramicciaG . The Garki Project. Research on the epidemiology and control of malaria in the Sudan Savanna of West Africa. 1980. https://apps.who.int/iris/handle/10665/40316 (accessed prior to 8 July 2021). MolineauxL , StoreyJ , CohenJE , ThomasA . A longitudinal study of human malaria in the West African savanna in the absence of control measures: relationships between different Plasmodium species, in particular P. falciparum and P. malariae. American Journal of Tropical Medicine and Hygiene1980;29(5):725-37. ">Molineaux 1980 NGA</a><sup>c</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low frequency MDA with SP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41.8 (525)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9 (40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49.1 (493)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.5 (380)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐23.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High frequency MDA with SP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44.9 (754)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.3 (109)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49.1 (493)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.5 (380)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐20.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="15" rowspan="1" valign="top"> <p><a href="./references#CD008846-bbs2-0009" title="RobertsJM . Pyrimethamine (Daraprim) in the control of epidemic malaria. American Journal of Tropical Medicine and Hygiene1956;59(9):201-8. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part I. Before the campaign. American Journal of Tropical Medicine and Hygiene1964;67(7):161-8. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part II. The campaign. American Journal of Tropical Medicine and Hygiene1964;67(8):191-9. RobertsJM . The control of epidemic malaria in the highlands of Western Kenya. Part III. After the campaign. American Journal of Tropical Medicine and Hygiene1964;67(9):230-7. ">Roberts 1964 KEN</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MDA with pyrimethamine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.3 (25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (188)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.9 (26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(27) (4.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(15) (5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 (154)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.4 (723)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.7 (366)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 (222)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 (78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐15.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐28.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐22.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐11.3</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="15"> <div class="table-footnote"> <p>AQ = amodiaquine, CQ = chloroquine, MDA = mass drug administration, ND = no data, PQ = primaquine, SP = sulfalene‐pyrimethamine </p> <p><sup>a</sup>Calculated as difference in proportion at the time period of during MDA or post‐MDA minus the proportion at pre‐MDA in the intervention and control separately and the difference in these two proportion differences between the intervention and control groups.<br/><sup>b</sup>MDA with AQ‐PQ or CQ‐PQ either every 4 weeks ('low frequency MDA') or every 2 weeks ('high frequency MDA').<br/><sup>c</sup>MDA with sulfalene‐pyrimethamine either every 10 weeks (low frequency MDA') or every 2 weeks during the wet season and every 10 weeks during the dry season ('high frequency MDA') to all ages except infants prior to their first malaria episode. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Difference‐in‐differences analysis of P falciparum parasitaemia prevalence in non‐randomized studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/full#CD008846-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD008846-tbl-0009"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Difference‐in‐differences analysis of P falciparum gametocytaemia prevalence in non‐randomized studies</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention, % (n)</b> </p> </th> <th align="center" class="headercell" colspan="3" rowspan="1" scope="col" valign="bottom"> <p><b>Control, % (n)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Difference‐in‐differences</b> </p> <p><b>percentage point<sup>a</sup> </b> </p> </th> </tr> <tr> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Pre‐MDA</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>During MDA</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Post‐MDA</b> </p> <p><b>1 to 3 months</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Pre‐MDA</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>During MDA</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Post‐MDA</b> </p> <p><b>1 to 3 months</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>During MDA</b> </p> </th> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Post‐MDA</b> </p> <p><b>1 to 3 months</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><a href="./references#CD008846-bbs2-0003" title="EscudieA , HamonJ , SchneiderJ . Results of mass antimalarial chemoprophylaxis with a combination of 4-aminoquinoline and 8-aminoquinoline under rural African conditions in the region of Bobo-Dioulasso (Upper Volta) 1960. Comparative study in a zone treated with DDT and outside this zone. Medecine Tropicale1962;22(2):268-305. SchneiderJ , EscudieA , HamonJ . Eradication of malaria and chemotherapy. Results obtained with the association amino-4 quinoline + amino-8 quinoline in the pilot area of Bobo-Dioulasso (Haute- Volta) [Eradication du paludismeet chimiotherapie resultats d’un essai de l’association:amino–4 quinoleine/amino–8 quinoleine dans la zonepilote de Bobo–Dioulasso (Haute Volta)]. Bulletin de la Societe de Pathologie Exotique1961;54(5):1012-25. ">Escudie 1962 BFA</a><sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low frequency MDA with AQ‐PQ or CQ‐PQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.3 (57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9 (3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.3 (35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.4 (42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.1 (102)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐14.1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High frequency MDA with AQ‐PQ or CQ‐PQ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.2 (32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9 (9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.4 (107)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.4 (42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.1 (102)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53.4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign="top"> <p><a href="./references#CD008846-bbs2-0006" title="BroggerRC , MathewsHM , StoreyJ , AshkarTS , BroggerS , MolineauxL . Changing patterns in the humoral immune response to malaria before, during and after the application of control measures: a longitudinal study in the West African savanna. Bulletin of the World Health Organization1978;56(4):579-600. MolineauxL , BroggerRC , MathewsHM , StoreyJ , AshkarTS . Longitudinal serological study of malaria in infants in the West African savanna. Comparisons in infants exposed to, or protected from, transmission from birth. Bulletin of the World Health Organisation1978;56(4):573-8. MolineauxL , GramicciaG . The Garki Project. Research on the epidemiology and control of malaria in the Sudan Savanna of West Africa. 1980. https://apps.who.int/iris/handle/10665/40316 (accessed prior to 8 July 2021). MolineauxL , StoreyJ , CohenJE , ThomasA . A longitudinal study of human malaria in the West African savanna in the absence of control measures: relationships between different Plasmodium species, in particular P. falciparum and P. malariae. American Journal of Tropical Medicine and Hygiene1980;29(5):725-37. ">Molineaux 1980 NGA</a><sup>c</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low frequency MDA with SP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.1 (127)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.6 (12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.4 (124)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.9 (92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High frequency MDA with SP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.4 (208)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.2 (48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.4 (124)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.9 (92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐4.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ND</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>AQ = amodiaquine, CQ = chloroquine, MDA = mass drug administration, ND = no data, SP = sulfalene‐pyrimethamine </p> <p><sup>a</sup>Calculated as difference in proportion at the time period of during MDA or post‐MDA minus the proportion at pre‐MDA in the intervention and control separately and the difference in these two proportion differences between the intervention and control groups.<br/><sup>b</sup>MDA with AQ‐PQ or CQ‐PQ either every 4 weeks ('low frequency MDA') or every 2 weeks ('high frequency MDA').<br/><sup>c</sup>MDA with sulfalene‐pyrimethamine either every 10 weeks ('low frequency MDA') or every 2 weeks during the wet season and every 10 weeks during the dry season ('high frequency MDA') to all ages except infants prior to their first malaria episode. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Difference‐in‐differences analysis of P falciparum gametocytaemia prevalence in non‐randomized studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/full#CD008846-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008846-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">MDA versus no MDA in moderate to high endemicity (cRCTs) on P falciparum outcomes</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Parasitaemia prevalence (<i>P falciparum)</i> <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Baseline before MDA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 During MDA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 Post‐MDA 1‐3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.4 Post‐MDA 4‐6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Parasitaemia incidence (<i>P falciparum)</i> <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Post‐MDA 1‐3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Post‐MDA 4‐6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Confirmed malaria illness incidence (<i>P falciparum)</i> <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Baseline before MDA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Post‐MDA 1‐3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Gametocytaemia prevalence (<i>P falciparum)</i> <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Baseline before MDA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Post‐MDA 4‐6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Malaria‐specific mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Post‐MDA 4‐6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">MDA versus no MDA in moderate to high endemicity (cRCTs) on P falciparum outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/references#CD008846-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008846-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">MDA versus no MDA in very low to low endemicity (cRCTs) on P falciparum outcomes</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Parasitaemia prevalence (<i>P falciparum)</i> <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Baseline before MDA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2093</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.62, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 During‐MDA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>991</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.07, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.3 Post‐MDA &lt;1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.03, 0.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.4 Post‐MDA 1‐3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.15, 0.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.5 Post‐MDA 4‐6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.36, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.6 Post‐MDA 7‐12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3704</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.55, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.7 Post‐MDA 13‐18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>243</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.20, 3.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.8 Post‐MDA 19‐24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.06, 1.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.9 Post‐MDA 25‐30 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.22, 3.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.10 Post‐MDA 31‐36 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.25 [0.25, 6.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Parasitaemia incidence (<i>P falciparum)</i> <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Post‐MDA 1‐3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Confirmed malaria illness incidence (<i>P falciparum)</i> <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Baseline before MDA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.45, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 Post‐MDA 1‐3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.12, 2.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.3 Post‐MDA 4‐6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.07, 12.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.4 Post‐MDA 7‐12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.47 [0.21, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.5 Post‐MDA 13‐18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.20, 3.03]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">MDA versus no MDA in very low to low endemicity (cRCTs) on P falciparum outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/references#CD008846-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008846-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">MDA versus no MDA in very low to low endemicity (cRCTs) on P vivax outcomes</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Parasitaemia prevalence (<i>P vivax)</i> <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 Baseline before MDA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.86, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 Post‐MDA &lt;1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.08, 0.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.3 Post‐MDA 1‐3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2673</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.10, 0.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.4 Post‐MDA 4‐6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.63, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.5 Post‐MDA 7‐12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.94, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.6 Post‐MDA 13‐18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>243</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.44, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.7 Post‐MDA 19‐24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>239</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.38, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.8 Post‐MDA 25‐30 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.41, 1.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.9 Post‐MDA 31‐36 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.44, 3.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Confirmed malaria illness incidence (<i>P vivax)</i> <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 Baseline before MDA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.74 [0.67, 4.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 Post‐MDA 7‐12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Rate Ratio (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [0.97, 1.95]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">MDA versus no MDA in very low to low endemicity (cRCTs) on P vivax outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/references#CD008846-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008846-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Supplemental analysis: post‐hoc subgroup analysis by continent</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 <i>Plasmodium falciparum</i> parasitaemia prevalence post‐MDA 1‐3 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5718</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.15, 0.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 Africa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1033</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.32, 2.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 Asia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4685</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.11, 0.33]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Supplemental analysis: post‐hoc subgroup analysis by continent</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008846.pub3/references#CD008846-tbl-0013">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008846.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD008846-note-0018">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008846-note-0016">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD008846-note-0017">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD008846-note-0015">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD008846-note-0014">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD008846-note-0013">Português</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD008846-note-0011">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD008846-note-0012">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008846\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008846\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008846\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008846\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008846\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008846\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008846\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008846\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008846\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008846\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008846\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008846\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008846\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008846\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008846\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008846\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008846\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008846\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xx9QLps0&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008846.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008846.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008846.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008846.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008846.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715438176"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008846.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715438180"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008846.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d87175ba09374',t:'MTc0MDcxNTQzOC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 